Galápagos

STATISTICAL ANALYSIS PLAN

Project Number:	GLPG0634
Study Number:	GS-US-419-3896 (GLPG0634-CL-310)
Study Title:	A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease

Development Phase:	3		
Status:	Final		
Version:	2.0	Date:	1-Aug-2023
EudraCT:	2016-002763-34	IND:	129646
Sponsor:	Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium		
Biostatistician:	[redacted]		
Medical Leader:	[redacted]		

Confidentiality Statement

TABLE OF CONTENTS

LIST OF IN-TEXT TABLES

LIST OF IN-TEXT FIGURES

LIST OF ABBREVIATIONS

AE	adverse event
AEI	adverse events of interest
ALT	alanine aminotransferase
AST	aspartate aminotransferase
ASTE	arterial systemic thromboembolism
BMI	body mass index
CD	Crohn's disease
CDAI	Crohn's Disease Activity Index
CI	confidence interval
COVID-19	coronavirus disease 2019
CRF	case report form
CSR	clinical study report
CTCAE	Common Terminology Criteria for Adverse Events
CV	cardiovascular
CVEAC	cardiovascular safety endpoint adjudication committee
DMC	data monitoring committee
ECG	electrocardiogram
eCRF	electronic case report form
[redacted]	[redacted]
[redacted]	[redacted]
ET	early termination
Hb	hemoglobin
HDL	high-density lipoprotein
HLGT	high-level group term
HLT	high-level term
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
ID	identification
Ig	immunoglobulin
LDL	low-density lipoprotein
LOQ	limit of quantitation
LTE	long term extension
LTT	lower-level term
MACE	major adverse cardiovascular events
MedDRA	Medical Dictionary for Regulatory Activities
MI	myocardial infarction
[redacted]	[redacted]
MST	MedDRA search term
NLP	Natural Language Processing

PRO2	patient reported outcome consisting of 2 items: abdominal pain severity and liquid stool frequency
PT	preferred term
PTx	post-treatment
Q1	first quartile
Q3	third quartile
SAE	serious adverse event
SAP	statistical analysis plan
SD	standard deviation
SE	standard error
[redacted]	[redacted]
SMQ	Standardized MedDRA Query
SOC	system organ class
TE	treatment-emergent
TEAE	treatment-emergent adverse event
TFLs	tables, figures, and listings
ULN	upper limit of normal
V-Day	visit day
VAS	Visual Analogue Scale
VTE	venous thromboembolism
WHO	World Health Organization
[redacted]	[redacted]

1. INTRODUCTION

This statistical analysis plan (SAP) describes the statistical analysis methods and data presentations to be used in tables, figures, and listings (TFLs) in the interim analyses and clinical study report (CSR) for Study GS-US-419-3896 (GLPG0634-CL-310). This SAP is based on the study protocol Amendment 8 dated 2 December 2021 and the electronic case report form (eCRF). The SAP will be finalized before unblinding of Study GS-US-419-3895 (GLPG0634-CL-309), at which time this study will be unblinded. Any changes made after the finalization of the SAP will be documented in the CSR.

1.1. Study Objectives

The primary objective of this study is:

- To observe the long-term safety of filgotinib in subjects who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study for Crohn's disease (CD)

The secondary objective of this study is:

- To evaluate the effect of filgotinib on Patient Reported Outcomes (PRO2) and Crohn's Disease Activity Index (CDAI) scores

[redacted]

[redacted]

[redacted]

1.2. Study Design

This is a long-term extension (LTE) study to evaluate the safety of filgotinib administered to subjects with CD. Some subjects will receive open-label drug and some will continue to receive the blinded study drug assigned in the parent study until subject's treatment in the corresponding parent study (GS-US-419-4015, GS-US-419-4016, or GS-US-419-3895) is unblinded. The duration of treatment is up to 432 weeks.

In general, subjects who fully complete a parent study blinded will continue blinded treatment at the same regimen in the present study on 200 mg filgotinib, 100 mg filgotinib, or placebo. Subjects who enroll from a parent study and receive blinded treatment in the GS-US-419-3896 study will have their GS-US-419-3896 treatment assignment unblinded when the parent study is unblinded. After the study unblinding, subjects will continue on the same dose of open-label filgotinib as they had been receiving in blinded treatment; whereas subjects on placebo treatment

will discontinue study drug and study participation. Subjects who exit a parent study due to disease worsening or failure to meet response or remission criteria will receive open-label 200 mg filgotinib, with the exception of US and Korea males in this category who were not considered biologic refractory who will receive open-label 100 mg filgotinib.

This study includes:

- Day 1
- Treatment Visits: Week 2, Week 4, Week 12, and then every 12 weeks thereafter
- Post-Treatment (PTx) safety assessments (30 days after the last dose of study drug) for subjects who complete all study treatment visits or discontinue early

For additional details, please see the Schedule of Assessments in Appendix 1.

1.3. Sample Size and Power

No formal hypothesis testing is planned for this study and sample size calculation is not conducted. All subjects who have completed or met protocol-specified efficacy discontinuation criteria in a parent study (GS-US-419-4015, GS-US-419-4016, or GS-US-419-3895) may enroll in this study. The projected number of subjects enrolled is approximately 1000.

2. TYPE OF PLANNED ANALYSIS

2.1. Interim Analyses

Prior to the final analysis, interim analyses may be performed for regulatory submission and/or for publication purposes. The first interim analysis is planned to align with the final analysis of Study GS-US-419-3895, at which time this study will be unblinded.

Interim analyses may present a subset of the analyses included in this analysis plan.

2.2. Final Analysis

The final analysis will be performed after all subjects have completed the study.

3. GENERAL CONSIDERATIONS FOR DATA ANALYSES

All analyses described in this SAP will include data from the LTE study (GS-US-419-3896) exclusively, not from the corresponding parent studies, except for subgroup analyses based on parent study completion status. Consequently, any reference to study drug (e.g., first dosing date) implies study drug administered in Study GS-US-419-3896, unless specifically stated otherwise.

Analysis results will be presented using descriptive statistics. For categorical variables, the number and percentage of subjects in each category will be presented; for continuous variables, the number of subjects (n), mean, standard deviation (SD) or standard error (SE), median, first quartile (Q1), third quartile (Q3), minimum, and maximum will be presented.

By-subject listings will be presented for all subjects in the All Enrolled Analysis Set and sorted by subject identification (ID) number, visit date, and time (if applicable). Data collected on log forms, such as adverse events (AEs), will be presented in chronological order within the subject. The treatment group to which subjects were assigned at enrollment will be used in the listings. Age (on the first dosing day in the LTE), sex at birth, race, and ethnicity will be included in the listings, as space permits.

3.1. Analysis Sets

Analysis sets define the subjects to be included in an analysis. Analysis sets and their definitions are provided in this section. The analysis set will be identified and included as a subtitle of each table, figure, and listing.

For each analysis set, the number and percentage of subjects eligible for inclusion, as well as the number and percentage of subjects who were excluded and the reasons for their exclusion (if available), will be summarized by treatment group.

A listing of reasons for exclusion from analysis sets (if applicable) will be provided by subject.

3.1.1. All Enrolled Analysis Set

All Enrolled Analysis Set includes all subjects who enrolled into this study as recorded in the Enrollment eCRF.

3.1.2. Safety Analysis Set

The Safety Analysis Set includes all subjects who took at least 1 dose of study drug in Study GS-US-419-3896. This is the primary analysis set for safety and efficacy analyses.

3.1.3. [redacted]

[redacted]

3.2. Subject Grouping

For analyses based on the Safety Analysis Set and [redacted], subjects will be grouped according to the actual treatment received. The actual treatment received will differ from the assigned treatment only when their actual treatment differs from assigned treatment for the entire treatment duration.

For analyses of baseline characteristics and efficacy endpoints in the subset of subjects who rolled over into the LTE due to failure to meet response/remission criteria at W10 (see Section 3.4 and Section 6.3), subjects will be grouped according to the actual treatment received in both the parent study and the LTE study.

3.3. Strata and Covariates

This study does not use a stratified randomization schedule when enrolling subjects.
No covariates will be included in safety and efficacy analyses.

3.4. Subgroup Analyses

Subgroup analyses will be performed for the group of subjects who rolled over into the LTE due to failure to meet response/remission criteria at W10 (induction non-responders):

- Overall, and,
- By number of prior exposures to biologic agent (0 vs ≥1).

Subgroup analyses for efficacy endpoints are specified in Section 6.3.

3.5. Multiple Comparisons

Adjustments for multiplicity will not be made, because no formal statistical testing will be performed in this study.

3.6. Missing Data and Outliers

3.6.1. Missing Data

In general, missing data will not be imputed unless methods for handling missing data are specified. Exceptions are presented in this document.

For missing last dosing date of study drug, imputation rules are described in Section 4.2. Imputation and calculation rules for missing patient diary data are described in Section 6.1. The handling of missing or incomplete dates for AE onset is described in Section 7.1.6.2, and for concomitant medications in Section 7.4.

3.6.2. Outliers

Outliers will be identified during the data management and data analysis process, but no sensitivity analyses will be conducted. All data, including outliers, will be included in the data analysis, unless otherwise specified.

3.7. Data Handling Conventions and Transformations

In general, age (in years) on the date of the first dose of study drug will be used for analyses and presented in listings. If an enrolled subject was not dosed with any study drug, the enrollment date will be used instead of the first dosing date of study drug. If only the birth year is collected on the CRF, "01 July" will be used for the unknown birth day and month for the purpose of age calculation. If only birth year and month are collected, "15" will be used for the unknown birth day.

Non-pharmacokinetic data that are continuous in nature but are less than the lower limit of quantitation (LOQ) or above the upper LOQ will be imputed as follows:

- A value that is 1 unit less than the lower LOQ at the same precision level of the originally reported value will be used to calculate descriptive statistics if the datum is reported in the form of "< x" (where x is considered the lower LOQ). For example, if the values are reported as < 50 and < 5.0, values of 49 and 4.9, respectively, will be used to calculate summary statistics. An exception to this rule is any value reported as < 1 or < 0.1, etc. For values reported as < 1 or < 0.1, a value of 0.9 or 0.09, respectively, will be used to calculate summary statistics.

- A value that is 1 unit above the upper LOQ will be used to calculate descriptive statistics if the datum is reported in the form of "> x" (where x is considered the upper LOQ). Values with decimal points will follow the same logic as above.

- The lower or upper LOQ will be used to calculate descriptive statistics if the datum is reported in the form of "≤ x" or "≥ x" (where x is considered the lower or upper LOQ, respectively).

3.8. Analysis Visit Windows

3.8.1. Definition of Study Day

The First Dosing Date is defined as the date when subjects take the first dose of study drug in this study, as recorded in the Study Drug Administration eCRF.

The Last Dosing Date is defined as the date when subjects take the last dose of study drug in this study, as recorded in the Study Drug Administration eCRF.

Study day will be calculated from the first dosing date of study drug and derived as follows:

- For days on or after the first dosing date: Assessment Date – First Dosing Date + 1
- For days prior to the first dosing date: Assessment Date – First Dosing Date

Therefore, Study Day 1 is the day of first dose of study drug administration.

Baseline is defined as the last available observation on or prior to the first dosing date, unless otherwise specified.

3.8.2. Analysis Visit Windows

Subject visits might not occur on protocol-specified days. Therefore, for the purpose of analysis, observations will be assigned to analysis windows.

The analysis windows for CDAI, PRO2, vital signs, weight, hematology, and chemistry are provided in Table 3-1. The analysis windows for lipid profile, serum immunoglobulin, [redacted] re provided in Table 3-2. The analysis windows for [redacted]

Table 3-1. Analysis Visit Windows for CDAI, PRO2, Vital Signs, Weight, Hematology and Chemistry

Nominal Visit	Nominal Study Day	Visit Window Study Day	
		Lower Limit	Upper Limit
Baseline	1	(none)	1
Week 2	15	2	22
Week 4	29	23	57
Week 12	85	58	127
Week 24	169	128	211
Week 36	253	212	295
Week 48	337	296	379
Week 60	421	380	463
Week 72	505	464	547
Week 84	589	548	631
Week 96	673	632	715
Week 108	757	716	799
Week 120	841	800	883

Nominal Visit	Nominal Study Day	Visit Window Study Day	
		Lower Limit	Upper Limit
Week 132	925	884	967
Week 144	1009	968	1051
Week 156	1093	1052	1135
Week 168	1177	1136	1219
Week 180	1261	1220	1303
Week 192	1345	1304	1387
Week 204	1429	1388	1471
Week 216	1513	1472	1555
Week 228	1597	1556	1639
Week 240	1681	1640	1723
Week 252	1765	1724	1807
Week 264	1849	1808	1891
Week 276	1933	1892	1975
Week 288	2017	1976	2059
Week 300	2101	2060	2143
Week 312	2185	2144	2227
Week 324	2269	2228	2311
Week 336	2353	2312	2395
Week 348	2437	2396	2479
Week 360	2521	2480	2563
Week 372	2605	2564	2647
Week 384	2689	2648	2731
Week 396	2773	2732	2815
Week 408	2857	2816	2899
Week 420	2941	2900	2983
Week 432	3025	2984	$\geq$ 3025

CDAI = Crohn's Disease Activity Index; PRO2 = patient reported outcome consisting of 2 items: abdominal pain severity and liquid stool frequency

Table 3-2. Analysis Visit Windows for Lipid Profile, Serum Immunoglobulin, [redacted]

Nominal Visit	Nominal Study Day	Visit Window Study Day	
		Lower Limit	Upper Limit
Baseline	1	(none)	1
Week 24	169	2	253
Week 48	337	254	421
Week 72	505	422	589
Week 96	673	590	757
Week 120	841	758	925
Week 144	1009	926	1093
Week 168	1177	1094	1261
Week 192	1345	1262	1429
Week 216	1513	1430	1597
Week 240	1681	1598	1765
Week 264	1849	1766	1933
Week 288	2017	1934	2101
Week 312	2185	2102	2269
Week 336	2353	2270	2437
Week 360	2521	2438	2605
Week 384	2689	2606	2773
Week 408	2857	2774	2941
Week 432	3025	2942	≥ 3025

[redacted]

[redacted]

[redacted]

3.8.3. Selection of Data in the Event of Multiple Records in an Analysis Visit Window

Depending on the statistical analysis method, single values may be required for each analysis window. For example, change from baseline by visit usually requires a single value, whereas a time-to-event analysis would not require 1 value per analysis window.

If multiple valid, nonmissing measurements exist in a postbaseline analysis window, records will be chosen based on the following rules if a single value is needed:

- The record closest to the nominal day for that visit will be selected.
- If there are 2 records that are equidistant from the nominal day, the later record will be selected.
- If there is more than 1 record on the selected day, the average will be taken for continuous data and the worse severity will be taken for categorical data, unless otherwise specified.

3.8.4. Definition of Baseline

Baseline in the LTE is defined as the last nonmissing value on or prior to the first dosing date of study drug in Study GS-US-419-3896, unless specified differently. If there are multiple records with the same time or no time recorded on the same day, the baseline value will be the average of the measurements for continuous data, or the measurement with the lowest severity (eg, normal will be selected over abnormal for safety electrocardiogram [ECG] findings) for categorical data.

4. SUBJECT DISPOSITION

4.1. Subject Enrollment and Disposition

Key study dates (ie, first subject enrolled, last subject enrolled, last subject last visit for the primary endpoint, and last subject last visit for the clinical study report) will be provided.

A summary of subject enrollment will be provided by treatment group for each country, investigator within a country, and overall. The summary will present the number and percentage of subjects enrolled. For each column, the denominator for the percentage calculation will be the total number of subjects analyzed for that column.

A summary of subject disposition will be provided by treatment group. This summary will present the number of subjects in each of the categories listed below:

- All Enrolled Analysis Set
  - — By parent study (GS-US-419-4015, GS-US-419-4016, or GS-US-419-3895)
  - — By reason for exiting parent study, i.e., either completed to end, due to failure to meet response/remission criteria at W10 or due to protocol-specified disease worsening)
- Safety Analysis Set

[redacted]

- Continuing study drug (for analysis other than the final analysis)
- Completed study drug
- Did not complete study drug with reasons for premature discontinuation of study drug
- Continuing study (for analysis other than the final analysis)
- Completed study
- Did not complete the study with reasons for premature discontinuation of study

For the status of study drug and study completion and reasons for premature discontinuation, the number and percentage of subjects in each category will be provided. The denominator for the percentage calculation will be the total number of subjects in the Safety Analysis Set corresponding to that column.

The following by-subject listings will be provided by subject ID number in ascending order to support the above summary tables:

- Reasons for premature study drug or study discontinuation

- Lot number and kit ID of assigned study medication

4.2. Extent of Study Drug Exposure and Adherence

Extent of exposure to study drug will be examined by assessing the total duration of exposure to study drug and the level of adherence relative to the study drug regimen specified in the protocol.

If subjects are continuing study drug at the data cutoff date for an interim analysis, the data cutoff date will be used to impute the last dosing date for the calculation of duration of exposure to study drug and adherence to the study drug.

4.2.1. Duration of Exposure to Study Drug

Total duration of exposure to study drug will be defined as last dosing date minus first dosing date plus 1, regardless of any temporary interruptions in study drug administration, and will be expressed in weeks using up to 1 decimal place (eg, 4.5 weeks). If the last study drug dosing date is missing (for subjects that have stopped treatment or the study as indicated by a study disposition record), the latest date among the treatment (study) disposition date, clinical visit date, laboratory sample collection date, and vital signs assessment date that occurred during the on-treatment period (i.e., after exposure start date) will be used for subjects included in the final analyses or the last available date in the database snapshot at the time of an interim analysis.

If month and year of the last dose are known, and the last study drug dosing date imputed above is different from the month collected, the last date of that month will be used. If only year of the last dose is known, and the last study drug dosing date imputed above is after the year collected, the last date of that year will be used; if the last study drug dosing date imputed above is before the year collected, the first date of that year will be used.

The total duration of exposure to study drug will be summarized using descriptive statistics and using the number (ie, cumulative counts) and percentage of subjects exposed through the following time periods: 1 day, 2 weeks, 4 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 52 weeks, 60 weeks, and then every 12 weeks from Week 60. Summaries will be provided by treatment group for the Safety Analysis Set.

No formal statistical testing is planned.

4.2.2. Adherence to Study Drug

The total number of tablets taken will be summarized using descriptive statistics.

The presumed total number of tablets taken by a subject will be determined by the data collected on the drug accountability CRF using the following formula:

$$Total\ Number\ of\ Tablets\ Taken = \left(\sum No.of\ Tablets\ Dispensed\right) - \left(\sum No.of\ Tablets\ Returned\right)$$

If the bottle was not returned, it is assumed that the subject took all the study drug tablets from the dispensed bottle. The number of tablets returned will be imputed as zero for the given bottle for study drug adherence calculation purposes.

For calculation of the total number of tablets taken for the purposes of interim analyses (ie, prior to the return of all drug bottles), it will be assumed that each subject took the recommended daily dose from the dispensed bottle(s) until either the date of discontinuation, death or data cutoff date (whichever is earliest).

If the bottle has not been returned yet when the interim analysis is conducted, the number of tablets returned will be imputed as total pill count in the dispensed bottle – (the last dosing date – the last bottle dispensed date +1) for the given bottle for study drug adherence calculation purposes.

4.2.2.1. On-Treatment Adherence

The level of on-treatment adherence to the study drug regimen will be determined by the total amount of study drug taken relative to the total amount of study drug expected to be taken during a subject's actual on-treatment period based on the study drug regimen.

The level of on-treatment adherence will be expressed as a percentage using the following formula:

$$On - Treatment\ Adherence\ (\%) = \left(\frac{Total\ Amount\ of\ Study\ Drug\ Taken}{Study\ Drug\ Expected\ to\ be\ Taken\ on\ Treatment}\right) x100$$

Descriptive statistics for the level of on-treatment adherence with the number and percentage of subjects belonging to adherence categories (eg, < 80%, ≥ 80 to < 90%, ≥ 90% to <120, ≥120) will be provided by treatment group for the Safety Analysis Set.

No formal statistical testing is planned.

A by-subject listing of study drug intake and drug accountability will be provided separately by subject ID number (in ascending order) and visit (in chronological order).

4.3. Protocol Deviations

Subjects who did not meet the eligibility criteria for study entry but enrolled in the study, will be summarized regardless of whether they were exempted by the sponsor or not. The summary will present the number and percentage of subjects who did not meet at least 1 eligibility criterion and the number of subjects who did not meet specific criteria by treatment group based on the All Enrolled Analysis Set. A by-subject listing will be provided for those subjects who did not meet at least 1 eligibility (inclusion or exclusion) criterion. The listing will present the eligibility criterion (or criteria if more than 1 deviation) that subjects did not meet and related comments, if collected.

Protocol deviations occurring after subjects entered the study are documented during routine monitoring. The number and percentage of subjects with important protocol deviations by

deviation category (eg, eligibility criteria, informed consent) will be summarized by treatment group for the All Enrolled Analysis Set. A by-subject listing will be provided for those subjects with important protocol deviations.

4.4. Assessment of COVID-19 (Coronavirus Disease 2019) and Ukrainian Conflict Impact

This study was ongoing during the COVID-19 pandemic and the conflict in Ukraine, which have an impact on study conduct. Some subjects were unable to attend onsite visits due to shelter-in-place guidelines, site closures, or other public health measures in response to these situations. This section describes how the impact on study conduct will be handled in the analysis.

4.4.1. Study Drug or Study Discontinuation

Summaries of reasons for discontinuing study drug or study due to COVID-19 will be provided by treatment group and overall, similar to the summary described in the subject enrollment and disposition section (see Section 4.1).

By-subject listing of reasons for premature study drug or study discontinuation due to COVID-19 will be provided if applicable.

4.4.2. Study Drug Interruption

Summaries of number of subjects with study drug interruption due to COVID-19 will be provided by treatment group, if applicable.

By-subject listings of study drug administration for subjects with study drug interruption due to COVID-19 will be provided, if applicable.

4.4.3. Protocol Deviations

Summaries of important protocol deviations due to COVID-19 will be provided, similar to the summary described in the protocol deviations section (Section 4.3).

By-subject listings will be provided for subjects with important protocol deviations related to COVID-19 and the Ukrainian conflict, if applicable.

4.4.4. Missed or Virtual Visits

Summaries of subjects with missed or virtual visits due to the COVID-19 pandemic will be provided for each scheduled study visit by treatment group and overall, for the All Enrolled Analysis Set. For each visit, the summaries will present the number and percentage of subjects who missed the visit due to COVID-19 or had a virtual visit due to COVID-19. For each column, the denominator for the percentage calculation will be the total number of subjects in the All Enrolled Analysis Set for that column.

Overall summaries of the number and percentage of subjects with missed or virtual visits (eg, subjects with at least 1 missed or virtual visit, subjects with 1, 2, 3 or more missed or virtual visits) due to COVID-19 will be provided by treatment group and overall, for the All Enrolled Analysis Set. The denominator for the percentage calculation will be the total number of subjects in the All Enrolled Analysis Set for that column.

By-subject listings of subjects with missed or virtual visits due to COVID-19 will be provided by subject ID number in ascending order.

Information regarding missed or virtual visits due to COVID-19 will be collected as free text in the CRF comment fields. The determination of missed or virtual visits due to COVID-19 will be done using Natural Language Processing (NLP) to search the CRF comment fields. A detailed explanation of the algorithm is given in Appendix 3.

4.4.5. Adverse Events

By-subject listings will be provided for subjects with adverse events of COVID-19, as determined by COVID-19 Standardized MedDRA Query (SMQ) narrow search.

4.4.6. Comments

A by-subject listing of all comments related to the Ukrainian conflict will be provided.

5. BASELINE CHARACTERISTICS

5.1. Demographics and Baseline Characteristics

Subject demographic variables and baseline characteristics below will be summarized by treatment group and overall using descriptive statistics for continuous variables and using number and percentage of subjects for categorical variables. The summary of demographic data will be provided for the Safety Analysis Set. In addition, this summary will be provided for the induction non-responders (see Section 3.4), overall, and by prior exposure to biologic agents.

- Age (years, on the date of the first dose of study drug in Study GS-US-419-3896)
- Age group (< 65 years, ≥ 65 years)
- Sex at birth (female, male)
- Race
- Ethnicity (Hispanic or Latino, Not Hispanic or Latino)
- Geographic region (United States [US], non-US)
- Weight (in kg)
- Height (in cm)
- Body mass index (BMI; in kg/m^2)

A by-subject demographic listing, including the informed consent date, will be provided by subject ID number in ascending order.

5.2. Other Baseline Characteristics

Other baseline characteristics include

- CDAI score
- PRO2 subscores: liquid or very soft stool subscore and abdominal pain subscore
- [redacted]
- [redacted]
- [redacted]
- Concomitant treatment at baseline

- Concomitant use of systemically absorbed corticosteroid and/or immunomodulator, including: a) systemically absorbed corticosteroid only, b) immunomodulator only, c) both, and d) neither

- Prednisone equivalence dose for subjects who are on systemically absorbed corticosteroid (mg/day)

- Prednisone equivalence dose level for subjects who are on systemically absorbed corticosteroid (> 0 to 10 mg/day, > 10 to 20 mg/day, > 20 to 30 mg/day, > 30 mg/day)

- 5-aminosalicylates (yes, no)

These baseline characteristics will be summarized by treatment group and overall using descriptive statistics for continuous variables and using number and percentage of subjects for categorical variables. The summary of these baseline characteristics will be provided for the Safety Analysis Set. In addition, this summary will be provided for the induction non-responders (see Section 3.4), overall, and by prior exposure to biologic agents.

No formal statistical testing is planned.

A by-subject listing of other baseline characteristics will be provided by subject ID number in ascending order.

5.3. Medical History

Adverse events which occurred in a parent study and were ongoing when subject took the first dose in this LTE study were recorded as medical history for Study GS-US-419-3896, excluding AEs occurred after Study GS-US-419-3896 informed consent is signed and prior to initiation of Day 1 Study GS-US-419-3896 IMP but related to Study GS-US-419-3896 protocol-mandated procedures.

General medical history data will be collected at enrollment and listed only. General medical history data will be coded using the current version of Medical Dictionary for Regulatory Activities (MedDRA).

6. EFFICACY ANALYSES

6.1. General Considerations

The efficacy analysis will be conducted on the Safety Analysis Set, defined in Section 3.1.2, unless otherwise specified.

6.1.1. Calculation of CDAI and PRO2 Scores

The CDAI system is a composite index of 8 disease activity variables with scores ranging from 0 to over 600 based upon a composite of symptoms (eg, abdominal pain), signs (the presence of abdominal mass and weight), laboratory values (eg, hematocrit), and physician assessment amongst others. The CDAI has 3 PRO components: liquid or very soft stool frequency, abdominal pain and general wellbeing. The total CDAI score is calculated as a weighted sum of all 8 component subscores. Clinical remission by CDAI is defined as CDAI score < 150 points. If subjects have 1 or more of the 8 component subscores missing, then the subjects will be considered as having insufficient data to determine remission status and their total CDAI score will be considered missing.

The PRO2 instrument has 2 components: liquid or very soft stool frequency subscore and abdominal pain subscore. Clinical remission by PRO2 is defined as an abdominal pain score ≤1 and liquid or very soft stool frequency ≤ 3. If either subscore is missing, the subject will be considered as having insufficient data to determine clinical remission status by PRO2.
For further information on the CDAI/PRO2 and calculation rules at baseline and postbaseline, reference is made to Appendix 2.

6.2. Efficacy Endpoints

6.2.1. Definition of the Efficacy Endpoints

The secondary endpoints of this study are change in CDAI and PRO2 scores from baseline.

[redacted]

6.2.2. Analysis of the Efficacy Endpoints

CDAI and PRO2

Descriptive statistics and 95% CI based on normal approximation will be used to summarize the absolute values and change from baseline values in CDAI and PRO2 scores by analysis visit and treatment group using observed values. Mean absolute values of each score with 95% CI will be plotted over all analysis visits by treatment group. Mean change from baseline values of each score with 95% CI will also be plotted.

[redacted]

[redacted]

6.3. Subgroup Analyses

Subgroup analyses of endpoints related to CDAI and PRO2 will be performed for the induction non-responders (see Section 3.4), overall, and by prior exposure to biologic agents.

For these analyses, an imputation approach will be used for missing data due to premature discontinuation from the study (for any reason, except due to study closure). [redacted] In analyses of continuous CDAI/PRO2 scores, missing scores after discontinuation will be imputed by the LOCF approach using the most recent available value from all previous analysis visits.

6.4. [redacted]

[redacted]

[redacted]

6.5. Change from Protocol-Specified Efficacy Analyses

The following are added to the list of efficacy endpoints and the analyses on these endpoints are included as [redacted] (see Section 6.2.2):

- [redacted]

[redacted]

[redacted]

7. SAFETY ANALYSES

7.1. Adverse Events and Deaths

7.1.1. Adverse Event Dictionary

Clinical and laboratory AEs will be coded using a recent version of MedDRA. System organ class (SOC), high-level group term (HLGT), high-level term (HLT), preferred term (PT), and lower-level term (LLT) will be provided in the AE dataset.

7.1.2. Adverse Event Severity

The severity of AEs was graded using the modified Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. For each episode, the highest grade attained should be reported. If a CTCAE criterion does not exist, the investigator should use the grade or adjectives: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening) or Grade 5 (fatal) to describe the maximum intensity of the adverse event. For purposes of consistency with the CTCAE, these intensity grades are defined in the protocol in Table 7-1 and Appendix 5. The severity grade of events for which the investigator did not record severity will be categorized as "missing" for tabular summaries and data listings. The missing category will be listed last in summary presentation.

7.1.3. Relationship of Adverse Events to Study Drug

Related AEs are those for which the investigator selected "Related" on the AE CRF to the question of "Related to Study Treatment." Events for which the investigator did not record relationship to study drug will be considered related to study drug for summary purposes. However, by-subject data listings will show the relationship as missing.

7.1.4. Action Taken With Study Drug

Action taken is recorded for multiple study treatments on the AE CRF. In adverse event summaries a worst-case approach will be applied using all available information. For example, if for at least one of the study treatments "Drug Withdrawn" was recorded, the AE will be categorized as "leading to premature discontinuation of study drug".

7.1.5. Serious Adverse Events

Serious adverse events (SAEs) will be identified and captured as SAEs if the AEs met the definitions of SAEs that were specified in the study protocol. SAEs captured and stored in the clinical database will be reconciled with the SAE safety database before data finalization.

7.1.6. Treatment-Emergent Adverse Events

7.1.6.1. Definition of Treatment-Emergent Adverse Events

Treatment-emergent adverse events (TEAEs) are defined as 1 or both of the following:

- Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug
- Any AEs leading to premature discontinuation of study drug.

7.1.6.2. Incomplete Dates

If the onset date of the AE is incomplete and the AE stop date is not prior to the first dosing date of study drug, then the month and year (or year alone if month is not recorded) of onset determine whether an AE is treatment emergent. The event is considered treatment emergent if both of the following 2 criteria are met:

- The AE onset date is the same as or after the month and year (or year) of the first dosing date of study drug, and
- The AE onset date is the same as or before the month and year (or year) of the date corresponding to 30 days after the date of the last dose of study drug

An AE with completely missing onset and stop dates, or with the onset date missing and a stop date later than the first dosing date of study drug, will be considered to be treatment emergent. In addition, an AE with the onset date missing and incomplete stop date with the same or later month and year (or year alone if month is not recorded) as the first dosing date of study drug will be considered treatment emergent.

7.1.7. Summaries of Adverse Events and Deaths

Treatment-emergent AEs will be summarized based on the Safety Analysis Set.

No formal statistical testing is planned.

7.1.7.1. Summaries of AE incidence in Combined Severity Grade Subsets

A brief, high-level summary of the number and percentage of subjects who experienced at least 1 TEAE in the categories described below will be provided by treatment group. All deaths observed in the study will also be included in this summary.

The number and percentage of subjects who experienced at least 1 TEAE will be provided and summarized by SOC, PT, and treatment group. The same summary is provided for the other AE categories described below.

- TEAEs with Grade 3 or higher
- TEAEs with Grade 2 or higher
- Treatment-emergent (TE) treatment-related AEs
- TE treatment-related AEs with Grade 3 or higher
- TE treatment-related AEs with Grade 2 or higher
- TE SAEs
- TE treatment-related SAEs
- TEAEs leading to premature discontinuation of study drug
- TEAEs leading to premature discontinuation of study
- TE AEs leading to death (ie, outcome of death)
- TEAEs leading to temporary interruption of study drug

Multiple events will be counted only once per subject in each summary. Adverse events will be summarized and listed in descending order of frequency, first by SOC, then by PT and then alphabetically. For summaries by severity grade, the most severe grade will be used for those AEs that occurred more than once in an individual subject during the study.

In addition to the above summary tables, the following TEAEs will be summarized by PT only, in descending order of total frequency:

- TEAEs
- TEAEs with Grade 3 or higher
- TE SAEs
- TEAEs leading to premature discontinuation of study drug.

In addition, data listings will be provided for the following:

- All AEs, indicating whether the event is treatment emergent
- All SAEs
- All Deaths
- All SAEs leading to death (ie, outcome of death)

- All AEs with severity of Grade 3 or higher
- All AEs leading to premature discontinuation of study drug
- All AEs leading to premature discontinuation of study
- All AEs leading to temporary interruption of study drug

In addition, an XML file will be created to support EUDRACT reporting for the final analysis containing serious AEs, non-serious AEs and non-serious AEs occurring in at least 5% of subjects in at least one treatment arm, either at system organ class level or at PT level. (This XML file will be created in-house).

7.1.8. Adverse Events of Interest

Adverse events of interest (AEI) include infections, gastrointestinal perforations, herpes zoster, malignancies (excluding non-melanoma skin cancers), non-melanoma skin cancers, major adverse cardiovascular events (MACE), and thromboembolic events. Summaries of the following treatment-emergent AEI will be produced to enhance the analysis of safety data.

- Events of infections presented in the following subcategories:
  - AEs of infections, utilizing all AEs in the MedDRA Infections and Infestations SOC
  - AEs of serious infections, using all AEs in the MedDRA Infections and Infestations SOC that are classified as SAEs
  - AEs of herpes zoster, utilizing an MST list developed by the Sponsor
  - AEs of opportunistic infections, utilizing a narrow scope SMQ
- AEs of malignancies, excluding non-melanoma skin cancers, utilizing an MST list developed by the Sponsor
- AEs of non-melanoma skin cancers, utilizing an MST list developed by the Sponsor
- AEs of gastrointestinal perforation, utilizing an MST list developed by the Sponsor
- AEs of MACE, utilizing a positively adjudicated event list, presented in the following subcategories (Section 7.1.8.1):
  - Cardiovascular (CV) death
  - Non-fatal myocardial infarction (MI)
  - Non-fatal stroke
- AEs of arterial systemic thromboembolism (ASTE), utilizing a positively adjudicated event list (Section 7.1.8.1)

- AEs of venous thromboembolism (VTE), utilizing a positively adjudicated event list, presented in the following subcategories (Section 7.1.8.1):

  — Venous Thrombotic and Embolic Events

  — Other

The number and percentage of subjects with a reported event will be summarized for each treatment group by PT for each AEI category. Data listings for AEI will also be provided.

A by-subject listing for subjects with potential events for adjudication (MACE, ASTE, and VTE) and their respective adjudication results will be provided.

A by-subject listing of thromboembolic history and risk factors will be provided for subjects with potential events for adjudication (MACE, ASTE, and VTE).

7.1.8.1. Cardiovascular Safety Endpoint Adjudication Committee

An independent cardiovascular safety endpoint adjudication committee (CVEAC) was formed to periodically review and adjudicate all potential MACE and thromboembolic events in a blinded manner. To identify potential MACE and thromboembolic events, the following AEs were sent for adjudication. Refer to the Cardiovascular Event Adjudication Charter for more details.

- All AEs leading to death
- CV events (meeting seriousness criteria), utilizing an MST list developed by the Sponsor
- MI, utilizing a narrow scope SMQ
- Unstable angina (meeting hospitalization criteria), utilizing an MST list developed by the Sponsor
- Transient ischemic attack, utilizing an MST list developed by the Sponsor
- Stroke, utilizing an MST list developed by the Sponsor
- Cardiac failure (meeting hospitalization criteria), utilizing an MST list developed by the Sponsor
- Percutaneous coronary intervention, utilizing an MST list developed by the Sponsor
- Embolic and thrombotic events, utilizing a narrow scope SMQ

The CVEAC will review the above AEs, and related clinical data to adjudicate whether the criteria for MACE (CV death, MI, and/or stroke), ASTE, and VTE have been met for each AE.

7.2. Laboratory Evaluations

Laboratory data collected during the study will be analyzed and summarized using both quantitative and qualitative methods. Summaries of laboratory data will be provided for the Safety Analysis Set and will include data collected up to the last dose of study drug plus 30 days for subjects who have permanently discontinued study drug, or all available data at the time of the database snapshot for subjects who were ongoing at the time of an interim analysis. The analysis will be based on values reported in conventional units. When values are below the LOQ, they will be listed as such, and the closest imputed value will be used for the purpose of calculating summary statistics as specified in Section 3.7. Hemolized test results will not be included in the analysis, but they will be listed in by-subject laboratory listings.

A by-subject listing for laboratory test results will be provided by subject ID number and time point in chronological order for hematology, serum chemistry, urinalysis, lipid profile, and serum immunoglobulin separately. Values falling outside of the relevant reference range and/or having a severity grade of 1 or higher on the CTCAE severity grade will be flagged in the data listings, as appropriate.

Hematocrit results collected from local laboratories due to COVID-19 impact will not be included in the safety laboratory summary, but will be included in the listing with a flag to indicate which records were collected at local laboratories.

No formal statistical testing is planned.

7.2.1. Summaries of Numeric Laboratory Results

Descriptive statistics will be provided by treatment group for each laboratory test specified in the study protocol within hematology and chemistry panels including creatinine clearance, and also laboratory tests from lipids panel (under fasting status) including total cholesterol, LDL, HDL, triglycerides, non-HDL cholesterol (total cholesterol minus HDL cholesterol), LDL/HDL ratio, and total immunoglobulin (Ig), IgA, IgM, and IgG, as follows:

- Baseline values
- Values at each postbaseline time point
- Change from baseline at each postbaseline time point

A baseline laboratory value will be defined as the last measurement obtained on or prior to the date/time of first dose of study drug. Change from baseline to a postbaseline visit will be defined as the visit value minus the baseline value. The mean, median, Q1, Q3, minimum, and maximum values will be displayed to the reported number of digits; SD values will be displayed to the reported number of digits plus 1.

Median (Q1, Q3) of the observed change from baseline values for aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, alkaline phosphatase, serum creatine, creatinine clearance, creatine phosphokinase, white blood cell count, absolute neutrophils,

absolute lymphocytes, hemoglobin, platelets, total cholesterol, LDL, HDL, total Ig, IgG, IgA, and IgM, will be plotted using a line plot by treatment group and time point.

In the case of multiple values in an analysis window, data will be selected for analysis as described in Section 3.8.3.

7.2.2. Graded Laboratory Values

The CTCAE Version 4.03 will be used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 includes all values that do not meet the criteria for an abnormality of at least Grade 1. For laboratory tests with criteria for both increased and decreased levels, analyses for each direction (ie, increased, decreased) will be presented separately.

7.2.2.1. Treatment-Emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days for subjects who permanently discontinued study drug, or the last available date in the database snapshot for subjects who were still on treatment at the time of an interim analysis. If the relevant baseline laboratory value is missing, any abnormality of at least Grade 1 observed within the time frame specified above will be considered treatment emergent.

7.2.2.2. Treatment-Emergent Marked Laboratory Abnormalities

Treatment-emergent marked laboratory abnormalities are defined as values that increase from baseline by at least 3 toxicity grades at any postbaseline time point, up to and including the date of the last dose of study drug plus 30 days for subjects who permanently discontinued study drug or the last available date in the database snapshot for subjects who were still on treatment at the time of an interim analysis. If the relevant baseline laboratory value is missing, any Grade 3 or 4 values observed within the timeframe specified above will be considered treatment-emergent marked abnormalities.

7.2.2.3. Summaries of Laboratory Abnormalities

The following summaries (number and percentage of subjects) for treatment-emergent laboratory abnormalities will be provided by lab test and treatment group; subjects will be categorized according to the most severe postbaseline abnormality grade for a given lab test:

- Graded laboratory abnormalities
- Grade 3 or 4 laboratory abnormalities
- Marked laboratory abnormalities

For all summaries of laboratory abnormalities, the denominator is the number of subjects with nonmissing postbaseline values up to 30 days after last dosing date.

A by-subject listing of treatment-emergent Grade 3 or 4 laboratory abnormalities will be provided by subject ID number and time point in chronological order. This listing will include all test results that were collected throughout the study for the lab test of interest, with all applicable severity grades displayed.

7.2.3. Liver-Related Laboratory Evaluations

Liver-related abnormalities after initial study drug dosing will be examined and summarized using the number and percentage of subjects who were reported to have the following laboratory test values for postbaseline measurements:

- Aspartate aminotransferase (AST): (a) > 3 times of the upper limit of normal (ULN) reference range; (b) > 5 × ULN; (c) > 10 × ULN; (d) > 20 × ULN
- Alanine aminotransferase (ALT): (a) > 3 × ULN; (b) > 5 × ULN; (c) > 10 × ULN; (d) > 20 × ULN
- AST or ALT > 3 × ULN and total bilirubin > 2 × ULN

The summary will include data from all postbaseline visits up to 30 days after the last dose of study drug. For individual laboratory tests, subjects will be counted once based on the most severe postbaseline values. For both the composite endpoint of AST or ALT and total bilirubin, subjects will be counted once when the criteria are met at the same postbaseline visit date. The denominator is the number of subjects in the Safety Analysis Set who have nonmissing postbaseline values of all relevant tests at the same postbaseline visit date. A listing of subjects who met at least 1 of the above criteria will be provided.

7.3. Body Weight and Vital Signs

Descriptive statistics will be provided by treatment group for body weight, BMI and vital signs (resting blood pressure [systolic blood pressure and diastolic blood pressure], respiratory rate, pulse and temperate) as follows:

- Baseline value
- Values at each postbaseline time point
- Change from baseline at each postbaseline time point

A baseline value will be defined as the last available value collected on or prior to the date/time of first dose of study drug. Change from baseline to a postbaseline visit will be defined as the postbaseline value minus the baseline value. Body weight and vital signs measured at unscheduled visits will be included for the baseline value selection.

In the case of multiple values in an analysis window, data will be selected for analysis as described in Section 3.8.3. No formal statistical testing is planned.

A by-subject listing of vital signs will be provided by subject ID number and time point in chronological order. Body weight, height, and BMI will be included in the vital signs listing, if space permits. If not, they will be provided separately.

Body weight results measured by subjects at home from virtual visits due to COVID-19 impact will not be included in the vital signs summary, but will be included in the listing with a flag to indicate which records were collected at home.

7.4. Concomitant Medications

Medications collected during the study will be coded using the current version of the World Health Organization (WHO) Drug dictionary.

Concomitant medications are defined as medications taken while a subject took study drug. Use of concomitant medications will be summarized by therapeutic subgroup (ATC level 2) and preferred name using the number and percentage of subjects for each treatment group. A subject reporting the same medication more than once will be counted only once when calculating the number and percentage of subjects who received that medication. The summary will be ordered in descending overall frequency, first by ATC class and then by preferred term. For drugs with the same frequency, sorting will be done alphabetically.

For the purposes of analysis, any medications with a start date prior to or on the first dosing date of study drug and continued to be taken after the first dosing date, or started after the first dosing date but prior to or on the last dosing date of study drug will be considered concomitant medications. Medications started and stopped on the same day as the first dosing date or the last dosing date of study drug will also be considered concomitant. Medications with a stop date prior to the date of first dosing date of study drug or a start date after the last dosing date of study drug will be excluded from the concomitant medication summary. If a partial stop date is entered, any medication with the month and year (if day is missing) or year (if day and month are missing) prior to the date of first study drug administration will be excluded from the concomitant medication summary. If a partial start date is entered, any medication with the month and year (if day is missing) or year (if day and month are missing) after the study drug stop date will be excluded from the concomitant medication summary. Medications with completely missing start and stop dates will be included in the concomitant medication summary, unless otherwise specified. Summaries will be based on the Safety Analysis Set. No formal statistical testing is planned.

All concomitant medications (other than per-protocol study drugs) will be provided in a by-subject listing sorted by subject ID number and administration date in chronological order.

7.5. Electrocardiogram Results

A frequency table of the investigators' assessment of ECG results at each visit will be presented by treatment group, using the following categories: normal; abnormal, not clinically significant; abnormal, clinically significant. The number and percentage of subjects in each classification group will be presented.

No formal statistical testing is planned.

A by-subject listing for ECG assessment results will be provided by subject ID number and time point in chronological order.

7.6. Other Safety Measures

A data listing will be provided for subjects who become pregnant during the study.

[redacted]

9. SOFTWARE

SAS® Software Version 9.4. SAS Institute Inc., Cary, NC, USA.

10. SAP REVISION

Revision Date (DD MMM YYYY)	Section	Summary of Revision	Reason for Revision
Original Gilead draft (11 February 2022)			
Draft 0.3 (11 July 2022)	Global	Editorial changes have been made throughout the SAP, where appropriate	To align with GLPG wording / template
	4.4	Added assessment of Ukrainian conflict impact	To better understand the Ukrainian conflict impact on subject disposition and missing data
	6.2	Added remission by CDAI and PRO2 as efficacy endpoints	To support the secondary endpoints.
	6.3, 7.1.8	Added subgroup analyses for efficacy endpoints and adverse events	To assess benefit/risk in subjects who completed the parent study and subjects who met protocol-specified efficacy discontinuation criteria
Draft 0.4 (1 Augustus 2022)	Global	Editorial changes have been made throughout the SAP, where appropriate	For clarification, based on team feedback
	5.2	Added baseline disease characteristics by subgroup	To complement the efficacy/safety subgroup analyses
	7.1.6	AEs will be presented ordered by total frequency, not alphabetically	Requested by medical writing
	7.5	Addition of ECG shift table	Requested by medical leads
Draft 0.5 (12 November 2022)	Global	Clarifications and corrections have been made throughout the SAP, where appropriate	Based on dry-run findings
	3.4	Update definition subgroups.	Based on internal discussion
	4.4.5	Replacing COVID impact indicator by listing of AEs related to COVID	The impact indicator is a Gilead-defined analysis. Not deemed valuable
	7.4	Addition of ATC level 2 in summaries of concomitant medications	Requested by medical leads
	7.5	ECG shift table replaced by frequency table	Baseline ECG not available in this study
	Title page	Update medical leader	

Final Version 1.0 (13 January 2023)	4.4	Reduction of planned analyses related to the impact of the Ukrainian conflict	Data availability
	5.2	Update prednisone dose categories	Requested by medical leads
	7.1.4	Added section on the handling of "action taken" information in the summaries of AEs	Clarification
	Appendix 5	Addition of MST lists based on the latest MedDRA version	For transparency on which lists were used at the time of analysis
Final Version 2.0 (1 August 2023)	3.2, 3.4, 5.1, 5.2, 6.3	Extension of analyses of baseline characteristics and efficacy endpoints in the subset of induction non-responders: by prior exposure, addition of imputation rules	For better understanding of this specific subgroup
	7.1.7	Removal of specific AE summaries	Considered unnecessary by the team
	7.1.8	Addition of subcategories VTE	Request medical safety
	7.1.9	Removal of subgroup analyses for AE	Considered unnecessary by the team
	7.2.2	Removal lab shift tables	Considered unnecessary by the team

11. APPENDICES

Appendix 1. Schedule of Assessments

Study Procedures	Day 1[a]	Week 2 ± 3 days	Week 4 ± 3 days	Every 4 Weeks from Day 1 ± 7 days	Week 12 and then every 12 Weeks from Day 1 Clinic Visit ± 7 days	Every 24 Weeks from Day 1 Clinic Visit ± 7 days	Every 48 Weeks from Day 1 Clinic Visit ± 7 days	Early Termination (ET) Visit	Post-Treatment (PTx)[b] ± 3 days
Written Informed Consent	X								
Review Inclusion/Exclusion Criteria	X								
Medical History	X								
Symptom-Directed Examination (as needed)	X	X	X		X			X	X
Perianal fistulae assessment (for subjects rolling over from GS-US-419-4016 **only**) [c]					X			X	X
Vital Signs[d]	X	X	X		X			X	X
Height	X								
Weight	X	X	X		X			X	X
Hematology	X	X	X		X			X	X
Chemistry	X	X	X		X			X	X
Lipid Profile (fasting)[e]						X			
Urinalysis	X					X			
Pregnancy Test[f]	X		X	X				X	X
HBV DNA monitoring (Japan)[g]	X		X	X					
HBV DNA monitoring (other regions)[h]	X				X				
TB Assessment[i]	X						X		

Study Procedures	Day 1[a]	Week 2 ± 3 days	Week 4 ± 3 days	Every 4 Weeks from Day 1 ± 7 days	Week 12 and then every 12 Weeks from Day 1 Clinic Visit ± 7 days	Every 24 Weeks from Day 1 Clinic Visit ± 7 days	Every 48 Weeks from Day 1 Clinic Visit ± 7 days	Early Termination (ET) Visit	Post-Treatment (PTx)[b] ± 3 days
12-lead ECG							X		
Serum immunoglobulin	X					[redacted]			
[redacted]									
e-Diary Instruction & Review[l]	X	X	X		X				
PRO2[m]	X	X	X		X			X	
CDAI[m]	X	X	X		X			X	
[redacted]									
Enrollment	X								
Study Drug Dispensation	X		X		X				
Adverse Events[o]	X	X	X		X			X	X
Concomitant Medications	X	X	X		X			X	X

a Day 1 visit for this study may occur at the same time as the final scheduled treatment visit of the prior filgotinib study. All procedures necessary for the final visit in the prior filgotinib study will be completed as well as any additional procedures required for this study. Procedures that are duplicates of the final visit from prior filgotinib study do

not need to be performed again for this protocol. Day 1 may be delayed up to 10 days. If Day 1 of LTE is not the same as the last study visit of the prior study, a full set of Day 1 procedures should be performed. If a subject has already taken study drug for that day within the parent protocol, first dose should take place on Day 2.

b The Post-Treatment (PTx) Visit should occur 30 days after the last dose of study drug.

c The perianal fistula assessment entails tracking the clinical status of draining external openings of perianal fistulae that were identified at baseline of Study GS-US-419-4016 . For additional details on the perianal assessment, refer to the Perianal Fistula Assessment Manual

d Vital signs include resting blood pressure, respiratory rate, pulse, and temperature.

e Fasting means no food or drink except water, for 8 hours

f Females who are of childbearing potential only. A urine pregnancy test must be completed in clinic every 4 weeks at a minimum. If any pregnancy test is positive, study drug should be immediately interrupted and the subject should have a serum pregnancy test in clinic.

g In Japan, subjects with negative HBsAg, positive HBcAb and/or positive HBsAb in a parent CD protocol require HBV DNA monitoring every 4 weeks in accordance with local guidelines (Protocol Section 6.2.1).

h In other regions, subjects with negative HBsAg and positive HBcAb require HBV DNA monitoring every 3 months in accordance with local guidelines (Protocol Section 6.2.1)

i Subjects who were previously treated for TB do not need to have yearly QuantiFERON® (or centrally reported equivalent assay) tests but should be screened at least yearly for signs and symptoms of reactivation.

j [redacted]

k [redacted]

l At Day 1 visit, review diary of subject reported components from parent study. Subjects should begin filling out the Diary on Day 1 visit and continue to fill it out throughout the study.

m Colonoscopy with biopsies is optional per standard of care. The date of the procedure may be requested for accuracy of data analysis.

n [redacted]

o Ongoing AEs from previous filgotinib studies should be recorded as medical history. Collection of AEs and SAEs related to protocol-mandated procedures will begin once informed consent is signed and will continue through the Post-Treatment (PTx) Visit.

Appendix 2. CDAI and PRO2 Calculation

The total CDAI score is a weighted sum of all 8 variables as specified in Table 11-1, and the PRO2 scores will be assessed according to Table 11-2. Details for the calculations of CDAI and PRO2 scores at baseline and post-baseline visits are provided in this appendix.

Table 11-1. Calculation of Total CDAI Score

Variable no.	Variable	Variable description	Multiplier
1	Liquid or very soft stool	Daily stool count is summed for 7 days	2
2	Abdominal pain	Sum of 7 days of daily ratings as 0 = none, 1 = mild, 2 = moderate, 3 = severe	5
3	General wellbeing	Sum of 7 days of daily ratings as 0 = generally well, 1 = slightly below par, 2 = poor, 3 = very poor, 4 = terrible	7
4	Complications	Number of listed complications: - Arthritis or arthralgia - Erythema nodosum, pyoderma gangrenosum or apthous stomatitis - Iritis or uveitis - Anal fissures or fistulae or abscess - Other fistula - Fever over 37.8 C [100 F] during past week	20 each
5	Use of anti-diarrheal medications	Use of diphenoxylate or loperamide or other opiate for diarrhea 0 = No, 1 = Yes	30
6	Abdominal mass	0 = none, 2 = questionable, 5 = definite	10
7	Hematocrit*	Males: 47 – Hct [%] Females: 42 – Hct [%] *Result must be greater than or equal to 0. If negative result enter 0	6 × difference
8	Weight*	Percentage deviation from standard weight (1 – weight / standard weight) × 100 *Limit of -10 (Result must be greater than or equal to -10)	1
CDAI score			TOTAL

CDAI = Crohn's Disease Activity Index; Hct = hematocrit

Table 11-2. Calculation of PRO2 Components

Variable no.	Variable	Variable Description
1	Liquid or very soft stool	**Mean** of the daily (liquid or very soft) stool count for 7 days
2	Abdominal pain	**Mean** of 7 days of daily ratings as 0 = none, 1 = mild, 2 = moderate, 3 = severe

Each PRO2 subscore will be rounded to the nearest integer (eg, 2) in the determination of subject eligibility for the study and calculation of endpoints.

The 3 patient-reported outcome components for CDAI (and each subscore for PRO2) are determined using an electronic daily diary, which collects subject reported components directly. Given that the ileocolonoscopy procedure (non-protocol-directed procedures) may impact the validity of the diary data, diary data collected 1 day prior to and on the day of the procedure will not be used in the calculation of CDAI and PRO2 subscores for all visits. Those days are called non-evaluable days.

Calculation of CDAI and PRO2 Scores for Baseline and Post-baseline Visits

The calculations of CDAI and PRO2 scores for baseline and post-baseline visits are specified below:

1) The Day 1 visit date will be used as the anchor day for baseline and following visit dates will be used as the anchor day for post-baseline visits. The visit date for each analysis visit will be selected as the anchor day among all scheduled visits and unscheduled visits where CDAI were assessed within the analysis window as defined in Section 3.8.2. Only diary data collected on evaluable days within a 10-day window which starts 10 days prior to the selected visit date (V-Day 1) and ends on the day prior to V-Day 1 will be used for calculation.

2) If there are 7 or more evaluable records within the 10-day window, take the **sum** of the 7 evaluable records closest to V-Day 1 for the corresponding CDAI subject-reported component. For the corresponding PRO2 component, take the **average** of the 7 evaluable records within the 10-day window closest to V-Day 1.

   a) If there are 4 or more (but less than 7) evaluable records within this 10-day window, the average of the available records will be taken, and then multiplied by 7 for the corresponding CDAI patient-reported component. For the corresponding PRO2 component, the average of the available records will be taken.

   b) If subjects do not have at least 4 evaluable records within this 10-day window, the corresponding CDAI patient-reported component, and the corresponding PRO2 component will not be calculated and will be considered as missing for that visit.

A schema of this approach and some examples are included below for further explanation:

Figure 1. Selection of Diary Data for the Calculation for Baseline and Postbaseline Visits



Table 11-3. Calculation of CDAI Patient-Reported Outcome Components and PRO2 Scores for Baseline and Post-baseline Visits

	Diary Day Looking Backwards from Visit Date (V-Day)										Days for Calculation	Sum of 7 Days (CDAI Patient-Reported Component)	Average of 7 Days (PRO2)
Example	-10	-9	-8	-7	-6	-5	-4	-3	-2	-1			
Diary Subscore 1	1	2	2	M	0	1	2	2	1	X	-2,-3,-4,-5,-6,-8,-9	10.0	1.4
Diary Subscore 2	M	M	1	M	X	IL	2	2	1	M	-2,-3,-4, -8	10.5	1.5
Diary Subscore 3	M	M	1	X	IL	M	M	2	1	M	-2,-3,-8	Missing	Missing
Diary Subscore 4	0	M	2	2	1	0	M	2	X	IL	-3,-5,-6,-7,-8,-10	8.2	1.2

M = Missing; IL = Ileocolonoscopy day; X = non-evaluable (due to preparation for ileocolonoscopy).

Days are named relative to visit date (V-Day 1), where V-Day – 1 is the day prior to V-Day 1.

Rounding of subscores into one decimal place is for displaying purpose only. When calculating the total CDAI scores, the subscores will not be rounded.

3) The CDAI total score for a specific visit is based on a weighted sum (rounded to the nearest integer) of all 8 components. The CDAI total score will be set to 0 in the case the calculation leads to a CDAI total score < 0. Each component will be selected within the analysis window as defined in Table 3-1 in Section 3.8.2.

If subjects have at least 1 of the 8 CDAI components missing, then their total CDAI score will be considered missing. If at least 1 out of the 6 complications under the complication component is missing, then the complication component will be considered missing.

4) The PRO2 subscores for a specific visit are based on the evaluation of liquid or very soft stool frequency and abdominal pain subscores individually (rounded to the nearest integer) within the analysis window as defined in Section 3.8.2.

Source of Information Used for CDAI and PRO2 Calculation

The sources of information used for the calculations of CDAI and PRO2 scores as described above are given in **Error! Reference source not found.** (the calculated scores from ERT data w ill not be used for data analysis). Hematocrit results collected from local laboratories and body weight measured at home due to COVID-19 impact will be used in CDAI calculation.

Table 11-4. Sources of Information for Calculating CDAI and PRO2 Scores

Variable in Calculation	Data Source
Visit Date	VISITDAT in VISDT dataset from eCRF data
Stool Frequency Diary Data	QSSTRESN in DIARY dataset with QSTESTCD="SOFSTOOL" from vendor ERT data
Abdominal Pain Diary Data	QSSTRESN in DIARY dataset with QSTESTCD="ABDPAIN" from vendor ERT data
Subject Standard Weight	SEX_STD in DM dataset and HEIGHT_STD in VSPERF dataset from eCRF data will be used to determine the standard weight based on Appendix 4.
Subject Actual Weight	WEIGHT_STD in VSPERF dataset from eCRF data
Hematocrit Value	CNVRESN in COVLAB dataset with LBTEST="Hematocrit" from vendor Covance data or LBORRES in LB_HEM dataset with LBTEST="Hematocrit" from eCRF data if collected in local laboratory due to COVID-19 impact

Note: eCRF = electronic case report form(s). ERT is the vendor that electronically collects patient and investigator reported outcomes.

Appendix 3. Data Collection of COVID-19 Data

This appendix describes the clinical trial site collection of COVID-19 data pertaining to missed/virtual visits and the data processing algorithm that will be used to determine which visits are missing and which visits are virtual.

Data Collection

A COVID-19 supplement to the eCRF Completion Guidelines (CCG) was provided by Clinical Data Management to instruct clinical trial sites with data entry expectations pertaining to scenarios related to the COVID-19 pandemic. If a visit was missed, sites were instructed to enter "Visit missed due to COVID-19" and if an in-person visit was conducted virtually, sites were instructed to enter "Virtual visit due to COVID-19".

Determination of Missed and Virtual Visits

Natural Language Processing (NLP) will be used to search the CRF comment fields to identify instances of "COVID-19", "Virtual", or synonyms (see Table 11-5). The search terms will be maintained in a global lookup table and can be modified to tune the NLP model. Any comments with COVID-19 search terms, "Missed visit" or "Virtual visit will be assigned as follows:

i. If COVID-19 terms are identified through NLP and the visit date is missing, then result is "Missed Visit"
ii. If COVID-19 and Virtual terms are identified through NLP for a visit, then result is "Virtual Visit". When there are multiple records for the same subject and the same visit, if one record could be categorized as "Virtual Visit", all records associated with this subject and this visit will be categorized as "Virtual Visit"
iii. Otherwise result is missing

Table 11-5. Example Search Terms for "COVID-19" and "Virtual" Used to Identify Missed/Virtual Visits

Search Terms for "COVID-19"	Search Terms for "Virtual"
COVID19	VIRTUAL
CORONA	TELEMED
CORONAVIRUS	TELEHEALTH
PANDEMIC	TELEPHONE
OUTBREAK	REMOTE
CRISIS	TELEMEDICINE
LOCKDOWN	TELECONSULTATION
QUARANTINE	TELEPHONICALLY
SHELTER	PHONE
	HOME VISIT
	ZOOM
	SKYPE

Appendix 4. Calculation of Standard Body Weight

The following table will be used to determine the standard body weight for each subject. Height from the eCRF will be used and is assumed to be measured without shoes.

Women			
Height in *cm* (in shoes)*	**Standard Weight in *kg***	**Height in *cm* (in shoes)***	**Standard Weight in *kg***
127	41.2	163	60.2
128	41.7	164	60.7
129	42.3	165	61.3
130	42.8	166	61.9
131	43.3	167	62.4
132	43.8	168	62.9
133	44.4	169	63.4
134	44.9	170	63.9
135	45.4	171	64.5
136	45.9	172	65.0
137	46.4	173	65.5
138	47.0	174	66.0
139	47.5	175	66.6
140	48.0	176	67.2
141	48.6	177	67.7
142	49.1	178	68.3
143	49.6	179	68.8
144	50.2	180	69.3
145	50.7	181	69.8
146	51.2	182	70.3
147	51.8	183	70.8
148	52.3	184	71.3
149	52.8	185	71.8
150	53.1	186	72.3
151	54.1	187	72.8
152	54.5	188	73.3
153	55.0	189	73.8
154	55.4	190	74.3
155	55.9	191	74.9
156	56.4	192	75.4
157	57.0	193	76.0
158	57.5	194	76.5
159	58.1	195	77.0
160	58.6	196	77.6
161	59.1	197	78.1
162	59.6	198	78.6

* add 2.0 cm if shoeless. Please round height to a whole number and select the appropriate standard weight (eg, height 157.4 cm will be rounded to 157 cm; 157.5 cm will be rounded to 158 cm.)

Men			
Height in *cm* (in shoes)*	**Standard Weight in *kg***	**Height in *cm* (in shoes)***	**Standard Weight in *kg***
142	54.4	179	71.9
143	54.9	180	72.4
144	55.4	181	73.0
145	55.8	182	73.6
146	56.3	183	74.3
147	56.8	184	74.8
148	57.2	185	75.5
149	57.7	186	76.2
150	58.2	187	76.9
151	58.6	188	77.6
152	59.1	189	78.2
153	59.6	190	78.8
154	60.0	191	79.6
155	60.5	192	80.4
156	61.0	193	81.2
157	61.4	194	82.1
158	61.9	195	82.9
159	62.2	196	83.8
160	62.6	197	84.7
161	62.9	198	85.4
162	63.3	199	86.1
163	63.7	200	86.7
164	64.1	201	87.4
165	64.6	202	88.0
166	65.0	203	88.8
167	65.5	204	89.4
168	66.0	205	90.1
169	66.6	206	90.7
170	67.1	207	91.4
171	67.6	208	92.1
172	68.1	209	92.7
173	68.7	210	93.4
174	69.2	211	94.1
175	69.7	212	94.8
176	70.3	213	95.5
177	70.8	214	96.1
178	71.3		

* add 2.0 cm if shoeless. Please round height to a whole number and select the appropriate standard weight (eg, height 157.4 cm will be rounded to 157 cm; 157.5 cm will be rounded to 158 cm.)

Appendix 5. MST Lists for AEs of Interest

Herpes Zoster - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10019974	Herpes zoster	PT
10030865	Ophthalmic herpes zoster	PT
10061208	Herpes zoster infection neurological	PT
10063491	Herpes zoster oticus	PT
10065038	Herpes zoster disseminated	PT
10072210	Genital herpes zoster	PT
10074241	Varicella zoster gastritis	PT
10074243	Varicella zoster oesophagitis	PT
10074245	Herpes zoster pharyngitis	PT
10074248	Herpes zoster meningoencephalitis	PT
10074251	Herpes zoster meningomyelitis	PT
10074253	Herpes zoster necrotising retinopathy	PT
10074254	Varicella zoster pneumonia	PT
10074259	Herpes zoster meningitis	PT
10074297	Herpes zoster cutaneous disseminated	PT
10074298	Varicella zoster sepsis	PT
10075611	Varicella zoster virus infection	PT
10076667	Disseminated varicella zoster vaccine virus infection	PT
10079327	Herpes zoster meningoradiculitis	PT
10080516	Herpes zoster reactivation	PT
10082717	Herpetic radiculopathy	PT
10084396	Disseminated varicella zoster virus infection	PT
10086594	Oral herpes zoster	PT
10086746	Varicella encephalitis	PT
10086747	Varicella meningitis	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10000583	Acral lentiginous melanoma	PT
10000585	Acral lentiginous melanoma stage I	PT
10000586	Acral lentiginous melanoma stage II	PT
10000587	Acral lentiginous melanoma stage III	PT
10000588	Acral lentiginous melanoma stage IV	PT
10000739	Acute erythroid leukaemia	PT
10000830	Acute leukaemia	PT
10000846	Acute lymphocytic leukaemia	PT
10000847	Acute lymphocytic leukaemia (in remission)	PT
10000860	Acute megakaryocytic leukaemia	PT
10000871	Acute monocytic leukaemia	PT
10000872	Acute monocytic leukaemia (in remission)	PT
10000880	Acute myeloid leukaemia	PT
10000881	Acute myeloid leukaemia (in remission)	PT
10000890	Acute myelomonocytic leukaemia	PT
10001019	Acute promyelocytic leukaemia	PT
10001141	Adenocarcinoma	PT
10001150	Adenocarcinoma gastric	PT
10001167	Adenocarcinoma of colon	PT
10001197	Adenocarcinoma of the cervix	PT
10001244	Adenosquamous carcinoma of the cervix	PT
10001245	Adenosquamous cell lung cancer	PT
10001247	Adenosquamous cell lung cancer recurrent	PT
10001248	Adenosquamous cell lung cancer stage 0	PT
10001249	Adenosquamous cell lung cancer stage I	PT
10001250	Adenosquamous cell lung cancer stage II	PT
10001251	Adenosquamous cell lung cancer stage III	PT
10001254	Adenosquamous cell lung cancer stage IV	PT
10001388	Adrenocortical carcinoma	PT
10001413	Adult T-cell lymphoma/leukaemia	PT
10001416	Adult T-cell lymphoma/leukaemia recurrent	PT
10001417	Adult T-cell lymphoma/leukaemia refractory	PT
10001418	Adult T-cell lymphoma/leukaemia stage I	PT
10001419	Adult T-cell lymphoma/leukaemia stage II	PT
10001420	Adult T-cell lymphoma/leukaemia stage III	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10001421	Adult T-cell lymphoma/leukaemia stage IV	PT
10001433	Aesthesioneuroblastoma	PT
10001660	Aleukaemic leukaemia	PT
10001882	Alveolar soft part sarcoma	PT
10001884	Alveolar soft part sarcoma metastatic	PT
10001887	Alveolar soft part sarcoma recurrent	PT
10002133	Anal cancer recurrent	PT
10002134	Anal cancer stage 0	PT
10002135	Anal cancer stage I	PT
10002136	Anal cancer stage II	PT
10002137	Anal cancer stage III	PT
10002138	Anal cancer stage IV	PT
10002224	Anaplastic astrocytoma	PT
10002227	Anaplastic large cell lymphoma T- and null-cell types	PT
10002229	Anaplastic large cell lymphoma T- and null-cell types recurrent	PT
10002230	Anaplastic large cell lymphoma T- and null-cell types refractory	PT
10002231	Anaplastic large cell lymphoma T- and null-cell types stage I	PT
10002232	Anaplastic large cell lymphoma T- and null-cell types stage II	PT
10002233	Anaplastic large cell lymphoma T- and null-cell types stage III	PT
10002234	Anaplastic large cell lymphoma T- and null-cell types stage IV	PT
10002240	Anaplastic thyroid cancer	PT
10002411	Angiocentric lymphoma	PT
10002414	Angiocentric lymphoma recurrent	PT
10002415	Angiocentric lymphoma refractory	PT
10002416	Angiocentric lymphoma stage I	PT
10002417	Angiocentric lymphoma stage II	PT
10002418	Angiocentric lymphoma stage III	PT
10002419	Angiocentric lymphoma stage IV	PT
10002449	Angioimmunoblastic T-cell lymphoma	PT
10002452	Angioimmunoblastic T-cell lymphoma recurrent	PT
10002453	Angioimmunoblastic T-cell lymphoma refractory	PT
10002454	Angioimmunoblastic T-cell lymphoma stage I	PT
10002455	Angioimmunoblastic T-cell lymphoma stage II	PT
10002456	Angioimmunoblastic T-cell lymphoma stage III	PT
10002457	Angioimmunoblastic T-cell lymphoma stage IV	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10002476	Angiosarcoma	PT
10002477	Angiosarcoma metastatic	PT
10002480	Angiosarcoma recurrent	PT
10003506	Aspiration bone marrow abnormal	PT
10003571	Astrocytoma	PT
10003890	B precursor type acute leukaemia	PT
10003899	B-cell lymphoma	PT
10003902	B-cell lymphoma recurrent	PT
10003903	B-cell lymphoma refractory	PT
10003904	B-cell lymphoma stage I	PT
10003905	B-cell lymphoma stage II	PT
10003906	B-cell lymphoma stage III	PT
10003907	B-cell lymphoma stage IV	PT
10003908	B-cell small lymphocytic lymphoma	PT
10003911	B-cell small lymphocytic lymphoma recurrent	PT
10003912	B-cell small lymphocytic lymphoma refractory	PT
10003913	B-cell small lymphocytic lymphoma stage I	PT
10003914	B-cell small lymphocytic lymphoma stage II	PT
10003915	B-cell small lymphocytic lymphoma stage III	PT
10003916	B-cell small lymphocytic lymphoma stage IV	PT
10003917	B-cell type acute leukaemia	PT
10003922	B-cell unclassifiable lymphoma high grade	PT
10003923	B-cell unclassifiable lymphoma low grade	PT
10004585	Bile duct adenocarcinoma	PT
10004589	Bile duct adenosquamous carcinoma	PT
10004593	Bile duct cancer	PT
10004596	Bile duct cancer recurrent	PT
10004633	Bile duct squamous cell carcinoma	PT
10004738	Biopsy bone marrow abnormal	PT
10004798	Biopsy lymph gland abnormal	PT
10004986	Bladder adenocarcinoma recurrent	PT
10004987	Bladder adenocarcinoma stage 0	PT
10004988	Bladder adenocarcinoma stage I	PT
10004989	Bladder adenocarcinoma stage II	PT
10004990	Bladder adenocarcinoma stage III	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10004991	Bladder adenocarcinoma stage IV	PT
10004992	Bladder adenocarcinoma stage unspecified	PT
10005003	Bladder cancer	PT
10005005	Bladder cancer recurrent	PT
10005006	Bladder cancer stage 0, with cancer in situ	PT
10005007	Bladder cancer stage 0, without cancer in situ	PT
10005008	Bladder cancer stage I, with cancer in situ	PT
10005009	Bladder cancer stage I, without cancer in situ	PT
10005010	Bladder cancer stage II	PT
10005011	Bladder cancer stage III	PT
10005012	Bladder cancer stage IV	PT
10005075	Bladder squamous cell carcinoma recurrent	PT
10005076	Bladder squamous cell carcinoma stage 0	PT
10005077	Bladder squamous cell carcinoma stage I	PT
10005078	Bladder squamous cell carcinoma stage II	PT
10005079	Bladder squamous cell carcinoma stage III	PT
10005080	Bladder squamous cell carcinoma stage IV	PT
10005081	Bladder squamous cell carcinoma stage unspecified	PT
10005084	Bladder transitional cell carcinoma	PT
10005949	Bone cancer	PT
10006007	Bone sarcoma	PT
10006032	Borderline ovarian tumour	PT
10006131	Brain neoplasm malignant	PT
10006143	Brain stem glioma	PT
10006187	Breast cancer	PT
10006189	Breast cancer in situ	PT
10006198	Breast cancer recurrent	PT
10006199	Breast cancer stage I	PT
10006200	Breast cancer stage II	PT
10006201	Breast cancer stage III	PT
10006202	Breast cancer stage IV	PT
10006417	Bronchial carcinoma	PT
10006595	Burkitt's lymphoma	PT
10006598	Burkitt's lymphoma recurrent	PT
10006599	Burkitt's lymphoma refractory	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10006600	Burkitt's lymphoma stage I	PT
10006601	Burkitt's lymphoma stage II	PT
10006602	Burkitt's lymphoma stage III	PT
10006603	Burkitt's lymphoma stage IV	PT
10007275	Carcinoid tumour	PT
10007279	Carcinoid tumour of the gastrointestinal tract	PT
10007280	Carcinoid tumour of the prostate	PT
10007281	Carcinoid tumour of the stomach	PT
10007282	Carcinoid tumour pulmonary	PT
10007368	Carcinoma in situ of eye	PT
10007384	Carcinoma in situ of penis	PT
10007401	Carcinoma in situ of trachea	PT
10007953	Central nervous system lymphoma	PT
10008342	Cervix carcinoma	PT
10008344	Cervix carcinoma recurrent	PT
10008345	Cervix carcinoma stage I	PT
10008346	Cervix carcinoma stage II	PT
10008347	Cervix carcinoma stage III	PT
10008348	Cervix carcinoma stage IV	PT
10008583	Chloroma	PT
10008584	Chloroma (in remission)	PT
10008593	Cholangiocarcinoma	PT
10008734	Chondrosarcoma	PT
10008736	Chondrosarcoma metastatic	PT
10008738	Chondrosarcoma recurrent	PT
10008747	Chordoma	PT
10008757	Choriocarcinoma	PT
10008773	Choroid melanoma	PT
10008943	Chronic leukaemia	PT
10008958	Chronic lymphocytic leukaemia	PT
10008959	Chronic lymphocytic leukaemia (in remission)	PT
10008961	Chronic lymphocytic leukaemia recurrent	PT
10008962	Chronic lymphocytic leukaemia refractory	PT
10008963	Chronic lymphocytic leukaemia stage 0	PT
10008964	Chronic lymphocytic leukaemia stage 1	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10008965	Chronic lymphocytic leukaemia stage 2	PT
10008966	Chronic lymphocytic leukaemia stage 3	PT
10008967	Chronic lymphocytic leukaemia stage 4	PT
10009013	Chronic myeloid leukaemia	PT
10009014	Chronic myeloid leukaemia (in remission)	PT
10009018	Chronic myelomonocytic leukaemia	PT
10009019	Chronic myelomonocytic leukaemia (in remission)	PT
10009252	Clear cell endometrial carcinoma	PT
10009253	Clear cell sarcoma of the kidney	PT
10009944	Colon cancer	PT
10009952	Colon cancer recurrent	PT
10009953	Colon cancer stage I	PT
10009954	Colon cancer stage II	PT
10009955	Colon cancer stage III	PT
10009956	Colon cancer stage IV	PT
10010030	Colorectal cancer recurrent	PT
10010032	Colorectal cancer stage I	PT
10010033	Colorectal cancer stage II	PT
10010034	Colorectal cancer stage III	PT
10010035	Colorectal cancer stage IV	PT
10010038	Colorectal carcinoma stage 0	PT
10011548	CSF lymphocyte count abnormal	PT
10011549	CSF lymphocyte count increased	PT
10011683	Cutaneous T-cell lymphoma stage IV	PT
10012818	Diffuse large B-cell lymphoma	PT
10012821	Diffuse large B-cell lymphoma recurrent	PT
10012822	Diffuse large B-cell lymphoma refractory	PT
10012823	Diffuse large B-cell lymphoma stage I	PT
10012824	Diffuse large B-cell lymphoma stage II	PT
10012825	Diffuse large B-cell lymphoma stage III	PT
10012826	Diffuse large B-cell lymphoma stage IV	PT
10014720	Endometrial adenocarcinoma	PT
10014733	Endometrial cancer	PT
10014734	Endometrial cancer metastatic	PT
10014736	Endometrial cancer recurrent	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10014737	Endometrial cancer stage 0	PT
10014738	Endometrial cancer stage I	PT
10014739	Endometrial cancer stage II	PT
10014740	Endometrial cancer stage III	PT
10014741	Endometrial cancer stage IV	PT
10014958	Eosinophilic leukaemia	PT
10014968	Ependymoma malignant	PT
10015099	Epithelioid sarcoma	PT
10015101	Epithelioid sarcoma metastatic	PT
10015104	Epithelioid sarcoma recurrent	PT
10015246	Erythraemic myelosis (in remission)	PT
10015493	Essential thrombocythaemia	PT
10015560	Ewing's sarcoma	PT
10015562	Ewing's sarcoma metastatic	PT
10015564	Ewing's sarcoma recurrent	PT
10015759	Extra-osseous Ewing's sarcoma	PT
10015761	Extra-osseous Ewing's sarcoma metastatic	PT
10015764	Extra-osseous Ewing's sarcoma recurrent	PT
10015789	Extragonadal primary embryonal carcinoma	PT
10015800	Extragonadal primary germ cell tumour mixed stage I	PT
10015801	Extragonadal primary germ cell tumour mixed stage II	PT
10015802	Extragonadal primary germ cell tumour mixed stage III	PT
10015805	Extragonadal primary non-seminoma stage I	PT
10015806	Extragonadal primary non-seminoma stage II	PT
10015809	Extragonadal primary non-seminoma stage III	PT
10015810	Extragonadal primary non-seminoma stage IV	PT
10015811	Extragonadal primary seminoma (pure) stage I	PT
10015812	Extragonadal primary seminoma (pure) stage II	PT
10015815	Extragonadal primary seminoma (pure) stage III	PT
10015816	Extragonadal primary seminoma (pure) stage IV	PT
10015823	Extranodal marginal zone B-cell lymphoma (MALT type) recurrent	PT
10015824	Extranodal marginal zone B-cell lymphoma (MALT type) refractory	PT
10015825	Extranodal marginal zone B-cell lymphoma (MALT type) stage I	PT
10015826	Extranodal marginal zone B-cell lymphoma (MALT type) stage II	PT
10015827	Extranodal marginal zone B-cell lymphoma (MALT type) stage III	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10015828	Extranodal marginal zone B-cell lymphoma (MALT type) stage IV	PT
10015831	Extraocular retinoblastoma	PT
10015840	Extraskeletal chondrosarcoma metastatic	PT
10015843	Extraskeletal chondrosarcoma recurrent	PT
10015847	Extraskeletal osteosarcoma	PT
10015849	Extraskeletal osteosarcoma metastatic	PT
10015852	Extraskeletal osteosarcoma recurrent	PT
10016180	Fallopian tube cancer	PT
10016182	Fallopian tube cancer metastatic	PT
10016184	Fallopian tube cancer stage I	PT
10016185	Fallopian tube cancer stage II	PT
10016186	Fallopian tube cancer stage III	PT
10016187	Fallopian tube cancer stage IV	PT
10016632	Fibrosarcoma	PT
10016635	Fibrosarcoma metastatic	PT
10016897	Follicle centre lymphoma diffuse small cell lymphoma recurrent	PT
10016898	Follicle centre lymphoma diffuse small cell lymphoma refractory	PT
10016899	Follicle centre lymphoma diffuse small cell lymphoma stage I	PT
10016900	Follicle centre lymphoma diffuse small cell lymphoma stage II	PT
10016901	Follicle centre lymphoma diffuse small cell lymphoma stage III	PT
10016902	Follicle centre lymphoma diffuse small cell lymphoma stage IV	PT
10016905	Follicle centre lymphoma, follicular grade I, II, III recurrent	PT
10016906	Follicle centre lymphoma, follicular grade I, II, III refractory	PT
10016907	Follicle centre lymphoma, follicular grade I, II, III stage I	PT
10016908	Follicle centre lymphoma, follicular grade I, II, III stage II	PT
10016909	Follicle centre lymphoma, follicular grade I, II, III stage III	PT
10016910	Follicle centre lymphoma, follicular grade I, II, III stage IV	PT
10016935	Follicular thyroid cancer	PT
10017614	Gallbladder cancer	PT
10017619	Gallbladder cancer recurrent	PT
10017701	Ganglioglioma	PT
10017708	Ganglioneuroblastoma	PT
10017758	Gastric cancer	PT
10017761	Gastric cancer recurrent	PT
10017762	Gastric cancer stage 0	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10017763	Gastric cancer stage I	PT
10017764	Gastric cancer stage II	PT
10017765	Gastric cancer stage III	PT
10017940	Gastrointestinal carcinoma	PT
10017973	Gastrointestinal lymphoma	PT
10018160	Genital neoplasm malignant female	PT
10018336	Glioblastoma	PT
10018337	Glioblastoma multiforme	PT
10018338	Glioma	PT
10018340	Gliosarcoma	PT
10018395	Glottis carcinoma	PT
10018404	Glucagonoma	PT
10018825	Haemangiopericytoma	PT
10018826	Haemangiopericytoma of meninges	PT
10019053	Hairy cell leukaemia	PT
10019823	Hepatoblastoma recurrent	PT
10020067	High grade B-cell lymphoma Burkitt-like lymphoma	PT
10020070	High grade B-cell lymphoma Burkitt-like lymphoma recurrent	PT
10020071	High grade B-cell lymphoma Burkitt-like lymphoma refractory	PT
10020072	High grade B-cell lymphoma Burkitt-like lymphoma stage I	PT
10020073	High grade B-cell lymphoma Burkitt-like lymphoma stage II	PT
10020074	High grade B-cell lymphoma Burkitt-like lymphoma stage III	PT
10020075	High grade B-cell lymphoma Burkitt-like lymphoma stage IV	PT
10020206	Hodgkin's disease	PT
10020208	Hodgkin's disease lymphocyte depletion stage I site unspecified	PT
10020209	Hodgkin's disease lymphocyte depletion stage I subdiaphragm	PT
10020210	Hodgkin's disease lymphocyte depletion stage I supradiaphragm	PT
10020211	Hodgkin's disease lymphocyte depletion stage II site unspecified	PT
10020212	Hodgkin's disease lymphocyte depletion stage II subdiaphragm	PT
10020213	Hodgkin's disease lymphocyte depletion stage II supradiaphragm	PT
10020215	Hodgkin's disease lymphocyte depletion type recurrent	PT
10020216	Hodgkin's disease lymphocyte depletion type refractory	PT
10020217	Hodgkin's disease lymphocyte depletion type stage III	PT
10020218	Hodgkin's disease lymphocyte depletion type stage IV	PT
10020219	Hodgkin's disease lymphocyte depletion type stage unspecified	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10020220	Hodgkin's disease lymphocyte predominance stage I site unspec	PT
10020221	Hodgkin's disease lymphocyte predominance stage I subdiaphragm	PT
10020222	Hodgkin's disease lymphocyte predominance stage I supradiaphragm	PT
10020223	Hodgkin's disease lymphocyte predominance stage II site unspec	PT
10020224	Hodgkin's disease lymphocyte predominance stage II subdiaphragm	PT
10020225	Hodgkin's disease lymphocyte predominance stage II supradiaphragm	PT
10020227	Hodgkin's disease lymphocyte predominance type recurrent	PT
10020228	Hodgkin's disease lymphocyte predominance type refractory	PT
10020229	Hodgkin's disease lymphocyte predominance type stage III	PT
10020230	Hodgkin's disease lymphocyte predominance type stage IV	PT
10020231	Hodgkin's disease lymphocyte predominance type stage unspecified	PT
10020233	Hodgkin's disease mixed cellularity recurrent	PT
10020234	Hodgkin's disease mixed cellularity refractory	PT
10020235	Hodgkin's disease mixed cellularity stage I site unspecified	PT
10020236	Hodgkin's disease mixed cellularity stage I subdiaphragmatic	PT
10020237	Hodgkin's disease mixed cellularity stage I supradiaphragmatic	PT
10020238	Hodgkin's disease mixed cellularity stage II subdiaphragmatic	PT
10020239	Hodgkin's disease mixed cellularity stage II supradiaphragmatic	PT
10020240	Hodgkin's disease mixed cellularity stage III	PT
10020241	Hodgkin's disease mixed cellularity stage IV	PT
10020242	Hodgkin's disease mixed cellularity stage unspecified	PT
10020244	Hodgkin's disease nodular sclerosis	PT
10020245	Hodgkin's disease nodular sclerosis recurrent	PT
10020246	Hodgkin's disease nodular sclerosis refractory	PT
10020252	Hodgkin's disease nodular sclerosis stage III	PT
10020253	Hodgkin's disease nodular sclerosis stage IV	PT
10020266	Hodgkin's disease recurrent	PT
10020267	Hodgkin's disease refractory	PT
10020268	Hodgkin's disease stage I	PT
10020269	Hodgkin's disease stage II	PT
10020270	Hodgkin's disease stage III	PT
10020271	Hodgkin's disease unclassifiable	PT
10020391	Hormone-secreting ovarian tumour	PT
10021042	Hypopharyngeal cancer	PT
10021044	Hypopharyngeal cancer recurrent	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10021045	Hypopharyngeal cancer stage 0	PT
10021046	Hypopharyngeal cancer stage I	PT
10021047	Hypopharyngeal cancer stage II	PT
10021048	Hypopharyngeal cancer stage III	PT
10021049	Hypopharyngeal cancer stage IV	PT
10021977	Inflammatory carcinoma of breast recurrent	PT
10021978	Inflammatory carcinoma of breast stage III	PT
10021979	Inflammatory carcinoma of breast stage IV	PT
10021980	Inflammatory carcinoma of the breast	PT
10022498	Insulinoma	PT
10022706	Intestinal T-cell lymphoma recurrent	PT
10022707	Intestinal T-cell lymphoma refractory	PT
10022708	Intestinal T-cell lymphoma stage I	PT
10022709	Intestinal T-cell lymphoma stage II	PT
10022710	Intestinal T-cell lymphoma stage III	PT
10022711	Intestinal T-cell lymphoma stage IV	PT
10022770	Intracranial meningioma malignant	PT
10023249	Juvenile chronic myelomonocytic leukaemia	PT
10023774	Large cell lung cancer	PT
10023775	Large cell lung cancer recurrent	PT
10023776	Large cell lung cancer stage 0	PT
10023777	Large cell lung cancer stage I	PT
10023778	Large cell lung cancer stage II	PT
10023779	Large cell lung cancer stage III	PT
10023780	Large cell lung cancer stage IV	PT
10023791	Large granular lymphocytosis	PT
10023825	Laryngeal cancer	PT
10023828	Laryngeal cancer recurrent	PT
10023829	Laryngeal cancer stage 0	PT
10023830	Laryngeal cancer stage I	PT
10023831	Laryngeal cancer stage II	PT
10023832	Laryngeal cancer stage III	PT
10023833	Laryngeal cancer stage IV	PT
10023841	Laryngeal neoplasm	PT
10023856	Laryngeal squamous cell carcinoma	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10024189	Leiomyosarcoma	PT
10024191	Leiomyosarcoma metastatic	PT
10024194	Leiomyosarcoma recurrent	PT
10024218	Lentigo maligna	PT
10024220	Lentigo maligna recurrent	PT
10024221	Lentigo maligna stage I	PT
10024222	Lentigo maligna stage II	PT
10024223	Lentigo maligna stage III	PT
10024224	Lentigo maligna stage IV	PT
10024288	Leukaemia	PT
10024293	Leukaemia basophilic	PT
10024299	Leukaemia granulocytic	PT
10024305	Leukaemia monocytic	PT
10024325	Leukaemic lymphoma	PT
10024407	Leydig cell tumour of the testis	PT
10024520	Linitis plastica	PT
10024535	Lip and/or oral cavity cancer recurrent	PT
10024536	Lip and/or oral cavity cancer stage 0	PT
10024537	Lip and/or oral cavity cancer stage I	PT
10024538	Lip and/or oral cavity cancer stage II	PT
10024539	Lip and/or oral cavity cancer stage III	PT
10024540	Lip and/or oral cavity cancer stage IV	PT
10024557	Lip neoplasm malignant stage unspecified	PT
10024627	Liposarcoma	PT
10024629	Liposarcoma metastatic	PT
10024632	Liposarcoma recurrent	PT
10025031	Lung adenocarcinoma	PT
10025033	Lung adenocarcinoma recurrent	PT
10025034	Lung adenocarcinoma stage 0	PT
10025035	Lung adenocarcinoma stage I	PT
10025036	Lung adenocarcinoma stage II	PT
10025037	Lung adenocarcinoma stage III	PT
10025038	Lung adenocarcinoma stage IV	PT
10025065	Lung carcinoma cell type unspecified recurrent	PT
10025066	Lung carcinoma cell type unspecified stage 0	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10025067	Lung carcinoma cell type unspecified stage I	PT
10025068	Lung carcinoma cell type unspecified stage II	PT
10025069	Lung carcinoma cell type unspecified stage III	PT
10025070	Lung carcinoma cell type unspecified stage IV	PT
10025120	Lung squamous cell carcinoma recurrent	PT
10025121	Lung squamous cell carcinoma stage 0	PT
10025122	Lung squamous cell carcinoma stage I	PT
10025123	Lung squamous cell carcinoma stage II	PT
10025124	Lung squamous cell carcinoma stage III	PT
10025125	Lung squamous cell carcinoma stage IV	PT
10025223	Lymphangiosarcoma	PT
10025270	Lymphocytic leukaemia	PT
10025300	Lymphoid leukaemia (in remission)	PT
10025310	Lymphoma	PT
10025312	Lymphoma AIDS related	PT
10025342	Lymphoplasmacytoid lymphoma/immunocytoma	PT
10025345	Lymphoplasmacytoid lymphoma/immunocytoma recurrent	PT
10025346	Lymphoplasmacytoid lymphoma/immunocytoma refractory	PT
10025347	Lymphoplasmacytoid lymphoma/immunocytoma stage I	PT
10025348	Lymphoplasmacytoid lymphoma/immunocytoma stage II	PT
10025349	Lymphoplasmacytoid lymphoma/immunocytoma stage III	PT
10025350	Lymphoplasmacytoid lymphoma/immunocytoma stage IV	PT
10025552	Malignant fibrous histiocytoma	PT
10025554	Malignant fibrous histiocytoma metastatic	PT
10025557	Malignant fibrous histiocytoma of bone	PT
10025561	Malignant fibrous histiocytoma recurrent	PT
10025566	Malignant haemangiopericytoma	PT
10025567	Malignant haemangiopericytoma metastatic	PT
10025570	Malignant haemangiopericytoma recurrent	PT
10025581	Malignant histiocytosis	PT
10025598	Malignant hydatidiform mole	PT
10025635	Malignant lymphoma unclassifiable high grade	PT
10025636	Malignant lymphoma unclassifiable low grade	PT
10025638	Malignant mast cell neoplasm	PT
10025650	Malignant melanoma	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10025652	Malignant melanoma in situ	PT
10025654	Malignant melanoma of sites other than skin	PT
10025668	Malignant melanoma stage I	PT
10025669	Malignant melanoma stage II	PT
10025670	Malignant melanoma stage III	PT
10025671	Malignant melanoma stage IV	PT
10025674	Malignant mesenchymoma metastatic	PT
10025677	Malignant mesenchymoma recurrent	PT
10025697	Malignant neoplasm of ampulla of Vater	PT
10025839	Malignant neoplasm of choroid	PT
10025861	Malignant neoplasm of conjunctiva	PT
10025871	Malignant neoplasm of cornea	PT
10025910	Malignant neoplasm of eye	PT
10025997	Malignant neoplasm of islets of Langerhans	PT
10026030	Malignant neoplasm of lacrimal duct	PT
10026031	Malignant neoplasm of lacrimal gland	PT
10026183	Malignant neoplasm of orbit	PT
10026326	Malignant neoplasm of paraurethral glands	PT
10026350	Malignant neoplasm of placenta	PT
10026351	Malignant neoplasm of pleura	PT
10026426	Malignant neoplasm of renal pelvis	PT
10026432	Malignant neoplasm of retina	PT
10026470	Malignant neoplasm of spermatic cord	PT
10026472	Malignant neoplasm of spinal cord	PT
10026532	Malignant neoplasm of thorax	PT
10026533	Malignant neoplasm of thymus	PT
10026616	Malignant neoplasm of uterine adnexa	PT
10026659	Malignant oligodendroglioma	PT
10026662	Malignant ovarian cyst	PT
10026663	Malignant palate neoplasm	PT
10026672	Malignant pituitary tumour	PT
10026702	Malignant splenic neoplasm	PT
10026800	Mantle cell lymphoma recurrent	PT
10026801	Mantle cell lymphoma refractory	PT
10026802	Mantle cell lymphoma stage I	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10026803	Mantle cell lymphoma stage II	PT
10026804	Mantle cell lymphoma stage III	PT
10026805	Mantle cell lymphoma stage IV	PT
10026945	Mature B-cell type acute leukaemia	PT
10027095	Medullary carcinoma of breast	PT
10027105	Medullary thyroid cancer	PT
10027107	Medulloblastoma	PT
10027193	Meningioma malignant	PT
10027406	Mesothelioma	PT
10027407	Mesothelioma malignant	PT
10027411	Mesothelioma malignant recurrent	PT
10027450	Metastases to abdominal cavity	PT
10027451	Metastases to adrenals	PT
10027452	Metastases to bone	PT
10027454	Metastases to breast	PT
10027455	Metastases to kidney	PT
10027457	Metastases to liver	PT
10027458	Metastases to lung	PT
10027459	Metastases to lymph nodes	PT
10027460	Metastases to neck	PT
10027462	Metastases to ovary	PT
10027463	Metastases to pleura	PT
10027465	Metastases to skin	PT
10027468	Metastases to spine	PT
10027469	Metastases to the mediastinum	PT
10027480	Metastatic malignant melanoma	PT
10027761	Mixed hepatocellular cholangiocarcinoma	PT
10028076	Mucinous endometrial carcinoma	PT
10028533	Myelodysplastic syndrome	PT
10028535	Myelodysplastic syndrome unclassifiable	PT
10028537	Myelofibrosis	PT
10028549	Myeloid leukaemia	PT
10028561	Myeloid metaplasia	PT
10028729	Nasal cavity cancer	PT
10028767	Nasal sinus cancer	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10028787	Nasopharyngeal cancer recurrent	PT
10028788	Nasopharyngeal cancer stage 0	PT
10028789	Nasopharyngeal cancer stage I	PT
10028790	Nasopharyngeal cancer stage II	PT
10028791	Nasopharyngeal cancer stage III	PT
10028792	Nasopharyngeal cancer stage IV	PT
10028811	Natural killer-cell leukaemia	PT
10028997	Neoplasm malignant	PT
10029145	Nephroblastoma	PT
10029260	Neuroblastoma	PT
10029274	Neurofibrosarcoma metastatic	PT
10029277	Neurofibrosarcoma recurrent	PT
10029341	Neurotensinoma	PT
10029460	Nodal marginal zone B-cell lymphoma	PT
10029463	Nodal marginal zone B-cell lymphoma recurrent	PT
10029464	Nodal marginal zone B-cell lymphoma refractory	PT
10029465	Nodal marginal zone B-cell lymphoma stage I	PT
10029466	Nodal marginal zone B-cell lymphoma stage II	PT
10029467	Nodal marginal zone B-cell lymphoma stage III	PT
10029468	Nodal marginal zone B-cell lymphoma stage IV	PT
10029488	Nodular melanoma	PT
10029515	Non-small cell lung cancer recurrent	PT
10029516	Non-small cell lung cancer stage 0	PT
10029517	Non-small cell lung cancer stage I	PT
10029518	Non-small cell lung cancer stage II	PT
10029519	Non-small cell lung cancer stage III	PT
10029520	Non-small cell lung cancer stage IIIA	PT
10029521	Non-small cell lung cancer stage IIIB	PT
10029522	Non-small cell lung cancer stage IV	PT
10029547	Non-Hodgkin's lymphoma	PT
10029600	Non-Hodgkin's lymphoma recurrent	PT
10029601	Non-Hodgkin's lymphoma refractory	PT
10029602	Non-Hodgkin's lymphoma stage I	PT
10029603	Non-Hodgkin's lymphoma stage II	PT
10029604	Non-Hodgkin's lymphoma stage III	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10029605	Non-Hodgkin's lymphoma stage IV	PT
10029609	Non-Hodgkin's lymphoma unspecified histology aggressive recurrent	PT
10029610	Non-Hodgkin's lymphoma unspecified histology aggressive refractory	PT
10029611	Non-Hodgkin's lymphoma unspecified histology aggressive stage I	PT
10029612	Non-Hodgkin's lymphoma unspecified histology aggressive stage II	PT
10029613	Non-Hodgkin's lymphoma unspecified histology aggressive stage III	PT
10029614	Non-Hodgkin's lymphoma unspecified histology aggressive stage IV	PT
10029622	Non-Hodgkin's lymphoma unspecified histology indolent stage I	PT
10029623	Non-Hodgkin's lymphoma unspecified histology indolent stage II	PT
10029624	Non-Hodgkin's lymphoma unspecified histology indolent stage III	PT
10029625	Non-Hodgkin's lymphoma unspecified histology indolent stage IV	PT
10030137	Oesophageal adenocarcinoma	PT
10030140	Oesophageal adenocarcinoma recurrent	PT
10030141	Oesophageal adenocarcinoma stage 0	PT
10030142	Oesophageal adenocarcinoma stage I	PT
10030143	Oesophageal adenocarcinoma stage II	PT
10030144	Oesophageal adenocarcinoma stage III	PT
10030145	Oesophageal adenocarcinoma stage IV	PT
10030155	Oesophageal carcinoma	PT
10030159	Oesophageal carcinoma recurrent	PT
10030162	Oesophageal carcinoma stage 0	PT
10030187	Oesophageal squamous cell carcinoma recurrent	PT
10030188	Oesophageal squamous cell carcinoma stage 0	PT
10030189	Oesophageal squamous cell carcinoma stage I	PT
10030190	Oesophageal squamous cell carcinoma stage II	PT
10030191	Oesophageal squamous cell carcinoma stage III	PT
10030192	Oesophageal squamous cell carcinoma stage IV	PT
10030286	Oligodendroglioma	PT
10031096	Oropharyngeal cancer	PT
10031098	Oropharyngeal cancer recurrent	PT
10031099	Oropharyngeal cancer stage 0	PT
10031100	Oropharyngeal cancer stage I	PT
10031101	Oropharyngeal cancer stage II	PT
10031102	Oropharyngeal cancer stage III	PT
10031104	Oropharyngeal lymphoepithelioma	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10031112	Oropharyngeal squamous cell carcinoma	PT
10031291	Osteosarcoma	PT
10031294	Osteosarcoma metastatic	PT
10031296	Osteosarcoma recurrent	PT
10033128	Ovarian cancer	PT
10033144	Ovarian dysgerminoma stage I	PT
10033148	Ovarian dysgerminoma stage II	PT
10033152	Ovarian dysgerminoma stage III	PT
10033156	Ovarian dysgerminoma stage IV	PT
10033158	Ovarian epithelial cancer metastatic	PT
10033160	Ovarian epithelial cancer recurrent	PT
10033161	Ovarian epithelial cancer stage I	PT
10033162	Ovarian epithelial cancer stage II	PT
10033163	Ovarian epithelial cancer stage III	PT
10033164	Ovarian epithelial cancer stage IV	PT
10033183	Ovarian germ cell choriocarcinoma stage I	PT
10033187	Ovarian germ cell choriocarcinoma stage II	PT
10033191	Ovarian germ cell choriocarcinoma stage III	PT
10033195	Ovarian germ cell choriocarcinoma stage IV	PT
10033196	Ovarian germ cell embryonal carcinoma stage I	PT
10033200	Ovarian germ cell embryonal carcinoma stage II	PT
10033204	Ovarian germ cell embryonal carcinoma stage III	PT
10033208	Ovarian germ cell embryonal carcinoma stage IV	PT
10033218	Ovarian germ cell endodermal sinus tumour stage I	PT
10033219	Ovarian germ cell endodermal sinus tumour stage II	PT
10033220	Ovarian germ cell endodermal sinus tumour stage III	PT
10033221	Ovarian germ cell endodermal sinus tumour stage IV	PT
10033223	Ovarian germ cell polyembryoma stage I	PT
10033227	Ovarian germ cell polyembryoma stage II	PT
10033231	Ovarian germ cell polyembryoma stage III	PT
10033235	Ovarian germ cell polyembryoma stage IV	PT
10033237	Ovarian germ cell teratoma stage I	PT
10033241	Ovarian germ cell teratoma stage II	PT
10033245	Ovarian germ cell teratoma stage III	PT
10033249	Ovarian germ cell teratoma stage IV	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10033268	Ovarian low malignant potential tumour	PT
10033364	Paget's disease of nipple	PT
10033365	Paget's disease of penis	PT
10033369	Paget's disease of the vulva	PT
10033572	Pancoast's tumour	PT
10033609	Pancreatic carcinoma	PT
10033610	Pancreatic carcinoma metastatic	PT
10033613	Pancreatic carcinoma recurrent	PT
10033700	Papillary serous endometrial carcinoma	PT
10033701	Papillary thyroid cancer	PT
10033791	Paraganglion neoplasm malignant	PT
10033855	Paranasal sinus and nasal cavity malignant neoplasm recurrent	PT
10033856	Paranasal sinus and nasal cavity malignant neoplasm stage 0	PT
10033857	Paranasal sinus and nasal cavity malignant neoplasm stage I	PT
10033858	Paranasal sinus and nasal cavity malignant neoplasm stage II	PT
10033859	Paranasal sinus and nasal cavity malignant neoplasm stage III	PT
10033860	Paranasal sinus and nasal cavity malignant neoplasm stage IV	PT
10033965	Parathyroid tumour malignant	PT
10034299	Penile cancer	PT
10034329	Penis carcinoma metastatic	PT
10034331	Penis carcinoma recurrent	PT
10034332	Penis carcinoma stage I	PT
10034333	Penis carcinoma stage II	PT
10034334	Penis carcinoma stage III	PT
10034335	Penis carcinoma stage IV	PT
10034480	Pericardial mesothelioma malignant recurrent	PT
10034603	Peripheral neuroepithelioma of bone metastatic	PT
10034605	Peripheral neuroepithelioma of bone recurrent	PT
10034623	Peripheral T-cell lymphoma unspecified	PT
10034625	Peripheral T-cell lymphoma unspecified recurrent	PT
10034626	Peripheral T-cell lymphoma unspecified refractory	PT
10034627	Peripheral T-cell lymphoma unspecified stage I	PT
10034628	Peripheral T-cell lymphoma unspecified stage II	PT
10034629	Peripheral T-cell lymphoma unspecified stage III	PT
10034630	Peripheral T-cell lymphoma unspecified stage IV	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10034671	Peritoneal mesothelioma malignant recurrent	PT
10034811	Pharyngeal cancer	PT
10034813	Pharyngeal cancer recurrent	PT
10034814	Pharyngeal cancer stage 0	PT
10034815	Pharyngeal cancer stage I	PT
10034816	Pharyngeal cancer stage II	PT
10034817	Pharyngeal cancer stage III	PT
10034818	Pharyngeal cancer stage IV	PT
10035052	Pineal germinoma	PT
10035222	Plasma cell leukaemia	PT
10035226	Plasma cell myeloma	PT
10035484	Plasmacytoma	PT
10035603	Pleural mesothelioma	PT
10035607	Pleural mesothelioma malignant recurrent	PT
10036057	Polycythaemia vera	PT
10036334	Postcricoid cancer	PT
10036523	Precursor B-lymphoblastic lymphoma	PT
10036532	Precursor B-lymphoblastic lymphoma stage I	PT
10036533	Precursor B-lymphoblastic lymphoma stage II	PT
10036534	Precursor B-lymphoblastic lymphoma stage III	PT
10036535	Precursor B-lymphoblastic lymphoma stage IV	PT
10036543	Precursor T-lymphoblastic lymphoma/leukaemia	PT
10036546	Precursor T-lymphoblastic lymphoma/leukaemia recurrent	PT
10036547	Precursor T-lymphoblastic lymphoma/leukaemia refractory	PT
10036548	Precursor T-lymphoblastic lymphoma/leukaemia stage I	PT
10036549	Precursor T-lymphoblastic lymphoma/leukaemia stage II	PT
10036550	Precursor T-lymphoblastic lymphoma/leukaemia stage III	PT
10036551	Precursor T-lymphoblastic lymphoma/leukaemia stage IV	PT
10036710	Primary mediastinal large B-cell lymphoma	PT
10036713	Primary mediastinal large B-cell lymphoma recurrent	PT
10036714	Primary mediastinal large B-cell lymphoma refractory	PT
10036715	Primary mediastinal large B-cell lymphoma stage I	PT
10036716	Primary mediastinal large B-cell lymphoma stage II	PT
10036717	Primary mediastinal large B-cell lymphoma stage III	PT
10036718	Primary mediastinal large B-cell lymphoma stage IV	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10036888	Prolymphocytic leukaemia	PT
10036909	Prostate cancer metastatic	PT
10036911	Prostate cancer recurrent	PT
10036912	Prostate cancer stage 0	PT
10036917	Prostate cancer stage I	PT
10036918	Prostate cancer stage II	PT
10036919	Prostate cancer stage III	PT
10036920	Prostate cancer stage IV	PT
10038019	Rectal adenocarcinoma	PT
10038038	Rectal cancer	PT
10038046	Rectal cancer recurrent	PT
10038047	Rectal cancer stage 0	PT
10038048	Rectal cancer stage I	PT
10038049	Rectal cancer stage II	PT
10038050	Rectal cancer stage III	PT
10038051	Rectal cancer stage IV	PT
10038086	Rectosigmoid cancer	PT
10038094	Rectosigmoid cancer recurrent	PT
10038095	Rectosigmoid cancer stage 0	PT
10038096	Rectosigmoid cancer stage I	PT
10038097	Rectosigmoid cancer stage II	PT
10038098	Rectosigmoid cancer stage III	PT
10038099	Rectosigmoid cancer stage IV	PT
10038111	Recurrent cancer	PT
10038270	Refractory anaemia with an excess of blasts	PT
10038272	Refractory anaemia with ringed sideroblasts	PT
10038389	Renal cancer	PT
10038390	Renal cancer recurrent	PT
10038391	Renal cancer stage I	PT
10038392	Renal cancer stage II	PT
10038393	Renal cancer stage III	PT
10038394	Renal cancer stage IV	PT
10038410	Renal cell carcinoma recurrent	PT
10038411	Renal cell carcinoma stage I	PT
10038412	Renal cell carcinoma stage II	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10038413	Renal cell carcinoma stage III	PT
10038414	Renal cell carcinoma stage IV	PT
10038724	Respiratory tract carcinoma in situ	PT
10038878	Retinal melanoma	PT
10038916	Retinoblastoma	PT
10038977	Retroperitoneal cancer	PT
10039019	Rhabdoid tumour of the kidney	PT
10039022	Rhabdomyosarcoma	PT
10039027	Rhabdomyosarcoma recurrent	PT
10039398	Salivary gland cancer recurrent	PT
10039399	Salivary gland cancer stage 0	PT
10039400	Salivary gland cancer stage I	PT
10039401	Salivary gland cancer stage II	PT
10039402	Salivary gland cancer stage III	PT
10039403	Salivary gland cancer stage IV	PT
10039491	Sarcoma	PT
10039497	Sarcoma uterus	PT
10039500	Sarcomatosis	PT
10039744	Scrotal cancer	PT
10039801	Second primary malignancy	PT
10039956	Seminoma	PT
10041056	Small cell carcinoma	PT
10041057	Small cell carcinoma of the cervix	PT
10041067	Small cell lung cancer	PT
10041068	Small cell lung cancer extensive stage	PT
10041069	Small cell lung cancer limited stage	PT
10041070	Small cell lung cancer recurrent	PT
10041121	Small intestine carcinoma metastatic	PT
10041124	Small intestine carcinoma recurrent	PT
10041127	Small intestine leiomyosarcoma	PT
10041329	Somatostatinoma	PT
10041580	Spinal meningioma malignant	PT
10041652	Splenic marginal zone lymphoma recurrent	PT
10041653	Splenic marginal zone lymphoma refractory	PT
10041654	Splenic marginal zone lymphoma stage I	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10041655	Splenic marginal zone lymphoma stage II	PT
10041656	Splenic marginal zone lymphoma stage III	PT
10041657	Splenic marginal zone lymphoma stage IV	PT
10041826	Squamous cell carcinoma of lung	PT
10041848	Squamous cell carcinoma of the cervix	PT
10041849	Squamous cell carcinoma of the hypopharynx	PT
10041857	Squamous cell carcinoma of the oral cavity	PT
10041865	Squamous cell carcinoma of the tongue	PT
10041866	Squamous cell carcinoma of the vagina	PT
10041875	Squamous cell carcinoma of the vulva	PT
10041883	Squamous endometrial carcinoma	PT
10042549	Superficial spreading melanoma stage I	PT
10042550	Superficial spreading melanoma stage II	PT
10042551	Superficial spreading melanoma stage III	PT
10042552	Superficial spreading melanoma stage IV	PT
10042553	Superficial spreading melanoma stage unspecified	PT
10042863	Synovial sarcoma	PT
10042864	Synovial sarcoma metastatic	PT
10042867	Synovial sarcoma recurrent	PT
10042970	T-cell chronic lymphocytic leukaemia	PT
10042971	T-cell lymphoma	PT
10042979	T-cell lymphoma recurrent	PT
10042980	T-cell lymphoma refractory	PT
10042981	T-cell lymphoma stage I	PT
10042982	T-cell lymphoma stage II	PT
10042983	T-cell lymphoma stage III	PT
10042984	T-cell lymphoma stage IV	PT
10042985	T-cell prolymphocytic leukaemia	PT
10042987	T-cell type acute leukaemia	PT
10042989	T-cell unclassifiable lymphoma high grade	PT
10042990	T-cell unclassifiable lymphoma low grade	PT
10043303	Testicular choriocarcinoma stage I	PT
10043304	Testicular choriocarcinoma stage II	PT
10043305	Testicular choriocarcinoma stage III	PT
10043309	Testicular embryonal carcinoma stage I	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10043310	Testicular embryonal carcinoma stage II	PT
10043311	Testicular embryonal carcinoma stage III	PT
10043331	Testicular germ cell tumour mixed stage I	PT
10043332	Testicular germ cell tumour mixed stage II	PT
10043333	Testicular germ cell tumour mixed stage III	PT
10043339	Testicular malignant teratoma stage I	PT
10043340	Testicular malignant teratoma stage II	PT
10043341	Testicular malignant teratoma stage III	PT
10043350	Testicular seminoma (pure) stage I	PT
10043351	Testicular seminoma (pure) stage II	PT
10043352	Testicular seminoma (pure) stage III	PT
10043357	Testicular yolk sac tumour stage I	PT
10043358	Testicular yolk sac tumour stage II	PT
10043359	Testicular yolk sac tumour stage III	PT
10043515	Throat cancer	PT
10043581	Thrombophlebitis migrans	PT
10043674	Thymoma malignant recurrent	PT
10043966	Tongue neoplasm malignant stage unspecified	PT
10044002	Tonsil cancer	PT
10044285	Tracheal cancer	PT
10044406	Transitional cell cancer of renal pelvis and ureter metastatic	PT
10044407	Transitional cell cancer of the renal pelvis and ureter	PT
10044408	Transitional cell cancer of the renal pelvis and ureter localised	PT
10044410	Transitional cell cancer of the renal pelvis and ureter recurrent	PT
10044411	Transitional cell cancer of the renal pelvis and ureter regional	PT
10044412	Transitional cell carcinoma	PT
10044426	Transitional cell carcinoma urethra	PT
10045515	Undifferentiated sarcoma	PT
10046392	Ureteric cancer	PT
10046393	Ureteric cancer local	PT
10046394	Ureteric cancer metastatic	PT
10046396	Ureteric cancer recurrent	PT
10046397	Ureteric cancer regional	PT
10046431	Urethral cancer	PT
10046433	Urethral cancer metastatic	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10046435	Urethral cancer recurrent	PT
10046766	Uterine cancer	PT
10046770	Uterine carcinoma in situ	PT
10046799	Uterine leiomyosarcoma	PT
10046885	Vaginal cancer	PT
10046887	Vaginal cancer metastatic	PT
10046889	Vaginal cancer recurrent	PT
10046890	Vaginal cancer stage 0	PT
10046891	Vaginal cancer stage I	PT
10046892	Vaginal cancer stage II	PT
10046893	Vaginal cancer stage III	PT
10046894	Vaginal cancer stage IVA	PT
10046895	Vaginal cancer stage IVB	PT
10047430	Vipoma	PT
10047741	Vulval cancer	PT
10047742	Vulval cancer metastatic	PT
10047744	Vulval cancer recurrent	PT
10047745	Vulval cancer stage 0	PT
10047746	Vulval cancer stage I	PT
10047747	Vulval cancer stage II	PT
10047748	Vulval cancer stage III	PT
10047749	Vulval cancer stage IV	PT
10047801	Waldenstrom's macroglobulinaemia	PT
10047804	Waldenstrom's macroglobulinaemia recurrent	PT
10047805	Waldenstrom's macroglobulinaemia refractory	PT
10047806	Waldenstrom's macroglobulinaemia stage I	PT
10047807	Waldenstrom's macroglobulinaemia stage II	PT
10047808	Waldenstrom's macroglobulinaemia stage III	PT
10047809	Waldenstrom's macroglobulinaemia stage IV	PT
10048251	Yolk sac tumour site unspecified	PT
10048397	Endometrial stromal sarcoma	PT
10049067	Spindle cell sarcoma	PT
10049556	Bone marrow tumour cell infiltration	PT
10049557	Bone marrow leukaemic cell infiltration	PT
10049717	Metastases to heart	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10049718	Metastases to stomach	PT
10049721	Metastases to pancreas	PT
10049722	Metastases to bladder	PT
10049723	Metastases to thyroid	PT
10049724	Metastases to eye	PT
10049725	Metastases to placenta	PT
10049726	Metastases to uterus	PT
10049727	Metastases to fallopian tube	PT
10049728	Metastases to pituitary gland	PT
10049730	Metastases to muscle	PT
10050017	Lung cancer metastatic	PT
10050018	Renal cancer metastatic	PT
10050282	Blast crisis in myelogenous leukaemia	PT
10050487	Pinealoblastoma	PT
10050513	Metastatic renal cell carcinoma	PT
10051066	Gastrointestinal stromal tumour	PT
10051141	Myeloblastoma	PT
10051358	Post transplant lymphoproliferative disorder	PT
10051398	Malignant neoplasm progression	PT
10051662	Metastases to bone marrow	PT
10051663	Metastases to chest wall	PT
10051664	Metastases to abdominal wall	PT
10051665	Metastases to diaphragm	PT
10051666	Metastases to Eustachian tube	PT
10051667	Metastases to gallbladder	PT
10051668	Metastases to larynx	PT
10051669	Metastases to mouth	PT
10051670	Metastases to nasal sinuses	PT
10051671	Metastases to oesophagus	PT
10051672	Metastases to penis	PT
10051673	Metastases to perineum	PT
10051674	Metastases to peripheral nervous system	PT
10051676	Metastases to peritoneum	PT
10051677	Metastases to pharynx	PT
10051678	Metastases to prostate	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10051679	Metastases to rectum	PT
10051680	Metastases to retroperitoneum	PT
10051681	Metastases to salivary gland	PT
10051682	Metastases to spleen	PT
10051683	Metastases to testicle	PT
10051684	Metastases to thorax	PT
10051685	Metastases to trachea	PT
10051690	Urinary bladder sarcoma	PT
10051696	Metastases to meninges	PT
10051709	Gastrinoma malignant	PT
10051710	Phaeochromocytoma malignant	PT
10051807	Pseudosarcoma	PT
10051925	Intestinal adenocarcinoma	PT
10051949	Peritoneal sarcoma	PT
10051950	Pleural sarcoma	PT
10052178	Lymphocytic lymphoma	PT
10052358	Colorectal cancer metastatic	PT
10052360	Colorectal adenocarcinoma	PT
10052368	Leukaemic infiltration pulmonary	PT
10052399	Neuroendocrine tumour	PT
10052747	Adenocarcinoma pancreas	PT
10052759	Ovarian dysgerminoma stage unspecified	PT
10052819	Carcinoid tumour of the small bowel	PT
10052903	Neoplasm of cornea unspecified malignancy	PT
10052974	Lymphoma operation	PT
10052975	Lymphoid tissue operation	PT
10053128	Malignant nipple neoplasm male	PT
10053129	Malignant nipple neoplasm female	PT
10053132	Lymphangiosis carcinomatosa	PT
10053180	Leukaemia cutis	PT
10053190	Splenic neoplasm malignancy unspecified	PT
10053231	Adenoid cystic carcinoma	PT
10053504	Scan bone marrow abnormal	PT
10053548	Gastrointestinal cancer metastatic	PT
10053574	Immunoblastic lymphoma	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10053747	Blast cell crisis	PT
10054184	Small intestine carcinoma	PT
10054912	Cystadenocarcinoma ovary	PT
10054913	Serous cystadenocarcinoma ovary	PT
10054914	Mucinous cystadenocarcinoma ovary	PT
10054946	Malignant pericardial neoplasm	PT
10054951	Disseminated large cell lymphoma	PT
10055006	Pancreatic sarcoma	PT
10055007	Carcinoid tumour of the pancreas	PT
10055008	Gastric sarcoma	PT
10055017	Ear neoplasm malignant	PT
10055093	Brain cancer metastatic	PT
10055094	Cervix cancer metastatic	PT
10055095	Adrenal gland cancer metastatic	PT
10055096	Anal cancer metastatic	PT
10055097	Rectal cancer metastatic	PT
10055098	Oral cavity cancer metastatic	PT
10055099	Ocular cancer metastatic	PT
10055100	Otic cancer metastatic	PT
10055101	Bone cancer metastatic	PT
10055102	Oesophageal cancer metastatic	PT
10055103	Testicular cancer metastatic	PT
10055104	Pharyngeal cancer metastatic	PT
10055105	Sinus cancer metastatic	PT
10055106	Pituitary cancer metastatic	PT
10055107	Thyroid cancer metastatic	PT
10055108	Thymic cancer metastatic	PT
10055109	Tongue cancer metastatic	PT
10055110	Hepatic cancer metastatic	PT
10055111	Biliary cancer metastatic	PT
10055113	Breast cancer metastatic	PT
10055114	Colon cancer metastatic	PT
10055115	Skin cancer metastatic	PT
10056251	Metastases to urinary tract	PT
10056266	Ovarian embryonal carcinoma	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10056450	Mastocytic leukaemia	PT
10056558	Peritoneal mesothelioma malignant	PT
10056672	Neuroectodermal neoplasm	PT
10057194	Acute megakaryocytic leukaemia (in remission)	PT
10057266	Signet-ring cell carcinoma	PT
10057269	Mucoepidermoid carcinoma	PT
10057270	Neuroendocrine carcinoma	PT
10057340	Testicular leiomyosarcoma	PT
10057352	Metastatic carcinoma of the bladder	PT
10057376	Ovarian granulosa-theca cell tumour	PT
10057416	Ocular haemangiopericytoma	PT
10057529	Ovarian cancer metastatic	PT
10057644	Testis cancer	PT
10057646	Peripheral neuroepithelioma of soft tissue	PT
10057649	Endometrial sarcoma	PT
10057654	Breast cancer female	PT
10057700	Angiosarcoma non-metastatic	PT
10057838	Pituitary neoplasm malignant recurrent	PT
10057846	Primitive neuroectodermal tumour	PT
10058281	Gallbladder cancer stage II	PT
10058282	Gallbladder cancer stage III	PT
10058283	Gallbladder cancer stage IV	PT
10058286	Gallbladder adenocarcinoma	PT
10058306	Metastatic bronchial carcinoma	PT
10058307	Metastases to peripheral vascular system	PT
10058354	Bronchioloalveolar carcinoma	PT
10058429	Tongue carcinoma stage 0	PT
10058430	Tongue carcinoma stage I	PT
10058431	Tongue carcinoma stage II	PT
10058432	Tongue carcinoma stage III	PT
10058433	Tongue carcinoma stage IV	PT
10058467	Lung neoplasm malignant	PT
10058527	Oesophageal squamous cell carcinoma metastatic	PT
10058671	Leukaemic infiltration hepatic	PT
10058717	Chronic lymphocytic leukaemia transformation	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10058728	Richter's syndrome	PT
10058975	Natural killer-cell lymphoblastic lymphoma	PT
10059034	Acute myeloid leukaemia recurrent	PT
10059227	Biopsy spleen abnormal	PT
10059239	Leukaemic retinopathy	PT
10059282	Metastases to central nervous system	PT
10059316	Gallbladder cancer stage 0	PT
10059317	Gallbladder cancer stage I	PT
10059318	Hepatic cancer stage I	PT
10059319	Hepatic cancer stage II	PT
10059320	Pancreatic carcinoma stage 0	PT
10059321	Pancreatic carcinoma stage I	PT
10059322	Pancreatic carcinoma stage II	PT
10059323	Pancreatic carcinoma stage III	PT
10059324	Hepatic cancer stage III	PT
10059325	Hepatic cancer stage IV	PT
10059326	Pancreatic carcinoma stage IV	PT
10059368	Small intestine carcinoma stage 0	PT
10059369	Small intestine carcinoma stage I	PT
10059370	Small intestine carcinoma stage II	PT
10059371	Small intestine carcinoma stage III	PT
10059372	Small intestine carcinoma stage IV	PT
10059373	Bile duct cancer stage I	PT
10059374	Bile duct cancer stage II	PT
10059375	Bile duct cancer stage III	PT
10059376	Bile duct cancer stage IV	PT
10059384	Bile duct cancer stage 0	PT
10059427	Buschke-Lowenstein's tumour	PT
10059498	Stewart-Treves syndrome	PT
10059514	Small cell lung cancer metastatic	PT
10059515	Non-small cell lung cancer metastatic	PT
10059518	Pleural mesothelioma malignant	PT
10059631	Penile squamous cell carcinoma	PT
10060121	Squamous cell carcinoma of head and neck	PT
10060406	Plasma cell leukaemia in remission	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10060862	Prostate cancer	PT
10060910	Precursor B-lymphoblastic lymphoma recurrent	PT
10060911	Precursor B-lymphoblastic lymphoma refractory	PT
10060930	Acute leukaemia in remission	PT
10060971	Astrocytoma malignant	PT
10061020	Breast cancer male	PT
10061025	Cardiac neoplasm malignant	PT
10061031	Thymoma malignant	PT
10061042	Chronic leukaemia in remission	PT
10061122	Endocrine neoplasm malignant	PT
10061154	Female reproductive tract carcinoma in situ	PT
10061168	Gastrointestinal carcinoma in situ	PT
10061170	Follicle centre lymphoma, follicular grade I, II, III	PT
10061184	Germ cell cancer	PT
10061220	Leukaemia in remission	PT
10061232	Lymphoproliferative disorder	PT
10061233	Lymphoproliferative disorder in remission	PT
10061237	Malignant anorectal neoplasm	PT
10061238	Malignant cranial nerve neoplasm	PT
10061240	Malignant lymphoid neoplasm	PT
10061241	Malignant mediastinal neoplasm	PT
10061267	Malignant middle ear neoplasm	PT
10061268	Malignant nervous system neoplasm	PT
10061269	Malignant peritoneal neoplasm	PT
10061270	Malignant respiratory tract neoplasm	PT
10061272	Malignant urinary tract neoplasm	PT
10061275	Mantle cell lymphoma	PT
10061287	Metastases to nervous system	PT
10061288	Metastases to reproductive organ	PT
10061289	Metastatic neoplasm	PT
10061295	Monocytic leukaemia in remission	PT
10061301	Myeloid leukaemia in remission	PT
10061306	Nasopharyngeal cancer	PT
10061328	Ovarian epithelial cancer	PT
10061342	Peripheral neuroepithelioma of bone	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10061378	Testicular germ cell cancer	PT
10061396	Urinary tract carcinoma in situ	PT
10061424	Anal cancer	PT
10061450	Carcinoma in situ	PT
10061451	Colorectal cancer	PT
10061523	Lip and/or oral cavity cancer	PT
10061526	Malignant mesenchymoma	PT
10061527	Neurofibrosarcoma	PT
10061534	Oesophageal squamous cell carcinoma	PT
10061537	Pineal parenchymal neoplasm malignant	PT
10061597	Hodgkin's disease stage IV	PT
10061600	Metastases to the respiratory system	PT
10061809	Cervix carcinoma stage 0	PT
10061848	Extragonadal primary malignant teratoma	PT
10061849	Extragonadal primary non-seminoma	PT
10061850	Extranodal marginal zone B-cell lymphoma (MALT type)	PT
10061871	Non-Hodgkin's lymphoma transformed recurrent	PT
10061872	Non-renal cell carcinoma of kidney	PT
10061873	Non-small cell lung cancer	PT
10061893	Ovarian germ cell cancer	PT
10061894	Ovarian germ cell cancer stage I	PT
10061895	Ovarian germ cell cancer stage II	PT
10061896	Ovarian germ cell cancer stage III	PT
10061897	Ovarian germ cell cancer stage IV	PT
10061909	Paranasal sinus and nasal cavity malignant neoplasm	PT
10061934	Salivary gland cancer	PT
10061957	Follicle centre lymphoma diffuse small cell lymphoma	PT
10061967	Gastric cancer stage IV	PT
10061988	Gestational trophoblastic tumour	PT
10062001	Hepatoblastoma	PT
10062041	Lung infiltration malignant	PT
10062047	Lymphocyte morphology abnormal	PT
10062050	Malignant muscle neoplasm	PT
10062051	Malignant nipple neoplasm	PT
10062113	Splenic marginal zone lymphoma	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10062122	Testicular choriocarcinoma	PT
10062123	Testicular embryonal carcinoma	PT
10062124	Testicular seminoma (pure)	PT
10062142	Spleen scan abnormal	PT
10062194	Metastasis	PT
10062195	Metastases to biliary tract	PT
10062196	Metastases to gastrointestinal tract	PT
10062197	Metastases to soft tissue	PT
10062485	Retroperitoneal neoplasm metastatic	PT
10062489	Leukaemia recurrent	PT
10062878	Gastrooesophageal cancer	PT
10062904	Hormone-refractory prostate cancer	PT
10063157	Metastatic glioma	PT
10063523	Colon cancer stage 0	PT
10063536	Vulvar adenocarcinoma	PT
10063569	Metastatic squamous cell carcinoma	PT
10063609	Porocarcinoma	PT
10063616	Radiotherapy to lymph nodes	PT
10063620	Acute lymphocytic leukaemia recurrent	PT
10063693	Malignant neoplasm of eyelid	PT
10063706	Malignant melanoma of eyelid	PT
10063908	Non-Hodgkin's lymphoma unspecified histology aggressive	PT
10063916	Metastatic gastric cancer	PT
10064055	Lip squamous cell carcinoma	PT
10064099	Oropharyngeal cancer stage IV	PT
10064344	Lymphoma transformation	PT
10064581	Desmoplastic small round cell tumour	PT
10064605	Sezary cells increased	PT
10064912	Malignant transformation	PT
10065039	Plasmablastic lymphoma	PT
10065305	Cancer in remission	PT
10065349	Vaginal adenocarcinoma	PT
10065430	HER2 positive breast cancer	PT
10065443	Malignant glioma	PT
10065852	CNS germinoma	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10065854	Chronic eosinophilic leukaemia	PT
10065856	Non-Hodgkin's lymphoma unspecified histology indolent	PT
10065857	Primary effusion lymphoma	PT
10065858	Ovarian stromal cancer	PT
10065867	Alveolar rhabdomyosarcoma	PT
10065868	Embryonal rhabdomyosarcoma	PT
10065871	Nongerminomatous germ cell tumour of the CNS	PT
10065907	Atypical teratoid/rhabdoid tumour of CNS	PT
10065908	Cystadenocarcinoma pancreas	PT
10066057	Mueller's mixed tumour	PT
10066136	Huerthle cell carcinoma	PT
10066206	Apocrine breast carcinoma	PT
10066231	Central nervous system leukaemia	PT
10066254	Gliomatosis cerebri	PT
10066384	Conjunctival melanoma	PT
10066471	Squamous cell carcinoma of pharynx	PT
10066474	Thyroid cancer	PT
10066476	Haematological malignancy	PT
10066594	Medulloblastoma recurrent	PT
10066595	Neuroblastoma recurrent	PT
10066600	Melanoma recurrent	PT
10066697	Ovarian cancer recurrent	PT
10066749	Bladder transitional cell carcinoma stage 0	PT
10066750	Bladder transitional cell carcinoma recurrent	PT
10066751	Bladder transitional cell carcinoma stage I	PT
10066752	Bladder transitional cell carcinoma stage IV	PT
10066753	Bladder transitional cell carcinoma stage II	PT
10066754	Bladder transitional cell carcinoma stage III	PT
10066879	Gallbladder cancer metastatic	PT
10066882	Metastatic salivary gland cancer	PT
10066896	HER2 positive gastric cancer	PT
10066948	Myxofibrosarcoma	PT
10066957	Hepatosplenic T-cell lymphoma	PT
10067064	Endometrial sarcoma recurrent	PT
10067065	Endometrial sarcoma metastatic	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10067117	Leukaemic infiltration extramedullary	PT
10067184	Burkitt's leukaemia	PT
10067369	Malignant mesenteric neoplasm	PT
10067387	Myelodysplastic syndrome transformation	PT
10067388	Hepatic angiosarcoma	PT
10067399	Acute biphenotypic leukaemia	PT
10067431	Leukaemic infiltration gingiva	PT
10067478	Choroid plexus carcinoma	PT
10067517	Pancreatic neuroendocrine tumour	PT
10067807	Gingival cancer	PT
10067821	Head and neck cancer	PT
10067917	Inflammatory myofibroblastic tumour	PT
10067943	Hereditary papillary renal carcinoma	PT
10067944	Hereditary leiomyomatosis renal cell carcinoma	PT
10067946	Renal cell carcinoma	PT
10067959	Refractory cytopenia with multilineage dysplasia	PT
10068068	Adenocarcinoma of salivary gland	PT
10068115	Metastatic carcinoid tumour	PT
10068116	Metastatic uterine cancer	PT
10068117	Metastatic ocular melanoma	PT
10068124	Malignant neoplasm of seminal vesicle	PT
10068223	Extramammary Paget's disease	PT
10068232	Chronic myeloid leukaemia transformation	PT
10068349	Epstein-Barr virus associated lymphoproliferative disorder	PT
10068532	5q minus syndrome	PT
10068582	Breast sarcoma	PT
10068583	Breast sarcoma metastatic	PT
10068584	Breast sarcoma recurrent	PT
10068595	Sarcoma metastatic	PT
10068601	Glioneuronal tumour	PT
10068694	Testicular germ cell cancer metastatic	PT
10068785	Histiocytic medullary reticulosis	PT
10068873	Adenosquamous cell carcinoma	PT
10068909	Pancreatic neuroendocrine tumour metastatic	PT
10068910	Primitive neuroectodermal tumour metastatic	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10068971	Germ cell cancer metastatic	PT
10068974	Peritoneal carcinoma metastatic	PT
10069345	Solid pseudopapillary tumour of the pancreas	PT
10069359	Leukaemic infiltration renal	PT
10069360	Leukaemic infiltration	PT
10069698	Langerhans' cell histiocytosis	PT
10069728	Rectosigmoid cancer metastatic	PT
10069730	Large cell lung cancer metastatic	PT
10069812	Testicular choriocarcinoma recurrent	PT
10069813	Testis cancer recurrent	PT
10070308	Refractory cancer	PT
10070567	Thyroid cancer stage 0	PT
10070902	Laryngeal cancer metastatic	PT
10070905	Ovarian cancer stage I	PT
10070906	Ovarian cancer stage II	PT
10070907	Ovarian cancer stage III	PT
10070908	Ovarian cancer stage IV	PT
10070913	Metastases to pelvis	PT
10071023	Abdominal wall neoplasm malignant	PT
10071027	Thyroid cancer stage I	PT
10071028	Thyroid cancer stage II	PT
10071029	Thyroid cancer stage III	PT
10071030	Thyroid cancer stage IV	PT
10071080	Transitional cell carcinoma metastatic	PT
10071119	Hormone-dependent prostate cancer	PT
10071251	Tongue cancer recurrent	PT
10071441	Epstein-Barr virus associated lymphoma	PT
10071532	Metastatic choriocarcinoma	PT
10071533	Lung squamous cell carcinoma metastatic	PT
10071535	Non-Hodgkin's lymphoma metastatic	PT
10071536	Head and neck cancer stage IV	PT
10071537	Head and neck cancer stage III	PT
10071538	Head and neck cancer stage II	PT
10071539	Head and neck cancer stage I	PT
10071540	Head and neck cancer metastatic	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10071541	Metastatic lymphoma	PT
10071542	Neuroendocrine carcinoma metastatic	PT
10071664	Bladder transitional cell carcinoma metastatic	PT
10071776	Phyllodes tumour	PT
10071978	Anaplastic lymphoma kinase gene and nucleophosmin gene fusion overexpression	PT
10072162	Thyroid cancer recurrent	PT
10072432	Malignant neoplasm of pleura metastatic	PT
10072448	Malignant blue naevus	PT
10072449	Desmoplastic melanoma	PT
10072613	Thyroid B-cell lymphoma	PT
10072684	Refractory cytopenia with unilineage dysplasia	PT
10072792	Tonsil cancer metastatic	PT
10072793	Urethral melanoma metastatic	PT
10072813	Breast angiosarcoma	PT
10072814	Breast angiosarcoma metastatic	PT
10073055	Extragonadal primary germ cell tumour	PT
10073056	Extragonadal primary germ cell tumour mixed	PT
10073057	Extragonadal primary seminoma (pure)	PT
10073059	Malignant neoplasm of unknown primary site	PT
10073062	Biphasic mesothelioma	PT
10073063	Desmoplastic mesothelioma	PT
10073064	Epithelioid mesothelioma	PT
10073065	Sarcomatoid mesothelioma	PT
10073066	Pericardial mesothelioma malignant	PT
10073067	Gallbladder adenosquamous carcinoma	PT
10073068	Gallbladder squamous cell carcinoma	PT
10073069	Hepatic cancer	PT
10073070	Hepatic cancer recurrent	PT
10073071	Hepatocellular carcinoma	PT
10073073	Hepatobiliary cancer	PT
10073074	Hepatobiliary cancer in situ	PT
10073086	Iris melanoma	PT
10073094	Intraductal proliferative breast lesion	PT
10073095	Invasive ductal breast carcinoma	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10073096	Invasive lobular breast carcinoma	PT
10073098	Invasive papillary breast carcinoma	PT
10073099	Lobular breast carcinoma in situ	PT
10073100	Metaplastic breast carcinoma	PT
10073101	Mucinous breast carcinoma	PT
10073103	Neuroendocrine breast tumour	PT
10073104	Tubular breast carcinoma	PT
10073106	Bone giant cell tumour malignant	PT
10073107	Peripheral primitive neuroectodermal bone tumour	PT
10073115	Epididymal cancer	PT
10073116	Genital cancer male	PT
10073117	Sertoli cell testicular tumour	PT
10073118	Spermatocytic seminoma	PT
10073119	Testicular germ cell tumour mixed	PT
10073120	Testicular malignant teratoma	PT
10073121	Testicular yolk sac tumour	PT
10073124	Genital cancer male in situ	PT
10073127	Anaplastic meningioma	PT
10073128	Anaplastic oligodendroglioma	PT
10073129	Angiocentric glioma	PT
10073130	Central nervous system neuroblastoma	PT
10073131	Oligoastrocytoma	PT
10073132	Plasma cell myeloma in remission	PT
10073133	Plasma cell myeloma recurrent	PT
10073134	Extraskeletal myxoid chondrosarcoma	PT
10073135	Dedifferentiated liposarcoma	PT
10073136	Mixed-type liposarcoma	PT
10073137	Myxoid liposarcoma	PT
10073138	Pleomorphic liposarcoma	PT
10073139	Round cell liposarcoma	PT
10073140	Clear cell sarcoma of soft tissue	PT
10073141	Malignant giant cell fibrous histiocytoma	PT
10073142	Inflammatory malignant fibrous histiocytoma	PT
10073143	Pleomorphic malignant fibrous histiocytoma	PT
10073144	Peripheral primitive neuroectodermal tumour of soft tissue	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10073152	Adrenal gland cancer	PT
10073153	Familial medullary thyroid cancer	PT
10073251	Clear cell renal cell carcinoma	PT
10073259	Ovarian germ cell tumour mixed	PT
10073260	Ovarian granulosa cell tumour	PT
10073261	Ovarian theca cell tumour	PT
10073262	Ovarian germ cell choriocarcinoma	PT
10073263	Ovarian germ cell endodermal sinus tumour	PT
10073264	Ovarian germ cell polyembryoma	PT
10073265	Ovarian germ cell teratoma	PT
10073266	Borderline mucinous tumour of ovary	PT
10073267	Borderline serous tumour of ovary	PT
10073268	Ovarian clear cell carcinoma	PT
10073269	Ovarian endometrioid carcinoma	PT
10073270	Ovarian Sertoli-Leydig cell tumour	PT
10073324	Keratinising squamous cell carcinoma of nasopharynx	PT
10073325	Nonkeratinising carcinoma of nasopharynx	PT
10073328	Undifferentiated nasopharyngeal carcinoma	PT
10073334	Rhabdoid tumour	PT
10073338	Optic glioma	PT
10073358	Anal squamous cell carcinoma	PT
10073359	Adenocarcinoma of appendix	PT
10073360	Appendix cancer	PT
10073361	Mucinous adenocarcinoma of appendix	PT
10073362	Undifferentiated carcinoma of colon	PT
10073363	Acinar cell carcinoma of pancreas	PT
10073364	Ductal adenocarcinoma of pancreas	PT
10073365	Intraductal papillary-mucinous carcinoma of pancreas	PT
10073367	Pancreatoblastoma	PT
10073369	Acinic cell carcinoma of salivary gland	PT
10073370	Adenoid cystic carcinoma of salivary gland	PT
10073371	Mucoepidermoid carcinoma of salivary gland	PT
10073373	Small intestine adenocarcinoma	PT
10073478	Anaplastic large-cell lymphoma	PT
10073479	Acute undifferentiated leukaemia	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10073480	B-cell prolymphocytic leukaemia	PT
10073481	Enteropathy-associated T-cell lymphoma	PT
10073534	Hodgkin's disease nodular sclerosis stage II	PT
10073535	Hodgkin's disease nodular sclerosis stage I	PT
10073540	Intraductal papillary breast neoplasm	PT
10073574	Dermatofibrosarcoma protuberans metastatic	PT
10073751	Intracranial germ cell tumour	PT
10073851	Tumour of ampulla of Vater	PT
10073857	Brain sarcoma	PT
10073957	Composite lymphoma	PT
10073978	Adenosquamous carcinoma of vagina	PT
10074340	Malignant connective tissue neoplasm	PT
10074419	Malignant genitourinary tract neoplasm	PT
10074909	Clear cell carcinoma of cervix	PT
10075081	Chronic myeloid leukaemia recurrent	PT
10075173	Bone marrow infiltration	PT
10075245	Metastatic glucagonoma	PT
10075324	Ocular lymphoma	PT
10075332	Follicular dendritic cell sarcoma	PT
10075333	Soft tissue sarcoma	PT
10075460	Blastic plasmacytoid dendritic cell neoplasia	PT
10075555	Metastases to vagina	PT
10075566	Triple negative breast cancer	PT
10075713	Invasive breast carcinoma	PT
10075811	Testicular germ cell tumour	PT
10075812	Ovarian germ cell tumour	PT
10075853	Leukaemic infiltration ovary	PT
10075993	Primary cardiac lymphoma	PT
10076596	Marginal zone lymphoma	PT
10076603	Poorly differentiated thyroid carcinoma	PT
10076748	Mixed adenoneuroendocrine carcinoma	PT
10076866	Acute lymphocytic leukaemia refractory	PT
10076868	Endotheliomatosis	PT
10076876	Histiocytic sarcoma	PT
10076935	Hormone refractory breast cancer	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10076969	Tumour budding	PT
10077051	Transitional cell carcinoma recurrent	PT
10077160	Central nervous system melanoma	PT
10077161	Primary myelofibrosis	PT
10077166	Genitourinary melanoma	PT
10077167	Gastrointestinal melanoma	PT
10077303	Malignant neoplasm papilla of Vater	PT
10077314	Skin squamous cell carcinoma metastatic	PT
10077403	Hairy cell leukaemia recurrent	PT
10077435	Carcinoma ex-pleomorphic adenoma	PT
10077465	Myeloproliferative neoplasm	PT
10077476	Metastases to tonsils	PT
10077529	Marginal zone lymphoma stage I	PT
10077530	Marginal zone lymphoma stage II	PT
10077531	Marginal zone lymphoma stage III	PT
10077532	Marginal zone lymphoma stage IV	PT
10077533	Marginal zone lymphoma recurrent	PT
10077534	Marginal zone lymphoma refractory	PT
10077559	Gastroenteropancreatic neuroendocrine tumour disease	PT
10077563	Leukaemic cardiac infiltration	PT
10077675	Musculoskeletal cancer	PT
10077703	Metastatic nervous system neoplasm	PT
10077758	Malignant meningioma metastatic	PT
10077861	Cholangiosarcoma	PT
10077888	Mismatch repair cancer syndrome	PT
10078145	Malignant joint neoplasm	PT
10078174	Neuroendocrine tumour of the lung	PT
10078175	Neuroendocrine tumour of the lung metastatic	PT
10078267	Metastases to spinal cord	PT
10078279	Myeloblast present	PT
10078282	Leptomeningeal myelomatosis	PT
10078295	NUT midline carcinoma	PT
10078341	Neuroendocrine carcinoma of the bladder	PT
10078493	Papillary renal cell carcinoma	PT
10078695	Malignant polyp	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10078782	Langerhans cell sarcoma	PT
10078934	Recurrent N-ras mutation-positive colorectal carcinoma	PT
10078972	Primary gastrointestinal follicular lymphoma	PT
10079054	Naevoid melanoma	PT
10079104	Nasopharyngeal cancer metastatic	PT
10079107	Transformation to acute myeloid leukaemia	PT
10079307	Squamous cell breast carcinoma	PT
10079386	Epstein Barr virus positive mucocutaneous ulcer	PT
10079618	Microsatellite instability cancer	PT
10079694	Chronic myelomonocytic leukaemia with N-ras gene mutation	PT
10079877	Maternal cancer in pregnancy	PT
10079987	Minimal residual disease	PT
10080017	Philadelphia positive acute lymphocytic leukaemia	PT
10080200	Triple hit lymphoma	PT
10080201	Nodular lymphocyte predominant Hodgkin lymphoma	PT
10080202	Double hit lymphoma	PT
10080215	High-grade B-cell lymphoma	PT
10080311	Intestinal metastasis	PT
10080323	Acute bilineal leukaemia	PT
10080324	Sarcomatoid carcinoma	PT
10080544	Chromophobe renal cell carcinoma	PT
10080682	Pleuropulmonary blastoma	PT
10080717	Primary pulmonary melanoma	PT
10081003	Gastrointestinal adenocarcinoma	PT
10081036	Primary breast lymphoma	PT
10081037	Tumour hyperprogression	PT
10081119	Carcinoid tumour of the liver	PT
10081189	Transdifferentiation of neoplasm	PT
10081367	Extranodal marginal zone B-cell lymphoma (BALT type)	PT
10081398	Gastrooesophageal cancer recurrent	PT
10081400	Sarcomatoid carcinoma of the lung	PT
10081421	Carcinoid tumour of the ovary	PT
10081428	Ciliary body melanoma	PT
10081431	Uveal melanoma	PT
10081437	Ewing-like sarcoma	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10081513	Acute myeloid leukaemia refractory	PT
10081590	Malignant biliary obstruction	PT
10081592	Malignant gastrointestinal obstruction	PT
10081653	Bing-Neel syndrome	PT
10081847	Plasma cell myeloma refractory	PT
10082075	Iatrogenic metastasis	PT
10082079	Ovarian melanoma	PT
10082180	Philadelphia positive chronic myeloid leukaemia	PT
10082230	Squamous cell carcinoma of the parotid gland	PT
10082277	External ear neoplasm malignant	PT
10082373	Precursor T-lymphoblastic leukaemia acute	PT
10082419	Pleomorphic leiomyosarcoma	PT
10082449	Ocular surface squamous neoplasia	PT
10082495	Breast implant-associated anaplastic large cell lymphoma	PT
10082804	Solitary fibrous tumour	PT
10082915	Neuroendocrine carcinoma of prostate	PT
10082968	Oesophageal adenosquamous carcinoma	PT
10083232	HER2 negative breast cancer	PT
10083233	Triple positive breast cancer	PT
10083234	Hormone receptor positive breast cancer	PT
10083253	Nasopharyngeal tumour	PT
10083456	Adenocarcinoma metastatic	PT
10083708	Basal cell carcinoma metastatic	PT
10083863	Ameloblastic carcinoma	PT
10084056	Epiglottic cancer	PT
10084088	Lacrimal gland neoplasm	PT
10084177	Intratumoural haematoma	PT
10084377	Grey zone lymphoma	PT
10084430	Malignant airway obstruction	PT
10084570	Pulmonary atypical adenomatous hyperplasia	PT
10084787	HER2 mutant non-small cell lung cancer	PT
10084789	Homologous recombination deficiency positive advanced ovarian cancer	PT
10084814	Craniopharyngioma malignant	PT
10085067	Perivascular epithelioid cell tumour	PT
10085091	Cancer with a high tumour mutational burden	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10085123	Follicular lymphoma stage I	PT
10085125	Follicular lymphoma stage II	PT
10085126	Follicular lymphoma stage IV	PT
10085127	Follicular lymphoma stage III	PT
10085128	Follicular lymphoma	PT
10085146	Appendix cancer metastatic	PT
10085254	Cancer cells urine present	PT
10085315	Malignant spinal cord compression	PT
10085431	HER2 positive salivary gland cancer	PT
10085443	Lineage switch leukaemia	PT
10085481	Hormone receptor positive HER2 negative breast cancer	PT
10085561	Hormone receptor negative HER2 positive breast cancer	PT
10085663	Clear cell papillary renal cell carcinoma	PT
10085759	Growing teratoma syndrome	PT
10085767	Neuroendocrine tumour of the rectum	PT
10085796	Meckel's cave tumour	PT
10085864	Hepatic neuroendocrine tumour	PT
10085940	Small intestine neuroendocrine tumour	PT
10086077	Malignant gastric ulcer	PT
10086455	Cholecystic intraepithelial neoplasia	PT
10086456	Intracholecystic papillary neoplasm	PT
10086585	Neuroendocrine carcinoma of the oesophagus	PT
10086686	Malignant central nervous system neoplasm	PT
10086693	Ocular melanoma	PT
10086698	Haematological neoplasm	PT
10086714	B-cell lymphoma unclassifiable	PT
10086715	Malignant unclassifiable lymphoma	PT
10086716	T-cell lymphoma unclassifiable	PT
10086769	Neuroendocrine carcinoma of the cervix	PT
10086779	Carcinoid tumour in the large intestine	PT
10086817	Malignant urinary tract neoplasm metastatic	PT
10086958	Hepatic sarcoma	PT
10086987	Skull base tumour	PT
10087104	Infected metastasis	PT
10087220	Thymic carcinoma	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Malignancies, Excluding Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10087266	Epiglottic neoplasm	PT
10087311	Adenocarcinoid tumour of the appendix	PT
10087324	Primary cutaneous adenoid cystic carcinoma	PT
10087362	Gastric neuroendocrine carcinoma	PT
10087363	Carcinoid tumour of the mesentery	PT
10087364	Gastrointestinal neuroendocrine carcinoma	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Nonmelanoma Skin Cancers - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10004146	Basal cell carcinoma	PT
10004178	Basosquamous carcinoma	PT
10004179	Basosquamous carcinoma of skin	PT
10006059	Bowen's disease	PT
10007390	Carcinoma in situ of skin	PT
10011677	Cutaneous T-cell lymphoma	PT
10011678	Cutaneous T-cell lymphoma recurrent	PT
10011679	Cutaneous T-cell lymphoma refractory	PT
10011680	Cutaneous T-cell lymphoma stage I	PT
10011681	Cutaneous T-cell lymphoma stage II	PT
10011682	Cutaneous T-cell lymphoma stage III	PT
10023284	Kaposi's sarcoma	PT
10023286	Kaposi's sarcoma AIDS related	PT
10023288	Kaposi's sarcoma classical type	PT
10023347	Keratoacanthoma	PT
10029266	Neuroendocrine carcinoma of the skin	PT
10037732	Queyrat erythroplasia	PT
10039495	Sarcoma of skin	PT
10040808	Skin cancer	PT
10041823	Squamous cell carcinoma	PT
10041834	Squamous cell carcinoma of skin	PT
10057070	Dermatofibrosarcoma protuberans	PT
10063609	Porocarcinoma	PT
10064755	Atypical fibroxanthoma	PT
10068784	Sebaceous carcinoma	PT
10069680	Eccrine carcinoma	PT
10072891	Skin angiosarcoma	PT
10073087	Malignant sweat gland neoplasm	PT
10073088	Hidradenocarcinoma	PT
10075614	Pilomatrix carcinoma	PT
10076248	Marjolin's ulcer	PT
10079945	Cutaneous lymphoma	PT
10080660	Trichoblastic carcinoma	PT
10081136	Skin squamous cell carcinoma recurrent	PT
10085518	Cutaneous B-cell lymphoma	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Gastrointestinal Perforations - Galapagos Search Term List

MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10002248	Anastomotic ulcer perforation	PT
10003012	Appendicitis perforated	PT
10013832	Duodenal perforation	PT
10013849	Duodenal ulcer perforation	PT
10013850	Duodenal ulcer perforation, obstructive	PT
10017815	Gastric perforation	PT
10017835	Gastric ulcer perforation	PT
10017836	Gastric ulcer perforation, obstructive	PT
10018001	Gastrointestinal perforation	PT
10021305	Ileal perforation	PT
10021310	Ileal ulcer perforation	PT
10022694	Intestinal perforation	PT
10023174	Jejunal perforation	PT
10023178	Jejunal ulcer perforation	PT
10023804	Large intestine perforation	PT
10030181	Oesophageal perforation	PT
10034354	Peptic ulcer perforation	PT
10034358	Peptic ulcer perforation, obstructive	PT
10038073	Rectal perforation	PT
10041103	Small intestinal perforation	PT
10052211	Oesophageal rupture	PT
10052488	Oesophageal ulcer perforation	PT
10052497	Large intestinal ulcer perforation	PT
10052498	Small intestinal ulcer perforation	PT
10061248	Intestinal ulcer perforation	PT
10061820	Diverticular perforation	PT
10061975	Gastrointestinal ulcer perforation	PT
10062065	Perforated ulcer	PT
10066993	Umbilical hernia perforation	PT
10074065	Procedural intestinal perforation	PT
10074442	Abdominal hernia perforation	PT
10075254	Inguinal hernia perforation	PT
10078413	Upper gastrointestinal perforation	PT
10078414	Lower gastrointestinal perforation	PT
10085627	Duodenal rupture	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10000358	Accelerated hypertension	PT
10000533	Acquired cardiac septal defect	PT
10000891	Acute myocardial infarction	PT
10001029	Acute pulmonary oedema	PT
10001053	Acute respiratory failure	PT
10001115	Adams-Stokes syndrome	PT
10001903	Amaurosis fugax	PT
10002329	Aneurysm	PT
10002331	Aneurysm arteriovenous	PT
10002383	Angina pectoris	PT
10002388	Angina unstable	PT
10002611	Anomalous atrioventricular excitation	PT
10002703	Anterior spinal artery syndrome	PT
10002847	Anuria	PT
10002882	Aortic aneurysm	PT
10002886	Aortic aneurysm rupture	PT
10002895	Aortic dissection	PT
10002897	Aortic embolus	PT
10002899	Aortic injury	PT
10002900	Aortic necrosis	PT
10002906	Aortic stenosis	PT
10002910	Aortic thrombosis	PT
10002912	Aortic valve disease mixed	PT
10002915	Aortic valve incompetence	PT
10002917	Aortic valve sclerosis	PT
10002918	Aortic valve stenosis	PT
10003119	Arrhythmia	PT
10003130	Arrhythmia supraventricular	PT
10003162	Arterial injury	PT
10003173	Arterial rupture	PT
10003175	Arterial spasm	PT
10003178	Arterial thrombosis	PT
10003192	Arteriovenous fistula thrombosis	PT
10003201	Arteriogram coronary abnormal	PT
10003210	Arteriosclerosis	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10003211	Arteriosclerosis coronary artery	PT
10003212	Arteriosclerosis Moenckeberg-type	PT
10003222	Arteriosclerotic gangrene	PT
10003225	Arteriospasm coronary	PT
10003226	Arteriovenous fistula	PT
10003232	Arteritis coronary	PT
10003445	Ascites	PT
10003658	Atrial fibrillation	PT
10003662	Atrial flutter	PT
10003664	Atrial septal defect	PT
10003665	Atrial septal defect acquired	PT
10003668	Atrial tachycardia	PT
10003671	Atrioventricular block	PT
10003673	Atrioventricular block complete	PT
10003674	Atrioventricular block first degree	PT
10003677	Atrioventricular block second degree	PT
10003880	Axillary vein thrombosis	PT
10004163	Basilar artery stenosis	PT
10004780	Biopsy heart abnormal	PT
10005144	Bleeding varicose vein	PT
10005468	Blood creatine phosphokinase abnormal	PT
10005470	Blood creatine phosphokinase increased	PT
10005472	Blood creatine phosphokinase MB abnormal	PT
10005474	Blood creatine phosphokinase MB increased	PT
10005736	Blood pressure diastolic abnormal	PT
10005737	Blood pressure diastolic decreased	PT
10005739	Blood pressure diastolic increased	PT
10005746	Blood pressure fluctuation	PT
10005748	Blood pressure immeasurable	PT
10005757	Blood pressure systolic abnormal	PT
10005758	Blood pressure systolic decreased	PT
10005760	Blood pressure systolic increased	PT
10006093	Bradycardia	PT
10006127	Brain hypoxia	PT
10006145	Brain stem haemorrhage	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10006147	Brain stem infarction	PT
10006148	Brain stem ischaemia	PT
10006578	Bundle branch block	PT
10006579	Bundle branch block bilateral	PT
10006580	Bundle branch block left	PT
10006582	Bundle branch block right	PT
10007509	Cardiac amyloidosis	PT
10007513	Cardiac aneurysm	PT
10007515	Cardiac arrest	PT
10007516	Cardiac arrest neonatal	PT
10007522	Cardiac asthma	PT
10007554	Cardiac failure	PT
10007556	Cardiac failure acute	PT
10007558	Cardiac failure chronic	PT
10007559	Cardiac failure congestive	PT
10007560	Cardiac failure high output	PT
10007567	Cardiac function disturbance postoperative	PT
10007572	Cardiac hypertrophy	PT
10007576	Cardiac index abnormal	PT
10007577	Cardiac index decreased	PT
10007578	Cardiac index increased	PT
10007595	Cardiac output decreased	PT
10007604	Cardiac sarcoidosis	PT
10007617	Cardio-respiratory arrest	PT
10007618	Cardio-respiratory arrest neonatal	PT
10007625	Cardiogenic shock	PT
10007632	Cardiomegaly	PT
10007636	Cardiomyopathy	PT
10007637	Cardiomyopathy alcoholic	PT
10007646	Cardiothoracic ratio increased	PT
10007649	Cardiovascular disorder	PT
10007651	Cardiovascular function test abnormal	PT
10007684	Carotid arterial embolus	PT
10007686	Carotid artery aneurysm	PT
10007687	Carotid artery stenosis	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10007688	Carotid artery thrombosis	PT
10007830	Cavernous sinus thrombosis	PT
10007980	Central venous pressure increased	PT
10008023	Cerebellar artery thrombosis	PT
10008030	Cerebellar haemorrhage	PT
10008034	Cerebellar infarction	PT
10008088	Cerebral artery embolism	PT
10008089	Cerebral artery occlusion	PT
10008092	Cerebral artery thrombosis	PT
10008097	Cerebral circulatory failure	PT
10008111	Cerebral haemorrhage	PT
10008118	Cerebral infarction	PT
10008120	Cerebral ischaemia	PT
10008132	Cerebral thrombosis	PT
10008138	Cerebral venous thrombosis	PT
10008190	Cerebrovascular accident	PT
10008196	Cerebrovascular disorder	PT
10008479	Chest pain	PT
10008499	Chest X-ray abnormal	PT
10008745	Chordae tendinae rupture	PT
10009192	Circulatory collapse	PT
10009243	Claudication of jaw muscles	PT
10009691	Clubbing	PT
10009838	Coeliac artery compression syndrome	PT
10010276	Conduction disorder	PT
10010967	Cor biloculare	PT
10010968	Cor pulmonale	PT
10010969	Cor pulmonale acute	PT
10010970	Cor pulmonale chronic	PT
10010972	Cor triatriatum	PT
10011071	Coronary artery aneurysm	PT
10011077	Coronary artery bypass	PT
10011078	Coronary artery disease	PT
10011084	Coronary artery embolism	PT
10011086	Coronary artery occlusion	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10011089	Coronary artery stenosis	PT
10011090	Coronary artery surgery	PT
10011091	Coronary artery thrombosis	PT
10011101	Coronary endarterectomy	PT
10011105	Coronary ostial stenosis	PT
10011254	Coxsackie carditis	PT
10011258	Coxsackie myocarditis	PT
10011703	Cyanosis	PT
10012118	Defect conduction intraventricular	PT
10012647	Diabetic cardiomyopathy	PT
10012758	Diastolic hypertension	PT
10012979	DiGeorge's syndrome	PT
10013002	Dilatation atrial	PT
10013012	Dilatation ventricular	PT
10013048	Directional Doppler flow tests abnormal	PT
10013573	Dizziness	PT
10013576	Dizziness exertional	PT
10013578	Dizziness postural	PT
10013968	Dyspnoea	PT
10013969	Dyspnoea at rest	PT
10013971	Dyspnoea exertional	PT
10013974	Dyspnoea paroxysmal nocturnal	PT
10014331	Ejection fraction abnormal	PT
10014363	Electrocardiogram abnormal	PT
10014369	Electrocardiogram ambulatory abnormal	PT
10014372	Electrocardiogram delta waves abnormal	PT
10014374	Electrocardiogram PR shortened	PT
10014380	Electrocardiogram QRS complex prolonged	PT
10014387	Electrocardiogram QT prolonged	PT
10014390	Electrocardiogram ST segment abnormal	PT
10014391	Electrocardiogram ST segment depression	PT
10014392	Electrocardiogram ST segment elevation	PT
10014395	Electrocardiogram T wave inversion	PT
10014498	Embolic stroke	PT
10014513	Embolism arterial	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10014522	Embolism venous	PT
10014663	Endocardial fibroelastosis	PT
10014961	Eosinophilic myocarditis	PT
10015488	Essential hypertension	PT
10015645	Exercise electrocardiogram abnormal	PT
10015653	Exercise test abnormal	PT
10015856	Extrasystoles	PT
10016427	Femoral artery aneurysm	PT
10018723	Grey syndrome neonatal	PT
10018964	Haemoptysis	PT
10018985	Haemorrhage intracranial	PT
10019005	Haemorrhagic cerebral infarction	PT
10019013	Haemorrhagic infarction	PT
10019016	Haemorrhagic stroke	PT
10019300	Heart rate abnormal	PT
10019301	Heart rate decreased	PT
10019303	Heart rate increased	PT
10019314	Heart transplant	PT
10019634	Hepatic artery aneurysm	PT
10019635	Hepatic artery embolism	PT
10019636	Hepatic artery thrombosis	PT
10019680	Hepatic infarction	PT
10019713	Hepatic vein thrombosis	PT
10019842	Hepatomegaly	PT
10019845	Hepatorenal failure	PT
10020772	Hypertension	PT
10020801	Hypertensive cardiomegaly	PT
10020802	Hypertensive crisis	PT
10020803	Hypertensive encephalopathy	PT
10020823	Hypertensive heart disease	PT
10020871	Hypertrophic cardiomyopathy	PT
10020919	Hypervolaemia	PT
10021076	Hypoplastic left heart syndrome	PT
10021097	Hypotension	PT
10021338	Iliac artery embolism	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10022562	Intermittent claudication	PT
10022626	Interventricular septum rupture	PT
10022640	Intestinal angina	PT
10022657	Intestinal infarction	PT
10022680	Intestinal ischaemia	PT
10022758	Intracranial aneurysm	PT
10023025	Ischaemic hepatitis	PT
10023237	Jugular vein thrombosis	PT
10023533	Labile blood pressure	PT
10024119	Left ventricular failure	PT
10024242	Leriche syndrome	PT
10024803	Long QT syndrome	PT
10024855	Loss of consciousness	PT
10024899	Low cardiac output syndrome	PT
10024984	Lown-Ganong-Levine syndrome	PT
10025600	Malignant hypertension	PT
10025603	Malignant hypertensive heart disease	PT
10026674	Malignant renal hypertension	PT
10027394	Mesenteric arterial occlusion	PT
10027395	Mesenteric artery embolism	PT
10027396	Mesenteric artery stenosis	PT
10027397	Mesenteric artery thrombosis	PT
10027401	Mesenteric vascular insufficiency	PT
10027402	Mesenteric vein thrombosis	PT
10027403	Mesenteric venous occlusion	PT
10028178	Multiple cardiac defects	PT
10028212	Multiple gated acquisition scan abnormal	PT
10028594	Myocardial fibrosis	PT
10028596	Myocardial infarction	PT
10028600	Myocardial ischaemia	PT
10028602	Myocardial necrosis	PT
10028604	Myocardial rupture	PT
10028606	Myocarditis	PT
10028612	Myocarditis meningococcal	PT
10028615	Myocarditis septic	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10028616	Myocarditis syphilitic	PT
10028617	Myocarditis toxoplasmal	PT
10028629	Myoglobinuria	PT
10028650	Myopericarditis	PT
10028862	Necrosis ischaemic	PT
10028872	Necrosis of artery	PT
10028975	Neonatal respiratory failure	PT
10029446	Nocturia	PT
10029458	Nodal arrhythmia	PT
10029470	Nodal rhythm	PT
10029538	Non-cardiogenic pulmonary oedema	PT
10029748	Noonan syndrome	PT
10030095	Oedema	PT
10030124	Oedema peripheral	PT
10030936	Optic nerve infarction	PT
10030941	Optic nerve sheath haemorrhage	PT
10031123	Orthopnoea	PT
10031127	Orthostatic hypotension	PT
10031131	Osler's nodes	PT
10033557	Palpitations	PT
10033697	Papillary muscle infarction	PT
10033698	Papillary muscle rupture	PT
10033929	Parasystole	PT
10034323	Penile vascular disorder	PT
10034324	Penile vein thrombosis	PT
10034567	Peripheral circulatory failure	PT
10034576	Peripheral ischaemia	PT
10034636	Peripheral vascular disorder	PT
10035092	Pituitary infarction	PT
10035550	Platypnoea	PT
10036155	Poor peripheral circulation	PT
10036511	Precerebral artery occlusion	PT
10036653	Presyncope	PT
10036759	Prinzmetal angina	PT
10037329	Pulmonary arterial wedge pressure increased	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10037338	Pulmonary artery stenosis	PT
10037340	Pulmonary artery thrombosis	PT
10037368	Pulmonary congestion	PT
10037377	Pulmonary embolism	PT
10037400	Pulmonary hypertension	PT
10037410	Pulmonary infarction	PT
10037421	Pulmonary microemboli	PT
10037423	Pulmonary oedema	PT
10037437	Pulmonary thrombosis	PT
10037456	Pulmonary vascular resistance abnormality	PT
10037458	Pulmonary veno-occlusive disease	PT
10037459	Pulmonary venous thrombosis	PT
10037469	Pulse absent	PT
10038372	Renal arteriosclerosis	PT
10038378	Renal artery stenosis	PT
10038380	Renal artery thrombosis	PT
10038435	Renal failure	PT
10038447	Renal failure neonatal	PT
10038464	Renal hypertension	PT
10038470	Renal infarct	PT
10038547	Renal vein embolism	PT
10038548	Renal vein thrombosis	PT
10038553	Renal vessel disorder	PT
10038562	Renovascular hypertension	PT
10038695	Respiratory failure	PT
10038748	Restrictive cardiomyopathy	PT
10038826	Retinal artery embolism	PT
10038827	Retinal artery occlusion	PT
10038830	Retinal artery stenosis	PT
10038831	Retinal artery thrombosis	PT
10038871	Retinal ischaemia	PT
10038901	Retinal vascular disorder	PT
10038903	Retinal vascular occlusion	PT
10038907	Retinal vein occlusion	PT
10038908	Retinal vein thrombosis	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10039111	Rhythm idioventricular	PT
10039163	Right ventricular failure	PT
10039281	Rubinstein-Taybi syndrome	PT
10039330	Ruptured cerebral aneurysm	PT
10040560	Shock	PT
10040581	Shock symptom	PT
10040736	Sinoatrial block	PT
10040738	Sinus arrest	PT
10040739	Sinus arrhythmia	PT
10040741	Sinus bradycardia	PT
10040752	Sinus tachycardia	PT
10041648	Splenic infarction	PT
10042246	Stroke volume decreased	PT
10042265	Sturge-Weber syndrome	PT
10042316	Subarachnoid haemorrhage	PT
10042332	Subclavian artery embolism	PT
10042334	Subclavian artery thrombosis	PT
10042335	Subclavian steal syndrome	PT
10042431	Subvalvular aortic stenosis	PT
10042434	Sudden death	PT
10042569	Superior vena cava syndrome	PT
10042598	Supravalvular aortic stenosis	PT
10042602	Supraventricular extrasystoles	PT
10042604	Supraventricular tachycardia	PT
10042772	Syncope	PT
10042957	Systolic hypertension	PT
10043071	Tachycardia	PT
10043079	Tachycardia paroxysmal	PT
10043337	Testicular infarction	PT
10043581	Thrombophlebitis migrans	PT
10043607	Thrombosis	PT
10043626	Thrombosis mesenteric vessel	PT
10043645	Thrombotic microangiopathy	PT
10043647	Thrombotic stroke	PT
10043742	Thyroid infarction	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10044066	Torsade de pointes	PT
10044390	Transient ischaemic attack	PT
10044590	Trepopnoea	PT
10044640	Tricuspid valve incompetence	PT
10044642	Tricuspid valve stenosis	PT
10044644	Trifascicular block	PT
10045413	Ultrasound Doppler abnormal	PT
10046797	Uterine ischaemia	PT
10047080	Vascular injury	PT
10047193	Vena cava embolism	PT
10047195	Vena cava thrombosis	PT
10047216	Venoocclusive liver disease	PT
10047236	Venous pressure increased	PT
10047238	Venous pressure jugular abnormal	PT
10047240	Venous pressure jugular increased	PT
10047249	Venous thrombosis	PT
10047279	Ventricle rupture	PT
10047281	Ventricular arrhythmia	PT
10047284	Ventricular asystole	PT
10047289	Ventricular extrasystoles	PT
10047290	Ventricular fibrillation	PT
10047294	Ventricular flutter	PT
10047295	Ventricular hypertrophy	PT
10047296	Ventricular hypoplasia	PT
10047298	Ventricular septal defect	PT
10047299	Ventricular septal defect acquired	PT
10047302	Ventricular tachycardia	PT
10047330	Vertebral artery stenosis	PT
10047334	Vertebrobasilar insufficiency	PT
10047470	Viral myocarditis	PT
10047818	Wandering pacemaker	PT
10047847	Waterhouse-Friderichsen syndrome	PT
10047903	Weil's disease	PT
10048007	Withdrawal hypertension	PT
10048015	Wolff-Parkinson-White syndrome	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10048294	Mental status changes	PT
10048377	Cardiomyopathy acute	PT
10048380	Aneurysm ruptured	PT
10048554	Endothelial dysfunction	PT
10048610	Cardiotoxicity	PT
10048620	Intracardiac thrombus	PT
10048623	Atrial hypertrophy	PT
10048631	Coronary artery dissection	PT
10048632	Atrial thrombosis	PT
10048661	Wyburn Mason's syndrome	PT
10048761	Atrial rupture	PT
10048804	Kearns-Sayre syndrome	PT
10048849	Myocardial haemorrhage	PT
10048858	Ischaemic cardiomyopathy	PT
10048951	Uhl's anomaly	PT
10048959	Peripheral swelling	PT
10048961	Localised oedema	PT
10048963	Basilar artery occlusion	PT
10048964	Carotid artery occlusion	PT
10048965	Vertebral artery occlusion	PT
10048974	Cardiac pseudoaneurysm	PT
10048975	Vascular pseudoaneurysm	PT
10048988	Renal artery occlusion	PT
10049001	Acute endocarditis	PT
10049003	Accelerated idioventricular rhythm	PT
10049060	Vascular graft occlusion	PT
10049079	Labile hypertension	PT
10049171	Pulmonary vein stenosis	PT
10049209	Aorta hypoplasia	PT
10049224	Electrocardiogram ST-T segment depression	PT
10049225	Electrocardiogram ST-T segment elevation	PT
10049235	Nocturnal dyspnoea	PT
10049251	Heyde's syndrome	PT
10049418	Sudden cardiac death	PT
10049430	Peripartum cardiomyopathy	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10049440	Spinal artery embolism	PT
10049446	Subclavian vein thrombosis	PT
10049447	Tachyarrhythmia	PT
10049632	Oedema due to cardiac disease	PT
10049633	Shoshin beriberi	PT
10049644	Williams syndrome	PT
10049671	Negative cardiac inotropic effect	PT
10049694	Left ventricular dysfunction	PT
10049760	Pituitary haemorrhage	PT
10049761	Ventricular pre-excitation	PT
10049765	Bradyarrhythmia	PT
10049768	Silent myocardial infarction	PT
10049773	Left ventricular hypertrophy	PT
10049778	Neonatal anuria	PT
10049779	Peripheral oedema neonatal	PT
10049780	Neonatal cardiac failure	PT
10049785	Atrial pressure increased	PT
10049813	Non-obstructive cardiomyopathy	PT
10049874	Cardio-respiratory distress	PT
10049887	Coronary revascularisation	PT
10049993	Cardiac death	PT
10050043	Left ventricular dilatation	PT
10050106	Paroxysmal arrhythmia	PT
10050111	Cardiomyopathy neonatal	PT
10050180	Subclavian artery stenosis	PT
10050202	Carotid sinus syndrome	PT
10050209	Spinal cord ischaemia	PT
10050257	Cardiovascular deconditioning	PT
10050326	Right ventricular hypertrophy	PT
10050329	Coronary angioplasty	PT
10050380	Electrocardiogram T wave abnormal	PT
10050401	Neonatal multi-organ failure	PT
10050403	Carotid artery dissection	PT
10050459	Pulmonary oedema neonatal	PT
10050496	Reversible ischaemic neurological deficit	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10050510	Ventricular hypokinesia	PT
10050528	Ejection fraction decreased	PT
10050559	Aortic valve calcification	PT
10050581	Left ventricular enlargement	PT
10050582	Right ventricular enlargement	PT
10050631	Postoperative hypertension	PT
10050900	Increased ventricular preload	PT
10050905	Decreased ventricular preload	PT
10050998	ECG signs of ventricular hypertrophy	PT
10051055	Deep vein thrombosis	PT
10051078	Lacunar infarction	PT
10051093	Cardiopulmonary failure	PT
10051099	Catheter site haemorrhage	PT
10051113	Arterial restenosis	PT
10051128	Blood pressure inadequately controlled	PT
10051177	Electrocardiogram Q wave abnormal	PT
10051199	Hepatic artery stenosis	PT
10051269	Graft thrombosis	PT
10051307	Ischaemic neuropathy	PT
10051328	Carotid aneurysm rupture	PT
10051448	Hepatojugular reflux	PT
10051550	Carotidynia	PT
10051592	Acute coronary syndrome	PT
10051624	Myocardial reperfusion injury	PT
10051734	Hepatic vein stenosis	PT
10051742	Retinal infarction	PT
10051860	Left atrial enlargement	PT
10051895	Acute chest syndrome	PT
10051951	Scimitar syndrome	PT
10051991	Hepatic artery occlusion	PT
10051994	Pacemaker syndrome	PT
10052076	Haemodynamic instability	PT
10052086	Coronary arterial stent insertion	PT
10052173	Cerebrospinal thrombotic tamponade	PT
10052289	Myocardial bridging	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10052313	Liddle's syndrome	PT
10052326	Femoral artery dissection	PT
10052333	Electrocardiogram ST-T segment abnormal	PT
10052337	Diastolic dysfunction	PT
10052348	Left ventricular heave	PT
10052371	Ventricular assist device insertion	PT
10052464	Electrocardiogram repolarisation abnormality	PT
10052840	Cardiac flutter	PT
10052895	Coronary artery insufficiency	PT
10052896	Ocular vascular disorder	PT
10053159	Organ failure	PT
10053182	Arteriovenous graft thrombosis	PT
10053216	Iliac artery stenosis	PT
10053261	Coronary artery reocclusion	PT
10053405	Brain natriuretic peptide increased	PT
10053408	Brain natriuretic peptide abnormal	PT
10053410	Atrial natriuretic peptide abnormal	PT
10053412	Atrial natriuretic peptide increased	PT
10053440	Cardiac monitoring abnormal	PT
10053444	Cardiac ventriculogram right abnormal	PT
10053447	Cardiac ventriculogram abnormal	PT
10053450	Cardiac telemetry abnormal	PT
10053453	Cardiac imaging procedure abnormal	PT
10053486	Pacemaker generated arrhythmia	PT
10053499	Cardiac ventriculogram left abnormal	PT
10053633	Cerebellar artery occlusion	PT
10053648	Vascular occlusion	PT
10053657	Electrocardiogram PR prolongation	PT
10053748	Cardiac valve replacement complication	PT
10053841	Sneddon's syndrome	PT
10053942	Cerebral haematoma	PT
10053949	Vascular pseudoaneurysm ruptured	PT
10053994	Cardiac ventricular thrombosis	PT
10054015	Agonal rhythm	PT
10054044	Diabetic microangiopathy	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10054092	Vessel puncture site haemorrhage	PT
10054122	Myocardial calcification	PT
10054123	Malarial myocarditis	PT
10054749	Charcot-Bouchard microaneurysms	PT
10054805	Macroangiopathy	PT
10054880	Vascular insufficiency	PT
10054936	Cardiac cirrhosis	PT
10054946	Malignant pericardial neoplasm	PT
10055009	Cardiac fibroma	PT
10055014	Cardiac stress test abnormal	PT
10055032	Electrocardiogram U-wave abnormality	PT
10055122	Arteriovenous fistula site complication	PT
10055123	Arteriovenous fistula site haemorrhage	PT
10055126	Arteriovenous graft site haemorrhage	PT
10055147	Arteriovenous graft site stenosis	PT
10055150	Arteriovenous fistula site haematoma	PT
10055152	Arteriovenous graft site haematoma	PT
10055171	Hypertensive nephropathy	PT
10055662	Catheter site haematoma	PT
10055677	Haemorrhagic transformation stroke	PT
10055803	Haemorrhage coronary artery	PT
10056237	Migrainous infarction	PT
10056261	Cytomegalovirus myocarditis	PT
10056293	Renal vein occlusion	PT
10056328	Hepatic ischaemia	PT
10056370	Congestive cardiomyopathy	PT
10056371	Cerebrovascular arteriovenous malformation	PT
10056382	Intraoperative cerebral artery occlusion	PT
10056409	Heart and lung transplant	PT
10056472	Ventricular hyperkinesia	PT
10056489	Coronary artery restenosis	PT
10057393	Bifascicular block	PT
10057403	Choroidal infarction	PT
10057453	Aortic dilatation	PT
10057454	Aortic valve prolapse	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10057455	Cardiac ventricular disorder	PT
10057461	Cardiac procedure complication	PT
10057462	Vascular procedure complication	PT
10057466	Tricuspid valve calcification	PT
10057467	Tricuspid valve sclerosis	PT
10057469	Vascular stenosis	PT
10057500	Left atrial hypertrophy	PT
10057501	Right atrial hypertrophy	PT
10057520	Peripheral artery dissection	PT
10057521	Peripheral artery aneurysm	PT
10057525	Peripheral artery occlusion	PT
10057576	Cardiac septal hypertrophy	PT
10057615	Endocrine hypertension	PT
10057777	Vertebral artery thrombosis	PT
10057799	Computerised tomogram thorax abnormal	PT
10057913	Electrocardiogram U wave present	PT
10057926	Long QT syndrome congenital	PT
10058039	Cardiac perforation	PT
10058079	Anomalous pulmonary venous connection	PT
10058093	Arrhythmogenic right ventricular dysplasia	PT
10058119	Neurogenic shock	PT
10058144	Postinfarction angina	PT
10058145	Subendocardial ischaemia	PT
10058151	Pulseless electrical activity	PT
10058155	Heart alternation	PT
10058156	Reperfusion arrhythmia	PT
10058177	Hyperkinetic heart syndrome	PT
10058178	Aortic occlusion	PT
10058179	Hypertensive emergency	PT
10058181	Hypertensive urgency	PT
10058184	Ventricular parasystole	PT
10058222	Hypertensive cardiomyopathy	PT
10058227	Right atrial enlargement	PT
10058267	Troponin increased	PT
10058268	Troponin I increased	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10058269	Troponin T increased	PT
10058317	ECG signs of myocardial ischaemia	PT
10058440	Myocardiac abscess	PT
10058479	Cardiac function test abnormal	PT
10058558	Hypoperfusion	PT
10058562	Arteriovenous fistula occlusion	PT
10058571	Spinal cord infarction	PT
10058597	Right ventricular dysfunction	PT
10058648	Aortic disorder	PT
10058735	Myoglobinaemia	PT
10058842	Cerebrovascular insufficiency	PT
10058939	Thalamus haemorrhage	PT
10058940	Putamen haemorrhage	PT
10058987	Inferior vena caval occlusion	PT
10058988	Superior vena cava occlusion	PT
10058990	Venous occlusion	PT
10058991	Hepatic vein occlusion	PT
10058992	Iliac vein occlusion	PT
10059025	Coronary bypass thrombosis	PT
10059026	Myocarditis mycotic	PT
10059027	Brugada syndrome	PT
10059028	Gastrointestinal ischaemia	PT
10059056	Ventricular dysfunction	PT
10059099	Atrophie blanche	PT
10059109	Cerebral vasoconstriction	PT
10059162	Ventricular dyskinesia	PT
10059164	Papillary muscle haemorrhage	PT
10059238	Hypertensive angiopathy	PT
10059245	Angiopathy	PT
10059399	Graft ischaemia	PT
10059483	Postpericardiotomy syndrome	PT
10059498	Stewart-Treves syndrome	PT
10059611	Coronary artery perforation	PT
10059613	Stroke in evolution	PT
10059862	Cardiac resynchronisation therapy	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10059865	Jugular vein distension	PT
10060089	Left ventricular end-diastolic pressure decreased	PT
10060237	Right ventricular systolic pressure decreased	PT
10060806	Computerised tomogram coronary artery abnormal	PT
10060839	Embolic cerebral infarction	PT
10060840	Ischaemic cerebral infarction	PT
10060874	Aortic rupture	PT
10060953	Ventricular failure	PT
10060963	Arterial disorder	PT
10060964	Arterial haemorrhage	PT
10060965	Arterial stenosis	PT
10061024	Cardiac disorder	PT
10061026	Cardiac operation	PT
10061038	Cerebellar haematoma	PT
10061116	Electrocardiogram change	PT
10061169	Embolism	PT
10061216	Infarction	PT
10061255	Ischaemia	PT
10061256	Ischaemic stroke	PT
10061317	Oedema neonatal	PT
10061330	Papillary muscle disorder	PT
10061340	Peripheral embolism	PT
10061369	Spinal vascular disorder	PT
10061389	Tricuspid valve disease	PT
10061406	Cardiac valve disease	PT
10061474	Pulmonary vascular disorder	PT
10061501	Scan myocardial perfusion abnormal	PT
10061589	Aortic valve disease	PT
10061592	Cardiac fibrillation	PT
10061593	Echocardiogram abnormal	PT
10061660	Artery dissection	PT
10061744	Carotid artery disease	PT
10061751	Cerebrovascular stenosis	PT
10061808	Cardiac electrophysiologic study abnormal	PT
10061815	Diabetic vascular disorder	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10062108	Retinal vascular thrombosis	PT
10062169	Vascular access complication	PT
10062170	Vascular bypass dysfunction	PT
10062173	Venoocclusive disease	PT
10062198	Microangiopathy	PT
10062314	Electrocardiogram U wave inversion	PT
10062542	Arterial insufficiency	PT
10062546	Thrombosis in device	PT
10062573	Brain stem thrombosis	PT
10062585	Peripheral arterial occlusive disease	PT
10062599	Arterial occlusive disease	PT
10062610	Ischaemic limb pain	PT
10062901	Multiple lentigines syndrome	PT
10062991	Positive cardiac inotropic effect	PT
10063079	Vascular anastomosis aneurysm	PT
10063080	Postural orthostatic tachycardia syndrome	PT
10063081	Acute left ventricular failure	PT
10063082	Acute right ventricular failure	PT
10063083	Chronic left ventricular failure	PT
10063084	Chronic right ventricular failure	PT
10063093	Basilar artery thrombosis	PT
10063164	Vestibular ischaemia	PT
10063176	Prosthetic cardiac valve thrombosis	PT
10063181	Propofol infusion syndrome	PT
10063363	Brachiocephalic vein thrombosis	PT
10063381	Polypoidal choroidal vasculopathy	PT
10063428	Athletic heart syndrome	PT
10063544	Renal embolism	PT
10063547	Diabetic macroangiopathy	PT
10063561	Pulmonary artery wall hypertrophy	PT
10063577	Graft haemorrhage	PT
10063587	Catheter site bruise	PT
10063588	Ortner's syndrome	PT
10063648	Cerebral artery stenosis	PT
10063732	Aorticopulmonary septal defect	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10063748	Electrocardiogram QT interval abnormal	PT
10063829	Device malfunction	PT
10063836	Atrioventricular septal defect	PT
10063837	Reperfusion injury	PT
10063868	Implant site thrombosis	PT
10063881	Vessel puncture site bruise	PT
10063897	Renal ischaemia	PT
10063927	Orthostatic intolerance	PT
10063934	Vascular stent thrombosis	PT
10063935	Kabuki make-up syndrome	PT
10064021	Cardiac septal defect	PT
10064063	CHARGE syndrome	PT
10064191	Atrial conduction time prolongation	PT
10064192	Parachute mitral valve	PT
10064195	Right ventricle outflow tract obstruction	PT
10064252	Vascular graft complication	PT
10064408	Cardiac vein dissection	PT
10064409	Cardiac vein perforation	PT
10064539	Autoimmune myocarditis	PT
10064550	Myocarditis post infection	PT
10064595	Haemorrhagic arteriovenous malformation	PT
10064601	Iliac artery occlusion	PT
10064730	Cerebral hyperperfusion syndrome	PT
10064771	Superior vena cava stenosis	PT
10064775	Arteriovenous graft aneurysm	PT
10064911	Pulmonary arterial hypertension	PT
10064939	Cardiovascular event prophylaxis	PT
10064949	Carotid artery insufficiency	PT
10064961	Thalamic infarction	PT
10064962	Hypoplastic right heart syndrome	PT
10064966	Myocardial oedema	PT
10064994	Subclavian coronary steal syndrome	PT
10065218	Myocarditis bacterial	PT
10065219	Myocarditis helminthic	PT
10065341	Ventricular tachyarrhythmia	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10065342	Supraventricular tachyarrhythmia	PT
10065384	Cerebral hypoperfusion	PT
10065420	Coronary artery dilatation	PT
10065508	Orthostatic hypertension	PT
10065510	Aortic elongation	PT
10065534	Macular ischaemia	PT
10065558	Aortic arteriosclerosis	PT
10065559	Cerebral arteriosclerosis	PT
10065560	Mesenteric arteriosclerosis	PT
10065561	Renal artery arteriosclerosis	PT
10065608	Percutaneous coronary intervention	PT
10065680	Embolic pneumonia	PT
10065902	Vessel puncture site haematoma	PT
10065918	Prehypertension	PT
10065929	Cardiovascular insufficiency	PT
10065930	Left ventricle outflow tract obstruction	PT
10066001	Cardiac autonomic neuropathy	PT
10066022	VACTERL syndrome	PT
10066059	Paradoxical embolism	PT
10066077	Diastolic hypotension	PT
10066111	Shunt blood flow excessive	PT
10066127	Ischaemic pancreatitis	PT
10066174	Transfusion-related circulatory overload	PT
10066243	Aortic wall hypertrophy	PT
10066286	Stress cardiomyopathy	PT
10066363	Haemodynamic rebound	PT
10066391	Lupus myocarditis	PT
10066591	Post procedural stroke	PT
10066592	Post procedural myocardial infarction	PT
10066801	Aortic valve atresia	PT
10066802	Shone complex	PT
10066857	Myocarditis infectious	PT
10066862	Tricuspid valve prolapse	PT
10066870	Aorto-oesophageal fistula	PT
10066881	Deep vein thrombosis postoperative	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10066907	Vertebral artery hypoplasia	PT
10066916	Arteriovenous fistula aneurysm	PT
10067057	Basal ganglia haemorrhage	PT
10067116	Carotid arteriosclerosis	PT
10067167	Cerebellar embolism	PT
10067207	Rebound tachycardia	PT
10067270	Thrombosis corpora cavernosa	PT
10067277	Cerebral microhaemorrhage	PT
10067282	Right atrial dilatation	PT
10067283	Right atrial pressure increased	PT
10067284	Pulmonary arteriopathy	PT
10067285	Vascular resistance pulmonary increased	PT
10067286	Left atrial dilatation	PT
10067325	Coeliac artery stenosis	PT
10067339	Arrhythmic storm	PT
10067347	Thrombotic cerebral infarction	PT
10067466	Cerebral microangiopathy	PT
10067598	Neurogenic hypertension	PT
10067618	Accessory cardiac pathway	PT
10067652	Electrocardiogram RR interval prolonged	PT
10067876	External counterpulsation	PT
10067975	Aortic intramural haematoma	PT
10068044	Cerebral amyloid angiopathy	PT
10068119	Aortic dissection rupture	PT
10068149	Vessel perforation	PT
10068165	Cardiac valve rupture	PT
10068180	Atrioventricular conduction time shortened	PT
10068230	Cardiorenal syndrome	PT
10068239	Pancreatic infarction	PT
10068359	Hyperdynamic left ventricle	PT
10068365	Femoral artery embolism	PT
10068534	Coronary no-reflow phenomenon	PT
10068605	Venous recanalisation	PT
10068621	Cerebellar ischaemia	PT
10068627	Chronotropic incompetence	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10068644	Brain stem stroke	PT
10068677	Splenic embolism	PT
10068690	Pulmonary vein occlusion	PT
10068726	Pulmonary hypertensive crisis	PT
10068767	Viral cardiomyopathy	PT
10068776	Post embolisation syndrome	PT
10068841	Cobb syndrome	PT
10069018	Brachiocephalic vein stenosis	PT
10069020	Basal ganglia infarction	PT
10069111	Inferior vena cava dilatation	PT
10069112	Hepatic vein dilatation	PT
10069121	Cardiac septal defect residual shunt	PT
10069140	Myocardial depression	PT
10069167	Kounis syndrome	PT
10069339	Acute kidney injury	PT
10069379	Peripheral arterial reocclusion	PT
10069384	Ischaemic nephropathy	PT
10069385	Ocular ischaemic syndrome	PT
10069469	Postimplantation syndrome	PT
10069550	Intrapericardial thrombosis	PT
10069571	Atrioventricular dissociation	PT
10069658	HIV cardiomyopathy	PT
10069694	Brachiocephalic artery occlusion	PT
10069695	Subclavian artery occlusion	PT
10069696	Coeliac artery occlusion	PT
10069713	Primary ciliary dyskinesia	PT
10069727	May-Thurner syndrome	PT
10069801	Cardiac complication associated with device	PT
10069886	Omental infarction	PT
10069922	Vascular graft thrombosis	PT
10070190	Ischaemic gastritis	PT
10070243	Endocardial varices	PT
10070296	Arterioenteric fistula	PT
10070511	Hypoxic-ischaemic encephalopathy	PT
10070589	Ischaemic contracture of the left ventricle	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10070649	Vessel puncture site thrombosis	PT
10070671	Cerebral septic infarct	PT
10070689	Dilatation of sinotubular junction	PT
10070746	Stress echocardiogram abnormal	PT
10070878	Cerebral small vessel ischaemic disease	PT
10070909	Metabolic cardiomyopathy	PT
10070911	Inferior vena cava syndrome	PT
10070955	Right ventricular heave	PT
10071010	Subchorionic haemorrhage	PT
10071043	Basal ganglia stroke	PT
10071138	Malnutrition-inflammation-atherosclerosis syndrome	PT
10071186	Ventricular dyssynchrony	PT
10071205	Brain stem microhaemorrhage	PT
10071206	Cerebellar microhaemorrhage	PT
10071316	Spinal artery thrombosis	PT
10071436	Systolic dysfunction	PT
10071505	Vertebrobasilar dolichoectasia	PT
10071573	Susac's syndrome	PT
10071660	N-terminal prohormone brain natriuretic peptide abnormal	PT
10071662	N-terminal prohormone brain natriuretic peptide increased	PT
10071666	Atrial parasystole	PT
10071710	Lenegre's disease	PT
10071716	Vertebral artery dissection	PT
10071747	Cerebral cavernous malformation	PT
10072043	Central nervous system haemorrhage	PT
10072052	Plaque shift	PT
10072066	Artificial heart implant	PT
10072186	Myocardial stunning	PT
10072226	Renal vascular thrombosis	PT
10072252	ECG electrically inactive area	PT
10072370	Prerenal failure	PT
10072557	Peripheral artery restenosis	PT
10072558	Carotid artery restenosis	PT
10072563	Peripheral artery stenosis	PT
10072564	Peripheral artery thrombosis	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10072629	Intrahepatic portal hepatic venous fistula	PT
10072685	Microvascular coronary artery disease	PT
10072744	Alcohol septal ablation	PT
10072788	False lumen dilatation of aortic dissection	PT
10072789	Iliac artery rupture	PT
10072809	Arterial wall hypertrophy	PT
10073230	Brain stem haematoma	PT
10073356	Cardiac contusion	PT
10073455	Twin reversed arterial perfusion sequence malformation	PT
10073565	Intracranial artery dissection	PT
10073708	Obstructive shock	PT
10073774	Lenticulostriatal vasculopathy	PT
10073856	Larsen syndrome	PT
10074063	Ischaemic enteritis	PT
10074222	Right ventricular dilatation	PT
10074269	Tachycardia induced cardiomyopathy	PT
10074301	Right ventricular hypertension	PT
10074337	Acute aortic syndrome	PT
10074349	Ophthalmic vein thrombosis	PT
10074359	Cardiopulmonary exercise test abnormal	PT
10074387	Axillary web syndrome	PT
10074396	Penetrating atherosclerotic ulcer	PT
10074422	Brain stem embolism	PT
10074494	Hepatic vascular thrombosis	PT
10074525	Mesenteric phlebosclerosis	PT
10074540	Tongue infarction	PT
10074583	Mesenteric vascular occlusion	PT
10074600	Splenic artery thrombosis	PT
10074621	Vein collapse	PT
10074639	Inferior vena cava stenosis	PT
10074640	Junctional ectopic tachycardia	PT
10074717	Precerebral artery thrombosis	PT
10074896	Device embolisation	PT
10074971	Arterial intramural haematoma	PT
10075043	Thyrotoxic cardiomyopathy	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10075049	Peripheral venous disease	PT
10075162	Coronary vascular graft occlusion	PT
10075211	Myocardial necrosis marker increased	PT
10075253	Atrio-oesophageal fistula	PT
10075291	Ventricular remodelling	PT
10075299	ECG signs of myocardial infarction	PT
10075337	Right ventricular ejection fraction decreased	PT
10075393	Positive vessel remodelling	PT
10075394	Cerebral aneurysm perforation	PT
10075395	Aneurysm perforation	PT
10075396	Aneurysm recanalisation	PT
10075401	Cerebral reperfusion injury	PT
10075423	Cerebral artery restenosis	PT
10075428	Mahler sign	PT
10075449	Brachiocephalic arteriosclerosis	PT
10075450	Brachiocephalic artery stenosis	PT
10075534	Cardiovascular symptom	PT
10075553	Enterovirus myocarditis	PT
10075565	Lower respiratory tract congestion	PT
10075633	Cerebral capillary telangiectasia	PT
10075728	Carotid artery perforation	PT
10075729	Aortic perforation	PT
10075730	Lower limb artery perforation	PT
10075731	Iliac artery perforation	PT
10075732	Arterial perforation	PT
10075733	Venous perforation	PT
10075734	Cerebral artery perforation	PT
10075735	Vertebral artery perforation	PT
10075736	Basilar artery perforation	PT
10075737	Renal artery perforation	PT
10075738	Splenic artery perforation	PT
10075739	Femoral artery perforation	PT
10075740	Subclavian artery perforation	PT
10075741	Superior vena cava perforation	PT
10075742	Inferior vena cava perforation	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10075743	Subclavian vein perforation	PT
10075744	Iliac vein perforation	PT
10075745	Femoral vein perforation	PT
10075851	Aortic valve thickening	PT
10075889	Sinus node dysfunction	PT
10075993	Primary cardiac lymphoma	PT
10076145	Medical device site thrombosis	PT
10076203	Radiation associated cardiac failure	PT
10076213	Irregular breathing	PT
10076389	Radiation myocarditis	PT
10076419	Anginal equivalent	PT
10076604	Atherosclerotic plaque rupture	PT
10076605	Right-to-left cardiac shunt	PT
10076627	Coronary brachytherapy	PT
10076692	Anterior segment ischaemia	PT
10076693	Arteriovenous fistula maturation failure	PT
10076713	Subclavian vein stenosis	PT
10076835	Jugular vein occlusion	PT
10076836	Aortic restenosis	PT
10076837	Brachiocephalic vein occlusion	PT
10076839	Incision site vessel occlusion	PT
10076895	Cerebral vascular occlusion	PT
10076898	Cardiac ventricular scarring	PT
10076916	Kidney congestion	PT
10076929	Cerebral congestion	PT
10076976	Systolic anterior motion of mitral valve	PT
10076981	Post stroke seizure	PT
10076982	Post stroke epilepsy	PT
10076994	Lacunar stroke	PT
10076999	Bezold-Jarisch reflex	PT
10077000	Hypertensive cerebrovascular disease	PT
10077031	Basal ganglia haematoma	PT
10077033	Precerebral arteriosclerosis	PT
10077115	Iliac artery disease	PT
10077143	Vascular stent occlusion	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10077144	Vascular stent stenosis	PT
10077146	Post angioplasty restenosis	PT
10077162	Abnormal precordial movement	PT
10077177	Pulmonary hypoperfusion	PT
10077260	Banti's syndrome	PT
10077285	Intracranial arterial fenestration	PT
10077330	Vascular graft stenosis	PT
10077331	Vascular graft restenosis	PT
10077334	Coronary vascular graft stenosis	PT
10077361	Multiple organ dysfunction syndrome	PT
10077454	Cardiac contractility modulation therapy	PT
10077455	Device related thrombosis	PT
10077498	Vertebral artery aneurysm	PT
10077503	Paroxysmal atrioventricular block	PT
10077607	Basilar artery aneurysm	PT
10077643	Vascular access site haemorrhage	PT
10077644	Vascular access site complication	PT
10077645	Vascular access site oedema	PT
10077647	Vascular access site haematoma	PT
10077648	Vascular access site occlusion	PT
10077649	Vascular access site pseudoaneurysm	PT
10077652	Vascular access site rupture	PT
10077721	Vascular graft haemorrhage	PT
10077763	Vascular access site dissection	PT
10077767	Vascular access site bruising	PT
10077781	Prohormone brain natriuretic peptide increased	PT
10077783	Prohormone brain natriuretic peptide abnormal	PT
10077819	Bendopnoea	PT
10077824	Coronary bypass stenosis	PT
10077828	Omental necrosis	PT
10077832	Vascular access malfunction	PT
10077834	Left-to-right cardiac shunt	PT
10077864	Ischaemic mitral regurgitation	PT
10077893	Atrioventricular node dispersion	PT
10077988	Neurovascular conflict	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10078046	Brachial artery entrapment syndrome	PT
10078078	Cardiovascular somatic symptom disorder	PT
10078118	Calcium embolism	PT
10078201	Pulmonary artery occlusion	PT
10078202	Post cardiac arrest syndrome	PT
10078218	Surgical ventricular restoration	PT
10078269	Vascular pseudoaneurysm thrombosis	PT
10078310	Central bradycardia	PT
10078311	Cerebral microembolism	PT
10078388	Delayed ischaemic neurological deficit	PT
10078417	Lyme carditis	PT
10078431	Coronary vein stenosis	PT
10078670	Gonococcal heart disease	PT
10078675	Vascular access site thrombosis	PT
10078980	Myocardial hypoxia	PT
10079016	Wall motion score index abnormal	PT
10079115	Respiratory sinus arrhythmia magnitude increased	PT
10079116	Respiratory sinus arrhythmia magnitude decreased	PT
10079117	Respiratory sinus arrhythmia magnitude abnormal	PT
10079253	Non-compaction cardiomyopathy	PT
10079319	Periprocedural myocardial infarction	PT
10079339	Ventricular enlargement	PT
10079340	Atrial enlargement	PT
10079586	Aortic annulus rupture	PT
10079588	Aortic root compression	PT
10079589	Coronary artery compression	PT
10079613	Right ventricular diastolic collapse	PT
10079751	Cardiac dysfunction	PT
10079769	Cavernous sinus syndrome	PT
10079904	Intracardiac pressure increased	PT
10080039	Oedema blister	PT
10080307	Arterial dolichoectasia	PT
10080308	Carotid artery dolichoectasia	PT
10080347	Extraischaemic cerebral haematoma	PT
10080484	Chagas' cardiomyopathy	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10080569	Cardiac iron overload	PT
10080787	Wellens' syndrome	PT
10080788	Diabetic coronary microangiopathy	PT
10080894	Procedural shock	PT
10080896	Perforation of great vessels	PT
10080987	Left ventricular diastolic collapse	PT
10080992	Ventricular compliance decreased	PT
10081004	Hypersensitivity myocarditis	PT
10081007	Obesity cardiomyopathy	PT
10081099	Acute cardiac event	PT
10081144	Ophthalmic artery thrombosis	PT
10081493	Electrocardiogram PR segment depression	PT
10081792	Lung opacity	PT
10081850	Jugular vein embolism	PT
10081886	Cardiac device reprogramming	PT
10081980	Subacute kidney injury	PT
10082009	Implantable cardiac monitor replacement	PT
10082160	Supra-aortic trunk sclerosis	PT
10082308	Internal carotid artery deformity	PT
10082367	Left atrial volume abnormal	PT
10082368	Left atrial volume decreased	PT
10082369	Left atrial volume increased	PT
10082459	Subendocardial haemorrhage	PT
10082480	Cardiohepatic syndrome	PT
10082493	Restenosis	PT
10082503	Venous hypertension	PT
10082504	Elastic vessel recoil complication	PT
10082565	Aorto-bronchial fistula	PT
10082580	Myocardial hypoperfusion	PT
10082594	Foville syndrome	PT
10082595	Arteriovenous graft site necrosis	PT
10082606	Immune-mediated myocarditis	PT
10082615	Coronary sinus dilatation	PT
10082739	Vascular access steal syndrome	PT
10082827	Iliac artery restenosis	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10082853	Peripheral vein thrombus extension	PT
10082919	Pericardial lipoma	PT
10082931	Vascular access site hypoaesthesia	PT
10083006	Eye infarction	PT
10083037	Cerebral venous sinus thrombosis	PT
10083102	Iliac vein stenosis	PT
10083103	Peripheral vein occlusion	PT
10083104	Peripheral vein stenosis	PT
10083109	Vascular access site erythema	PT
10083112	Vascular access site pruritus	PT
10083143	Magnetic resonance imaging thoracic abnormal	PT
10083244	Spontaneous internal carotid artery recanalisation	PT
10083275	Foix-Chavany-Marie syndrome	PT
10083302	Necrotic angiodermatitis	PT
10083408	Internal capsule infarction	PT
10083476	Reactive angioendotheliomatosis	PT
10083602	Cardiac perfusion defect	PT
10083635	Giant cell myocarditis	PT
10083657	Toxic cardiomyopathy	PT
10083659	Hypotensive crisis	PT
10083668	Cerebral microinfarction	PT
10083709	Holiday heart syndrome	PT
10083840	Hepatic perfusion disorder	PT
10084002	Ischaemic cholecystitis	PT
10084013	Post procedural hypotension	PT
10084057	Vascular graft infection	PT
10084058	Congestive hepatopathy	PT
10084072	Embolic cerebellar infarction	PT
10084073	BRASH syndrome	PT
10084081	Coronary steal syndrome	PT
10084085	Atrioventricular node dysfunction	PT
10084087	Cerebrovascular pseudoaneurysm	PT
10084092	Vascular anastomotic haemorrhage	PT
10084238	Neonatal dyspnoea	PT
10084339	Aorto-atrial fistula	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10084341	Subclavian artery dissection	PT
10084364	Mitochondrial cardiomyopathy	PT
10084482	Arterial revascularisation	PT
10084745	Temporary mechanical circulatory support	PT
10084750	Arteriovenous fistula site pseudoaneurysm	PT
10084753	Arteriovenous graft site pseudoaneurysm	PT
10084767	Multisystem inflammatory syndrome in children	PT
10084806	Coronary sinus injury	PT
10084862	Supra-aortic trunk stenosis	PT
10085242	Chronic coronary syndrome	PT
10085294	Acquired left ventricle outflow tract obstruction	PT
10085297	Paravalvular regurgitation	PT
10085742	Subclavian arteriosclerosis	PT
10085756	Atrial escape rhythm	PT
10085779	Pseudo-occlusion of internal carotid artery	PT
10085821	Iliac artery arteriosclerosis	PT
10085849	Superior mesenteric artery dissection	PT
10085850	Multisystem inflammatory syndrome in adults	PT
10085879	Myocardial injury	PT
10085935	Vascular access site necrosis	PT
10085944	Haemorrhagic cerebellar infarction	PT
10086091	Multisystem inflammatory syndrome	PT
10086097	Precerebral artery aneurysm	PT
10086098	Precerebral artery dissection	PT
10086099	Post procedural complication circulatory	PT
10086118	Pulmonary artery arteriosclerosis	PT
10086230	Early repolarisation syndrome	PT
10086250	Acquired coronary artery fistula	PT
10086295	Myocardial strain imaging abnormal	PT
10086308	Acquired right ventricle outflow obstruction	PT
10086395	Ophthalmic artery occlusion	PT
10086406	Ophthalmic artery aneurysm	PT
10086448	Cerebrocardiac syndrome	PT
10086546	Malignant middle cerebral artery syndrome	PT
10086552	Post procedural cardiac valve avulsion	PT

GLPG0634-CL-MACE, 20DEC22:15:49

CV Events - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10086558	Buttock claudication	PT
10086560	Aneurysm thrombosis	PT
10086620	Dynamic cardiomyoplasty	PT
10086684	Diabetic complication cardiovascular	PT
10086706	Cardiac contractility decreased	PT
10086740	Fascicular block	PT
10086997	Pacing induced cardiomyopathy	PT
10087101	Myofibrillar myopathy	PT
10087106	Chronic myocarditis	PT
10087136	Heart transplant failure	PT
10087137	Heart-lung transplant failure	PT
10087208	Sigmoid sinus thrombosis	PT
10087221	Septic cardiomyopathy	PT
10087237	Atrial standstill	PT
10087358	Prosthetic cardiac valve central regurgitation	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Unstable Angina - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10000891	Acute myocardial infarction	PT
10002383	Angina pectoris	PT
10002388	Angina unstable	PT
10003225	Arteriospasm coronary	PT
10028596	Myocardial infarction	PT
10028600	Myocardial ischaemia	PT
10033697	Papillary muscle infarction	PT
10036759	Prinzmetal angina	PT
10049768	Silent myocardial infarction	PT
10051592	Acute coronary syndrome	PT
10051624	Myocardial reperfusion injury	PT
10058144	Postinfarction angina	PT
10058145	Subendocardial ischaemia	PT
10066592	Post procedural myocardial infarction	PT
10068534	Coronary no-reflow phenomenon	PT
10069167	Kounis syndrome	PT
10072186	Myocardial stunning	PT
10072685	Microvascular coronary artery disease	PT
10076419	Anginal equivalent	PT
10079319	Periprocedural myocardial infarction	PT
10080787	Wellens' syndrome	PT
10083602	Cardiac perfusion defect	PT
10084081	Coronary steal syndrome	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Transient Ischemic Attack - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10006127	Brain hypoxia	PT
10006147	Brain stem infarction	PT
10006148	Brain stem ischaemia	PT
10008034	Cerebellar infarction	PT
10008118	Cerebral infarction	PT
10008120	Cerebral ischaemia	PT
10008190	Cerebrovascular accident	PT
10014498	Embolic stroke	PT
10019005	Haemorrhagic cerebral infarction	PT
10019016	Haemorrhagic stroke	PT
10028047	Moyamoya disease	PT
10043647	Thrombotic stroke	PT
10044390	Transient ischaemic attack	PT
10050209	Spinal cord ischaemia	PT
10050496	Reversible ischaemic neurological deficit	PT
10051078	Lacunar infarction	PT
10053841	Sneddon's syndrome	PT
10055677	Haemorrhagic transformation stroke	PT
10056237	Migrainous infarction	PT
10057375	Balint's syndrome	PT
10058571	Spinal cord infarction	PT
10058842	Cerebrovascular insufficiency	PT
10059613	Stroke in evolution	PT
10060839	Embolic cerebral infarction	PT
10060840	Ischaemic cerebral infarction	PT
10061256	Ischaemic stroke	PT
10064961	Thalamic infarction	PT
10065528	NIH stroke scale score increased	PT
10065531	NIH stroke scale abnormal	PT
10067347	Thrombotic cerebral infarction	PT
10067744	Capsular warning syndrome	PT
10068621	Cerebellar ischaemia	PT
10068644	Brain stem stroke	PT
10069020	Basal ganglia infarction	PT
10070511	Hypoxic-ischaemic encephalopathy	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Transient Ischemic Attack - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10070671	Cerebral septic infarct	PT
10070878	Cerebral small vessel ischaemic disease	PT
10071043	Basal ganglia stroke	PT
10073945	Perinatal stroke	PT
10075401	Cerebral reperfusion injury	PT
10076994	Lacunar stroke	PT
10078202	Post cardiac arrest syndrome	PT
10078388	Delayed ischaemic neurological deficit	PT
10079062	Cerebellar stroke	PT
10080347	Extraischaemic cerebral haematoma	PT
10080713	Hemihyperaesthesia	PT
10082031	Spinal stroke	PT
10082484	Vertebrobasilar stroke	PT
10082594	Foville syndrome	PT
10083174	Hemidysaesthesia	PT
10083408	Internal capsule infarction	PT
10083668	Cerebral microinfarction	PT
10084072	Embolic cerebellar infarction	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Stroke - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10006145	Brain stem haemorrhage	PT
10006147	Brain stem infarction	PT
10008030	Cerebellar haemorrhage	PT
10008034	Cerebellar infarction	PT
10008111	Cerebral haemorrhage	PT
10008118	Cerebral infarction	PT
10008120	Cerebral ischaemia	PT
10008190	Cerebrovascular accident	PT
10014498	Embolic stroke	PT
10018985	Haemorrhage intracranial	PT
10019005	Haemorrhagic cerebral infarction	PT
10019013	Haemorrhagic infarction	PT
10019016	Haemorrhagic stroke	PT
10022775	Intracranial tumour haemorrhage	PT
10022840	Intraventricular haemorrhage	PT
10030936	Optic nerve infarction	PT
10035092	Pituitary infarction	PT
10042316	Subarachnoid haemorrhage	PT
10043647	Thrombotic stroke	PT
10044390	Transient ischaemic attack	PT
10048992	Spinal cord haemorrhage	PT
10049236	Spinal epidural haemorrhage	PT
10049760	Pituitary haemorrhage	PT
10051078	Lacunar infarction	PT
10055677	Haemorrhagic transformation stroke	PT
10057403	Choroidal infarction	PT
10058571	Spinal cord infarction	PT
10058939	Thalamus haemorrhage	PT
10058940	Putamen haemorrhage	PT
10059613	Stroke in evolution	PT
10060839	Embolic cerebral infarction	PT
10060840	Ischaemic cerebral infarction	PT
10061256	Ischaemic stroke	PT
10063176	Prosthetic cardiac valve thrombosis	PT
10064961	Thalamic infarction	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Stroke - Galapagos Search Term List

MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10067057	Basal ganglia haemorrhage	PT
10067347	Thrombotic cerebral infarction	PT
10067744	Capsular warning syndrome	PT
10068644	Brain stem stroke	PT
10069020	Basal ganglia infarction	PT
10070671	Cerebral septic infarct	PT
10071043	Basal ganglia stroke	PT
10072043	Central nervous system haemorrhage	PT
10073563	Spinal subdural haemorrhage	PT
10073564	Spinal subarachnoid haemorrhage	PT
10077193	Hemihypoaesthesia	PT
10080347	Extraischaemic cerebral haematoma	PT
10082031	Spinal stroke	PT
10082484	Vertebrobasilar stroke	PT
10083006	Eye infarction	PT
10083087	Fluorescence angiogram abnormal	PT
10083408	Internal capsule infarction	PT
10083668	Cerebral microinfarction	PT
10083691	Lambl's excrescences	PT
10084072	Embolic cerebellar infarction	PT
10085447	Claude's syndrome	PT
10085448	Weber's syndrome	PT
10085451	Benedikt's syndrome	PT
10085944	Haemorrhagic cerebellar infarction	PT
10086546	Malignant middle cerebral artery syndrome	PT
10086596	Metabolic stroke	PT
10087275	Heidelberg classification	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Cardiac Failure - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10007554	Cardiac failure	PT
10007556	Cardiac failure acute	PT
10007558	Cardiac failure chronic	PT
10007559	Cardiac failure congestive	PT
10007560	Cardiac failure high output	PT
10007577	Cardiac index decreased	PT
10007595	Cardiac output decreased	PT
10007625	Cardiogenic shock	PT
10010968	Cor pulmonale	PT
10010969	Cor pulmonale acute	PT
10010970	Cor pulmonale chronic	PT
10013012	Dilatation ventricular	PT
10024119	Left ventricular failure	PT
10024899	Low cardiac output syndrome	PT
10031123	Orthopnoea	PT
10039163	Right ventricular failure	PT
10049632	Oedema due to cardiac disease	PT
10049694	Left ventricular dysfunction	PT
10050528	Ejection fraction decreased	PT
10051093	Cardiopulmonary failure	PT
10052337	Diastolic dysfunction	PT
10053405	Brain natriuretic peptide increased	PT
10053408	Brain natriuretic peptide abnormal	PT
10058597	Right ventricular dysfunction	PT
10059056	Ventricular dysfunction	PT
10060953	Ventricular failure	PT
10063081	Acute left ventricular failure	PT
10063082	Acute right ventricular failure	PT
10063083	Chronic left ventricular failure	PT
10063084	Chronic right ventricular failure	PT
10068230	Cardiorenal syndrome	PT
10069140	Myocardial depression	PT
10071436	Systolic dysfunction	PT
10071660	N-terminal prohormone brain natriuretic peptide abnormal	PT
10071662	N-terminal prohormone brain natriuretic peptide increased	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Cardiac Failure - Galapagos Search Term List

MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10075337	Right ventricular ejection fraction decreased	PT
10077781	Prohormone brain natriuretic peptide increased	PT
10077783	Prohormone brain natriuretic peptide abnormal	PT
10079613	Right ventricular diastolic collapse	PT
10079751	Cardiac dysfunction	PT
10080987	Left ventricular diastolic collapse	PT
10080992	Ventricular compliance decreased	PT
10082615	Coronary sinus dilatation	PT
10084058	Congestive hepatopathy	PT
10086295	Myocardial strain imaging abnormal	PT
10086620	Dynamic cardiomyoplasty	PT
10086706	Cardiac contractility decreased	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Percutaneous Coronary Intervention - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10002475	Angioplasty	PT
10003140	Arterectomy with graft replacement	PT
10003144	Arterial aneurysm repair	PT
10003148	Arterial catheterisation	PT
10003190	Arteriovenous fistula operation	PT
10007692	Carotid endarterectomy	PT
10011077	Coronary artery bypass	PT
10011090	Coronary artery surgery	PT
10011101	Coronary endarterectomy	PT
10014648	Endarterectomy	PT
10014649	Endarterectomy of aorta	PT
10022736	Intra-cerebral aneurysm operation	PT
10043530	Thrombectomy	PT
10043568	Thrombolysis	PT
10048932	Vena cava filter insertion	PT
10049071	Vascular operation	PT
10049887	Coronary revascularisation	PT
10050329	Coronary angioplasty	PT
10052086	Coronary arterial stent insertion	PT
10052371	Ventricular assist device insertion	PT
10052681	Valvuloplasty cardiac	PT
10052698	Catheterisation venous	PT
10052928	Clamping of blood vessel	PT
10052949	Arterial therapeutic procedure	PT
10052964	Venous repair	PT
10052989	Intra-aortic balloon placement	PT
10053003	Carotid artery bypass	PT
10053351	Peripheral revascularisation	PT
10053494	Aneurysmectomy	PT
10056418	Arterial bypass operation	PT
10057335	Therapeutic embolisation	PT
10057493	Renal artery angioplasty	PT
10057518	Peripheral artery angioplasty	PT
10057617	Aortic bypass	PT
10058408	Surgical vascular shunt	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Percutaneous Coronary Intervention - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10058794	Vasodilation procedure	PT
10059676	Arteriovenous graft	PT
10061656	Arterial repair	PT
10061657	Arterial stent insertion	PT
10062175	Venous operation	PT
10063025	Atherectomy	PT
10063170	Pulmonary artery banding	PT
10063382	Vascular stent insertion	PT
10063389	Venous stent insertion	PT
10063731	Pulmonary artery therapeutic procedure	PT
10064727	Renal artery stent placement	PT
10064778	Venous ligation	PT
10064958	Thromboembolectomy	PT
10065608	Percutaneous coronary intervention	PT
10066050	Aneurysm repair	PT
10066102	Carotid artery stent insertion	PT
10066129	Arterial switch operation	PT
10067740	Vascular graft	PT
10068628	Prosthetic vessel implantation	PT
10069948	Renal artery stent removal	PT
10069949	Vascular stent removal	PT
10069950	Arterial stent removal	PT
10069952	Carotid artery stent removal	PT
10069953	Coronary artery stent removal	PT
10071026	Arterectomy	PT
10071256	Aortic stent insertion	PT
10071260	Carotid angioplasty	PT
10071261	Mesenteric artery stent insertion	PT
10071508	Cerebral revascularisation	PT
10072559	Carotid revascularisation	PT
10072560	Peripheral endarterectomy	PT
10072561	Peripheral artery bypass	PT
10072562	Peripheral artery stent insertion	PT
10072893	Pulmonary endarterectomy	PT
10073598	Vascular anastomosis	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Percutaneous Coronary Intervention - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10074169	Vascular catheterisation	PT
10074397	Vena cava filter removal	PT
10075134	Prosthetic vessel removal	PT
10077079	Cerebral endovascular aneurysm repair	PT
10077826	Venous angioplasty	PT
10078636	Arteriotomy	PT
10081419	Vessel harvesting	PT
10081731	Arterial angioplasty	PT
10083018	Vascular ligation	PT
10084091	Revascularisation procedure	PT
10084482	Arterial revascularisation	PT
10084745	Temporary mechanical circulatory support	PT
10084977	Cardiac catheter removal	PT
10085325	Catheter directed thrombolysis	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Specific AE directly associated with the pathogen causing COVID-19 - Galapagos Search Term List
MedDRA Version 25.0

TERM_CODE	TERM_NAME	TERM_TYPE
10051905	Coronavirus infection	PT
10070255	Coronavirus test positive	PT
10084268	COVID-19	PT
10084271	SARS-CoV-2 test positive	PT
10084380	COVID-19 pneumonia	PT
10084381	Coronavirus pneumonia	PT
10084459	Asymptomatic COVID-19	PT
10084460	COVID-19 treatment	PT
10084461	SARS-CoV-2 carrier	PT
10084480	SARS-CoV-2 test false negative	PT
10084639	SARS-CoV-2 sepsis	PT
10084640	SARS-CoV-2 viraemia	PT
10085080	Congenital COVID-19	PT
10085492	Vaccine derived SARS-CoV-2 infection	PT
10085493	SARS-CoV-2 RNA	PT
10085495	SARS-CoV-2 RNA increased	PT
10085496	SARS-CoV-2 RNA decreased	PT
10085497	SARS-CoV-2 RNA fluctuation	PT
10085503	Post-acute COVID-19 syndrome	PT
10085850	Multisystem inflammatory syndrome in adults	PT
10086091	Multisystem inflammatory syndrome	PT
10086158	Thrombosis with thrombocytopenia syndrome	PT
10086861	Breakthrough COVID-19	PT

GLPG0634-CL-MACE, 20DEC22:15:49

Signature Page for gs-us-419-3896-sap 22323

Approval	[redacted] 02-Aug-2023 12:03:23 GMT+0000

Approval	[redacted] 03-Aug-2023 15:47:05 GMT+0000

Signature Page for gs-us-419-3896-sap43952_42958_121886